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Abstract 
This thesis describes an evaluation of next generation sequencing (NGS) as a tool 
to study melanoma genomics and identify prognostic biomarkers using formalin-
fixed paraffin-embedded (FFPE) primary tumours. I report the evaluation of different 
library preparation protocols as a pre-requisite for whole-genome DNA NGS. I show 
that libraries can be generated using small amounts of DNA extracted from primary 
melanomas (92% success rate). NGS data from 75 samples are presented. To 
ensure the accuracy of the data and in order to develop a robust protocol for copy 
number analysis using small FFPE tumours the quality of the data was assessed 
and potential biases were explored. I observed copy number changes previously 
reported in melanoma which provide some support of the validity of the data when 
small DNA input is used. Although, this is work under development, overall the data 
show that NGS using small FFPE tumours is likely to provide insight into melanoma 
biology. 
I report a study where osteopontin was tested as a potential prognostic biomarker in 
the plasma of patients with melanoma. The analysis suggests that measurement of 
plasma osteopontin is unlikely to serve as a useful blood prognostic marker in early-
stage disease patients, but it remains a possible marker of relapse in patients under 
follow up as part of a panel of such markers. 
The Leeds group have reported that low vitamin D levels at diagnosis are 
associated with thicker tumours and poorer outcome. I report an in vitro study 
where melanoma cells were cultured with and without vitamin D. Whole-genome 
gene expression data were generated using RNA from two vitamin D sensitive 
melanoma cell lines. The differentially expressed genes in response to vitamin D 
supported the anti-tumour effects of vitamin D previously reported in cancer 
models, providing some evidence for vitamin D as a potential adjuvant therapy.  
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Chapter 1  
Introduction 
 
1.1 The aims of the work reported in this thesis 
The major aims are: 
• To investigate the use of formalin-fixed paraffin-embedded (FFPE) primary 
melanoma tissue for genomic analyses, towards the aims of:  
o identifying novel independent prognostic factors; 
o better understanding the biology of melanoma; 
• To assess, in particular, the feasibility of using next generation sequencing 
(NGS) technology to analyse FFPE tissue;  
• To explore use of osteopontin blood levels as a potential prognostic 
biomarker for patients with melanoma; 
• To explore the biological effects of vitamin D in melanoma using an in vitro 
model. 
 
1.2 Aims of this chapter 
This chapter aims: 
• To describe what is known about cutaneous melanoma and common 
genetic alterations in melanoma tumours; 
• To describe current prognostic factors used in the American Joint 
Committee on Cancer (AJCC) staging system and their limitations; 
• To describe the clinico-pathological subtypes of melanoma and a new 
proposed classification system based on frequent genetic events in 
melanomas arising in sites of differential sun exposure;  
• To provide an overview of tumour and serological prognostic markers; 
• To describe current treatment options in melanoma; 
• To provide an overview of what is known about vitamin D and melanoma; 
• To introduce the following chapters of this thesis.   
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1.3 Cutaneous melanoma 
The malignant transformation of melanocytes, pigment-producing cells, is 
responsible for melanoma genesis (Chin, 2003). Melanoma was first described as a 
disease entity in 1806 by Rene Laennec, in his presentation to the Faculté de 
Médicine in Paris, but references to “black cancer” and “fatal black tumours with 
metastasis” are traced back to the writings of Hippocrates in the fifth century B.C 
(Chin et al., 1998). 
Melanoma can arise wherever pigment cells are found, but is most common in the 
skin where the greater part of pigment cell population lies. Melanomas may also 
arise however in non-skin sites including the mucosae (within the sinuses, mouth, 
nose or vagina) and in the pigmented cell surface of the eye and the internal 
surface of the eyelids (conjunctival, iris, ciliary body, choroidal). Melanomas arising 
from the iris, choroid and ciliary body are known as uveal melanomas. The genomic 
changes reported in uveal melanoma are different to melanomas of the skin and 
mucosae and I will not discuss uveal melanoma in this thesis. When I use the term 
henceforth I am referring to cutaneous melanoma unless stated otherwise. 
Both genetic and environmental risk factors contribute to the formation of 
melanoma (Chin, 2003). As originally described by Clark et al, primary melanomas 
progress through two well-defined phases; the radial growth phase (RGP) followed 
by the vertical growth phase (VGP). RGP is characterised by a flat lesion expanding 
horizontally in the epidermis and VGP is characterised by invasion into the dermis 
and other subcutaneous tissues. Finally, if these primary melanomas spread in the 
skin or other parts of the body, they lead to metastatic disease (Clark et al., 1984, 
Miller and Mihm, 2006, Gray-Schopfer et al., 2007).  
1.3.1 Incidence 
Cutaneous melanoma is the 5th most common cancer in the UK (Cancer Research 
UK  Statistical Information Team, 2010a). The observed increasing incidence rates 
in Great Britain since the mid-1970s might be in part due to early detection but most 
is likely to be due to changes in sun-related behaviour such as an increase in 
holidays in sunny places over time (Cancer Research UK  Statistical Information 
Team, 2010a). 
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1.4 Melanoma susceptibility 
The strongest environmental risk factor for melanoma is ultraviolet radiation 
(Gandini et al., 2005b, Parkin et al., 2011, Newton-Bishop et al., 2011). The type of 
sun exposure which is causal is now established to be intermittent and associated 
with sunburn (Chang et al., 2009, Newton-Bishop et al., 2011).  
That cutaneous melanoma is rare outside the pale skinned populations reflects the 
view that genetics is a strong determinant or risk. Family history is a significant risk 
factor (Gandini et al., 2005c, Law et al., 2012) especially where multiple cases 
occur in the family (Newton Bishop and Bishop, 2005). The phenotypes associated 
with melanoma risk such as sun-sensitive skin phenotype, red hair, blue eyes and 
presence of multiple melanocytic naevi (moles) are all genetically determined, with 
sun exposure having a relatively small effect on naevus number (Olsen et al., 2010, 
Gandini et al., 2005a, Newton-Bishop et al., 2010). 
The first high penetrance melanoma susceptibility gene (CDKN2A) was identified in 
1994 by Kamb et al (Kamb et al., 1994), and less common inherited mutations were 
subsequently reported in CDK4 (Soufir et al., 1998), and most recently in TERT 
(Horn et al., 2013). 
Genome-wide association studies have been used to identify lower penetrance 
susceptibility genes and associations between polymorphisms of pigmentation and 
naevus-related genes (MC1R, ASIP, TYR) and increased risk of melanoma have 
been reported (Barrett et al., 2011, Iles et al., 2013). Thus the genetic basis of the 
melanoma-related phenotypes is better understood now than before (Bishop et al., 
2009, Chatzinasiou et al., 2011). The more recent genome-wide association studies 
have highlighted the importance of cell cycle and DNA repair pathways as 
polymorphisms in genes such as CASP8 and CCND1 were reported to be 
associated with increased melanoma risk (Barrett et al., 2011, Law et al., 2012). 
 
1.5 Melanoma tumour development 
A number of key genetic and epigenetic events in melanomas have been identified 
through genome characterisation of melanoma compared to melanocytes. Indeed, 
melanomas have been shown to have very large numbers of mutations supposed 
to result from exposure to ultraviolet light (Hodis et al., 2012). Only some of these 
events contribute to the development of the tumour and are known as ‘driver 
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events’. The remaining mutations are denoted as ‘passengers’ having little or no 
phenotypic effect. In 2009 Meyle et al proposed a model of melanoma development 
(Figure 1-1) based on evidence from the genome analysis of melanoma (Meyle and 
Guldberg, 2009). The proposed model describes a linear series of events where a 
normal melanocyte becomes a benign naevus and then a melanoma (Meyle and 
Guldberg, 2009). However, it is known that melanoma might occur de novo with no 
pre-existence of a benign naevus. The altered key pathways thought to contribute 
to melanoma development from a pre-existing naevus are discussed below. 
1.5.1 Activation of mitogen-activated protein kinase (MAPK) 
pathway  
The most deregulated pathway in melanoma is the mitogen-activated protein kinase 
(MAPK) pathway which disrupts the cell cycle and induces proliferation (Figure 1-2) 
(Chin, 2003). BRAF mutations occur in 40% of primary melanomas with the V600E 
substitution be the most common mutation (Davies et al., 2002, Colombino et al., 
2012). BRAF is a proto-oncogene protein kinase and mutations are also found in 
melanocytic naevi which supports the view that this is an early event in the 
formation of melanoma arising from a naevus (Pollock et al., 2003, Poynter et al., 
2006). When BRAF is not mutated, other genes in the pathway (NRAS, KIT, 
GNAQ) are often found to be mutated (Meyle and Guldberg, 2009). BRAF and 
NRAS mutations are found in melanoma of the skin (Platz et al., 2008) while KIT 
mutations in melanomas arising in acral sites (palms, soles, under the nail bed) 
(Curtin et al., 2006) and GNAQ in uveal melanomas (Van Raamsdonk et al., 2009).   
Thus, the driver mutations identified to date in cutaneous melanoma, are 
predominantly within the MAPK signalling pathway. The dramatic responses to 
systemic therapies which target mutant BRAF (BRAF-i) (Chapman et al., 2011), 
confirm that BRAF at least is a driver, even though in the majority of patients, 
relapse subsequently occurs. 
 
 
  
Figure 1-1: A proposed model of melanoma development. 
The acquisition of genetic changes drives progression from melanocytes to benign naevus and then primary and metastatic melanoma 
(more details in text). Adapted from (Meyle and Guldberg, 2009). Abbreviations used: MAPK, mitogen-activated protein kinase; G1, gap 1 
phase of the cell cycle; PI3K, phosphatidylinositol-3-kinase. 
6
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Figure 1-2: Deregulated pathways in melanoma.  
Red represents gain of function (e.g. BRAF) and grey loss of function (e.g. 
p53) due to somatic alterations. Loss of p16INK4A (coded by CDKN2A) leads to 
release of E2F transcription factors stimulating entry into the cell cycle. 
Inactivation of p14ARF leads to HDM2-mediated inactivation of p53 through 
proteosomal degradation. The MAPK pathway can be activated by mutations 
in BRAF or NRAS. In the absence of BRAF and NRAS mutations, ERK can 
still be constitutively active. NRAS mutations can also activate the PI3K 
pathway. The PI3K pathway may also be activated by loss of the tumour 
suppressor PTEN, or by gene amplification of AKT3. Adapted from (Gray-
Schopfer et al., 2007, Tsao et al., 2012). 
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1.5.2 Inactivation of p16INK4a-RB and p14ARF-p53 senescence 
barrier 
When melanocytes acquire BRAF mutations they proliferate and then exit the cell 
cycle, entering a state known as senescence (a benign naevus has been formed) 
(Gray-Schopfer et al., 2006, Michaloglou et al., 2005). A BRAF mutated naevus 
evolves into a tumour when the cells exit senescence through inactivation of 
p16INK4a (Gray-Schopfer et al., 2006, Michaloglou et al., 2005). Normally, p16INK4a, 
encoded by the CDKN2A locus, inhibits cyclin-dependent kinases CDK4/6, which 
maintains the retinoblastoma protein (RB) in an inactive hypophosphorylated state 
and the cell does not enter the S phase of the cell cycle (Figure 1-2) (Meyle and 
Guldberg, 2009). In melanomas p16INK4a is usually inactivated through deletions, 
mutations and promoter hypermethylation of CDKN2A (Chin, 2003, Meyle and 
Guldberg, 2009). Less frequently, CDK4 mutations are found in melanomas. CDK4 
mutant proteins cannot bind p16INK4a and therefore RB protein remains in its active 
phosphorylated form (Meyle and Guldberg, 2009, Bartkova et al., 1996).  
An alternative senescence barrier is observed when melanocytic cells lack p16INK4a 
through up-regulation of the tumour suppressor p53 (Meyle and Guldberg, 2009, 
Sviderskaya et al., 2003). p14ARF induces p53 and therefore inactivation of the 
p14ARF-p53 barrier is considered essential for the melanocytic cells to exit 
senescence and evolve into a tumour (Meyle and Guldberg, 2009). TP53 mutations 
are found in 5-25% of melanomas (Meyle and Guldberg, 2009). P14ARF is encoded 
through the CDKN2A locus through an alternative reading frame to p16INK4a and 
therefore is often inactivated when CDKN2A is mutated (Figure 1-2) (Meyle and 
Guldberg, 2009, Tsao et al., 2012). p14ARF inactivation acts as an alternative way to 
abrogate the function of activated p53 through activation of HDM2 which targets 
p53 for proteosomal degradation (Figure 1-2) (Meyle and Guldberg, 2009, Tsao et 
al., 2012).  
1.5.3 Activation of the phosphatidylinositol-3-kinase (PI3K) 
pathway  
PTEN negatively regulates the PI3K pathway, which is important for the regulation 
of cell growth and survival (Figure 1-2) (Meyle and Guldberg, 2009). PTEN 
inactivation through copy number loss or mutations leads to activation of this 
pathway (Meyle and Guldberg, 2009, Tsao et al., 2012). Reports suggest that 
PTEN inactivation is a rare event in primary melanomas, but common in melanoma 
metastases, suggesting the importance of PI3K pathway activation in the late 
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stages of melanoma development (Meyle and Guldberg, 2009, Wu et al., 2003). 
Constitutive activation of this pathway occurs less frequently through copy number 
gain in AKT3 and mutations in NRAS, KIT and PIK3CA (Meyle and Guldberg, 2009, 
Tsao et al., 2012). PTEN loss is usually observed in BRAF mutated tumours and 
rarely in NRAS mutated tumours and therefore suggesting that BRAF and PTEN 
cooperate in melanoma progression (Tsao et al., 2012) (Jonsson et al., 2007).  
In summary then, since the identification of BRAF as commonly mutated in 
melanoma, there has been an explosion in knowledge about the genomic 
landscape of melanoma. Furthermore this has resulted for the first time in the 
development of targeted therapies having an effect on survival.  
 
1.6 Clinico-pathological subtypes of cutaneous melanoma 
There are 4 main clinico-pathological subtypes of melanoma: superficial spreading 
melanoma (SMM); lentigo maligna melanoma (LMM); nodular melanoma (NM); and 
acral lentiginous melanoma (ALM). This classification system was developed based 
on work by Clark et al in the 1970s (Clark et al., 1969, Clark et al., 1984) and it is 
still used in the clinic. The system incorporates histological features, anatomical site 
of the tumour and degree of sun damage to distinguish between the four subtypes.  
• SSM is the most common subtype and appears particularly on sites with 
intermittent sun exposure. SSM usually occurs in young people, mostly on the 
legs in women and on the trunk in men (Haneke and Bastian, 2006). 
Histologically, it is characterised by RGP with or without VGP and the cells 
typically form a pagetoid pattern (Haneke and Bastian, 2006). A “pagetoid” 
pattern refers to upward spread of atypical cells within the top layer of the skin, 
the epidermis. Clinically, SSM is presented as a flat lesion (plaque) with 
irregular pigmentation and margins (Haneke and Bastian, 2006). 
• NM is the second most common subtype of melanoma which appears not to 
have a precursor RGP, presenting exclusively in the VGP. NM usually appears 
in older people compared to SSM. NM may occur in various sites with the trunk, 
head and neck and lower legs being the most common (intermittent sun-
exposed sites) (Bergman et al., 2006). Histologically, it is characterised by 
atypical cells proliferating within the dermis (Bergman et al., 2006). Clinically, 
NM is presented as a papule or nodule usually symmetric, typically with 
abnormal pigmentation. A failure to diagnose this sort of melanoma early is 
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common resulting from an apparently more rapidly growth rate, and although 
such tumours may be deeply pigmented, they may also look very red.  Nodular 
melanomas are more likely to be ulcerated (Bergman et al., 2006). 
• LMM is a subtype which appears particularly on chronic sun-exposed sites in 
the RGP with or without VGP. LMM usually occurs in elderly people with the 
head and neck being the commonest sites in both sexes (Heenan et al., 2006). 
Histologically it is characterised by small naevoid or epithelioid cells usually 
extending down the walls of hair follicles and sweat ducts when in VGP 
(Heenan et al., 2006). Clinically, LMM appears as a plaque or a nodule with 
irregular pigmentation and well-defined irregular borders with evidence of 
severe solar skin damage (Heenan et al., 2006). 
• ALM is the rarest subtype which is defined based on the anatomic location of 
the tumour and a particular histological pattern, which occurs in palms, soles 
and subungual sites. ALM shows similarities to LMM histologically. In the RGP, 
lesions are characterised by variable size cells often dendritic and in the VGP, 
by small epithelioid often spindled (Tokura et al., 2006). Atypical melanocytes 
can extend along the sweat glands into the dermis (VGP) which shows nests of 
tumours (Tokura et al., 2006). Clinically, lesions in the RGP appear as a plaque 
with irregular borders and in the VGP as a nodule which may be accompanied 
by the presence of ulceration (Tokura et al., 2006).  
Rarer subtypes including desmoplastic, spitzoid, minimal deviation and malignant 
blue naevus account for the 5% of the rest of melanomas (Elder and Murphy, 
2010).  
These well-described clinico-pathologically determined subtypes of melanomas 
arising in the skin have been established to be biologically different to each other to 
a certain extent. Molecular changes might provide a more accurate classification 
system, which will not only reflect the biological differences between the subtypes 
but form the basis of predictive tests used for the selection of patients for clinical 
trials of targeted therapies (Kabbarah and Chin, 2005). In 2005, Curtin et al 
proposed such a classification system based on the genetic changes identified in 
melanomas in relation to the anatomical site of the tumour, and patterns of sun 
exposure (Curtin et al., 2005). These are broad groupings reflecting a tendency to 
see differences rather than absolutes. 
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The four biologically relevant-subtypes proposed by Curtin et al (Curtin et al., 2005), 
and more recently reviewed by Whiteman et al (Whiteman et al., 2011), are: 
• Melanomas arising on chronically sun-exposed skin (face) which usually 
appear in older people. These melanomas often do not arise from a pre-
existing naevus. At the molecular level, these melanomas have lower 
prevalence of mutations in BRAF than in melanomas arising on minimally or 
non-sun exposed sites, with 20-30% showing mutations in NRAS or KIT 
(Curtin et al., 2005, Curtin et al., 2006);  
• Melanomas arising on intermittently sun exposed skin (trunk, arms, legs) 
which represent the most common type of melanoma in European 
populations. These melanomas are more likely to be associated with either 
a pre-existing naevus or generally high number of naevi. Molecularly, these 
melanomas are more frequently associated with a high prevalence of BRAF 
mutations (about 70%) (Curtin et al., 2005); 
• Melanomas arising on minimally sun-exposed skin (soles, palms) for which 
there are few epidemiological data on causation, but are thought not to be 
related to sun exposure. About 20-30% of these melanomas show 
mutations in KIT (Curtin et al., 2006, Whiteman et al., 2011) and 40% show 
CCND1/CDK4 amplifications (Sauter et al., 2002), otherwise they are 
characterised by frequent copy number gains and losses;  
• Melanomas arising on sun-protected sites (mucosal membranes) are 
characterised by as frequent copy number alterations as melanomas arising 
on the acral sites (minimally sun-exposed skin). However, the regions 
affected by copy number gains or losses are different to those found on 
minimally sun-exposed melanomas. In melanomas arising on sun-protected 
sites, CCND1 amplifications are less frequent and CDK4 amplifications are 
more prevalent compared to melanomas arising on minimally sun-exposed 
sites (Curtin et al., 2005). 
Histopathologists have long recognised that there are marked differences in the 
appearance of melanomas both in terms of architecture of the tumour and the 
nature of the cells. As the genomics of melanoma are explored then there is an 
emerging pattern of genomic changes which reflects the histological subtypes of the 
tumours to a certain degree. These patterns give support to the view that 
melanoma represents a wide range of different tumours, but are recognised to be 
only the beginning of the process. My work was designed to add to the information 
on primary tumour genomics to allow the recognition of better prognostic and 
predictive biomarkers and to better understand the biology.  
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1.7 Prognosis in melanoma 
Survival from melanoma, as with other cancers, is improving over time, which is 
attributed to faster and earlier diagnosis and improvements in treatment (Cancer 
Research UK  Statistical Information Team, 2010b). In England survival rates have 
increased over the last 30 years (Cancer Research UK  Statistical Information 
Team, 2010b). Patients with thin melanomas (≤1mm) have excellent prognosis with 
90-95% surviving for at least 5 years, and 83-88% for at least 10 years (Table 1-1) 
(Balch et al., 2009). However, for patients with larger tumours or with metastasis 
survival rates are much lower (Table 1-1) (Balch et al., 2009). 
Currently, clinical and histopathological prognostic markers, which predict outcome 
for melanoma patients, are included in the final version of the American Joint 
Committee on Cancer (AJCC) staging system. This system uses primary tumour 
characteristics (Breslow thickness, mitotic rate per mm2, tumour ulceration), lymph 
node metastasis, site of distant metastasis, and serum lactate dehydrogenase 
(LDH) level, as criteria for the tumour-node-metastasis (TNM) classification and the 
group staging (Table 1-1) (Balch et al., 2009). These criteria reflect the most 
significant independent prognostic factors, as described and analysed in 30,946 
patients with stages I, II and III melanoma and 7,972 with stage IV melanoma.  
 
 Table 1-1: Current AJCC staging system (7th edition) for cutaneous melanoma. 
Survival rates for individual TNM stage are based on the 6th edition of the AJCC staging system where Clark’s level of invasion determine 
T1a and T1b stages and has now been replaced with mitotic rate (Balch et al., 2001a). Adapted from (Balch et al., 2009). Abbreviations: 
TNM (Tumour, Node, Metastasis); LDH (lactate dehydrogenase).  
Group 
staging 
TNM 
classification 
Thickness 
(mm) 
Ulceration & 
mitotic rate 
(per mm2) 
Positive nodes Nodal size Distant metastasis 
5-year 
survival 
10-year 
survival 
IA T1a ≤1 No & mitosis<1 0 - - 95.3 87.9 
IB 
T1b ≤1 Yes or mitosis ≥1 0 - - 90.9 83.1 
T2a 1.01-2.0 No 0 - - 89.0 79.2 
IIA 
T2b 1.01-2.0 Yes 0 - - 77.4 64.4 
T3a 2.01-4.0 No 0 - - 78.7 63.8 
IIB 
T3b 2.01-4.0 Yes 0 - - 63.0 50.8 
T4a >4.0 No 0 - - 67.4 53.9 
IIC T4b >4.0 Yes 0 - - 45.1 32.3 
IIIA 
N1a Any No 1 Micro - 69.5 63.0 
N2a Any No 2-3 Micro - 63.3 56.9 
IIIB 
N1a Any Yes 1 Micro - 52.8 37.8 
N2a Any Yes 2-3 Micro - 49.6 35.9 
N1b Any No 1 Macro - 59.0 47.7 
N2b Any No 2-3 - - 46.3 39.2 
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 Group 
staging 
TNM 
classification 
Thickness 
(mm) 
Ulceration & 
mitotic rate 
(per mm2) 
Positive nodes Nodal size Distant metastasis 
5-year 
survival 
10-year 
survival 
IIIB cont. N2c Any No 
In transit 
metastases/satellites 
without metastatic nodes 
    
IIIC 
N1b Any Yes 1 Macro - 29.0 24.4 
N2b Any Yes 2-3 Macro - 24.0 15.0 
N2c Any Yes 
In transit 
metastases/satellites 
without metastatic nodes 
- - 26.7 18.4 
N3 Any Any 
≥4 nodes, or matted nodes, 
or in transit 
metastases/satellites with 
metastatic nodes 
Micro/ Macro -   
IV 
M1a Any Any Any Any 
Distant skin, 
subcutaneous or nodal 
18.8 15.7 
M1b Any Any Any Any Lung 6.7 2.5 
M1c Any Any Any Any 
Other visceral or any 
distant metastases with 
elevated LDH level 
9.5 6.0 
 
1
4
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1.7.1 Primary tumour characteristics (Stage I/II) 
1.7.1.1 Breslow thickness 
Breslow identified back in 1970 that the thickness of the tumour predicts its ability to 
metastasise (Breslow, 1970). Breslow thickness is assessed by a pathologist as the 
vertical thickness of the tumour measured in millimetres at the thickest part of the 
lesion, from the granular layer of the epidermis to the deepest part of the tumour. It 
is the strongest prognostic factor in localised disease with thicker tumours indicating 
worse prognosis and therefore it has been incorporated into the AJCC staging 
system (Balch et al., 2009, Balch et al., 2001b). Breslow thickness also predicts 
survival for patients with nodal disease (stage III) (Balch et al., 2010, Balch et al., 
2009). 
1.7.1.2 Tumour ulceration 
Ulceration of a primary melanoma is determined histologically and defined as the 
absence of intact epidermis overlying a major part of the lesion (Balch et al., 
2001a). Ulceration is an independent prognostic factor for both localised and stage 
III melanomas (Balch et al., 2009, Balch et al., 2010). Breslow thickness remains 
the strongest predictor of survival in localised disease, but the presence of 
ulceration strongly influences survival. Thus, survival rates for patients with an 
ulcerated tumour are lower compared to patients with a non-ulcerated tumour in the 
same thickness group, and remarkably similar compared to patients with a non-
ulcerated tumour in the next thickness group (Table 1-1) (Balch et al., 2009). 
1.7.1.3 Mitotic rate 
Mitotic rate is defined as the number of mitoses per mm2 in the most mitotically 
active part of the lesion. Mitotic rate reflects tumour proliferation and is a strong 
prognostic factor in localised melanoma (Balch et al., 2009, Thompson et al., 2011). 
It has replaced the level of invasion as described by Clark (Clark et al., 1969) in the 
7th edition of AJCC staging system with mitotic rate >1mm2 and/or presence of 
ulceration to determine T1b subcategory (Balch et al., 2009, Thompson et al., 
2011).  
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1.7.2 Metastatic tumour characteristics 
There is evidence that a primary tumour is actually a heterogeneous cell population, 
with a minority of cells being able to metastasise through the lymphatic and 
haematogenous systems and form colonies in distant organs (Hanahan and 
Weinberg, 2011). Metastasis depends on tumour characteristics, such as loss of 
cell adhesion, greater motility and invasiveness, but also on tumour/host 
interactions which involve the immune system and tumour microenvironment 
(Hanahan and Weinberg, 2011). 
1.7.2.1 Nodal metastasis (Stage III) 
Typically, the first site of melanoma metastasis is the regional nodal basin, the 
sentinel node, which is the first tumour-draining node in the lymphatic chain (Leong 
et al., 2006). If clinical examination fails to detect lymph node involvement a 
sentinel node biopsy is used to identify metastatic deposits. This procedure involves 
injection of blue dye and radioactive tracer into the skin where melanoma was 
located and identification of the sentinel node (which takes up the isotope and 
appears as a “hot” node), which is then removed and assessed histologically using 
melanocyte lineage markers, such as S100 (Marsden et al., 2010). If a patient has 
a positive sentinel node biopsy, then patients undergo complete lymphadenectomy 
to remove all regional nodes and the number of nodes involved is evaluated 
histologically (Marsden et al., 2010). The number of tumour-involved nodes, and 
whether the tumour deposits in these nodes are microscopic (diagnosed after 
sentinel node biopsy and/or complete lymphadenectomy) or macroscopic 
(diagnosed clinically), are predictors of outcome, with larger tumour burden 
associated with worse prognosis (Balch et al., 2009, Balch et al., 2010). Primary 
Breslow thickness and ulceration remain significant prognostic factors for stage III 
disease (Balch et al., 2009). In transit and satellite lesions are defined as 
intralymphatic metastases and, combined with nodal metastases, are associated 
with worse prognosis when compared to the absence of nodal metastases (Table 
1-1) (Balch et al., 2009). It has been reported that the size of nodal metastasis is 
also of prognostic significance, with small tumour burden (<0.1mm) associated with 
a similar prognosis to patients with a negative sentinel node biopsy (van Akkooi et 
al., 2008). Also, location of tumour deposits in the nodes influences outcome, as 
tumour deposits in the subcapsular sinus are associated with better outcome 
compared to deposits within the parenchyma of the node (Dewar et al., 2004). The 
location and size of nodal metastasis is not currently involved in the AJCC staging 
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system, but this might change in the future with more sentinel node biopsies taking 
place and accurate pathological reporting. 
1.7.2.2 Systemic metastasis (Stage IV) 
A proportion of melanoma tumour cells acquire the ability to spread systemically, 
commonly to skin, lymph nodes, liver, lung and brain. The site of distant metastasis 
has prognostic significance, such that skin, subcutaneous and lymph node sites are 
associated with better survival rates than metastases at visceral sites, while lung 
confer slightly better prognosis than other visceral sites (Balch et al., 2009). These 
differences in outcome might depict biological differences between tumours growing 
at different sites but they are as yet poorly understood. 
Elevated serum lactate dehydrogenase (LDH) levels are associated with worse 
prognosis in stage IV disease irrespective of the site of metastasis (Balch et al., 
2009). LDH is thought to be involved in the cellular production of energy during the 
hypoxic conditions of the tumour microenvironment (Agarwala et al., 2009). 
Elevated LDH serum levels reflect cellular apoptosis when part of the tumour 
outgrows its blood supply and thus correlate with tumour burden (Deichmann et al., 
1999, Agarwala et al., 2009). 
1.7.3 Prognostic factors not included in the current staging 
system 
In addition to the current staging criteria, both host and tumour related factors have 
been related to outcome. Host factors, such as age, gender and anatomical site of 
the tumour have shown independent prognostic significance as reviewed by 
Payette et al (Payette et al., 2009). In 2001, when the AJCC staging guidelines 
were updated for the 6th edition, it was reported that increasing age, male gender 
and tumours arising on the trunk, head, neck, palms, soles and under the nails 
were associated with worse prognosis, even for patients with stage III disease 
(Balch et al., 2001b). Despite their exclusion from the staging guidelines, these 
factors are taken into account in several studies reporting multivariable models to 
predict outcome from melanoma (Elder and Murphy, 2010). 
Tumour characteristics such as clinico-pathological subtype, vascular invasion, 
tumour-infiltrating lymphocytes and tumour regression have also emerged as 
potential prognostic factors, reviewed by Ross and Payette et al (Ross, 2006, 
Payette et al., 2009), but they are not part of the current staging guidelines.  
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1.7.4 Limitations of the current staging system 
Despite the efforts placed to accurately identify prognostic factors for patients with 
melanoma, the variance in survival within stage is still quite large and cannot be 
explained using the current prognostic factors (Ross, 2006). There is a proportion of 
low-risk tumours which progress to advanced disease (Slingluff et al., 1988) and 
which are supposed to be biologically different and potentially therefore identifiable 
using genomics. There is an increasing need to identify new prognostic biomarkers 
to enable better stratification of risk of metastasis for patients with melanoma but 
also enable early treatment intervention for those at high risk. 
 
1.8 New prognostic biomarkers 
Increasing numbers of new prognostic biomarkers for melanoma are now emerging 
but their clinical utility in large-scale studies is still unproven. Biomarker 
development includes 5 phases: preclinical exploratory studies; assay development 
and validation; retrospective longitudinal clinical repository studies; prospective 
screening studies; and randomized control trials (Pepe et al., 2001). An ideal 
biomarker should be measured easily, reliably and with low cost, by a sensitive and 
specific assay (Kulasingam and Diamandis, 2008). The following sections outline 
used and under investigation tumour and blood biomarkers in melanoma. 
 
1.9 Tumour biomarkers 
The histopathological features of primary melanoma, such as Breslow thickness, 
ulceration and mitotic rate are robust prognostic indicators, and therefore likely 
correlate well with key biological changes in tumours. Independent prognostic 
biomarkers, both germline and tumour, would however be valuable biomarkers, and 
would likely give key biological insights into the determinants of relapse 
(Bosserhoff, 2006).  
Many studies have attempted to identify new tumour prognostic biomarkers. 
However, none have managed to improve risk stratification (Gould Rothberg et al., 
2009). Techniques such as immunohistochemistry (IHC) for protein expression, 
microarrays for gene expression profiling and detection of copy number changes, 
and Sanger sequencing for mutation screening have been used. Most studies have 
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used small sample numbers and lack multivariable analyses, therefore validation 
studies need to be done to assess the prognostic significance of markers identified 
(Gogas et al., 2009, Gould Rothberg et al., 2009). Emerging technologies, such as 
next generation sequencing (NGS), are promising tools for the validation of 
previous studies and identification of novel biomarkers. 
NGS technologies offer the advantage of high-throughput, massively-parallel 
sequencing of the genome, transcriptome and epigenome (Meyerson et al., 2010). 
All NGS technologies utilise the sequential addition of nucleotides in immobilised 
DNA templates on glass slides (flow cells). After years of evolution, NGS systems 
since their first release in 2005-2006 show better performance in terms of sequence 
length (read length), accuracy, applications and informatics infrastructure (Liu et al., 
2012). These technologies have revolutionised cancer research allowing fast, high-
depth sequencing of cancer cells (Ding et al., 2010). A number of different 
analytical tools have been developed to allow a variety of biological questions to be 
addressed. At the same time the analysis of the large amount of data generated 
(>600GB per run of the Illumina HiSeq system) has been a major challenge in 
understanding the complex cancer genome (Ding et al., 2010). 
In this thesis, in Chapters 3 and 4, I report attempts to develop a next generation 
sequencing assay to identify copy number changes using formalin-fixed paraffin-
embedded (FFPE) specimens as a means of generation of prognostic biomarkers 
in patients with melanoma. 
1.9.1 Copy number alterations 
DNA copy number changes (losses or gains) are an important part of genetic 
variation which may involve very large proportions of the cancer genome. Copy 
number changes are defined as being larger than 1kb in size (Shlien and Malkin, 
2009). Germline DNA copy number changes are usually referred as copy number 
variations (CNVs) while somatic DNA copy number changes are referred as copy 
number alterations (CNAs). If a copy number change in a specific region is shown 
to be associated with a given cancer or prognosis for example, the genes located in 
that region are candidates for playing a role in tumour development and/or 
progression (Shlien and Malkin, 2009). As was discussed above however for driver 
mutations, genes identified may be “passengers” rather than playing a causal role. 
An example of a causal deletion is genomic DNA copy number loss in the 
chromosome arm 9p affecting the CDKN2A gene, as was discussed above (Kamb 
et al., 1994).  
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A large number of studies have been conducted to identify somatic CNAs in 
melanoma as a means to identify key biological changes (Table 1-2). In the past, 
karyotype analysis was the only whole-genome method to identify such changes. 
More recently, single nucleotide polymorphism (SNP) arrays, array comparative 
genomic hybridisation (aCGH) and NGS are used. Most whole-genome studies 
conducted so far have used tumour cell lines or frozen tumours but only a few used 
FFPE tissue (Table 1-2). Melanoma tumours are small and they are usually 
preserved in formalin rather than cryopreserved, so availability of frozen tissue is 
limited. In Table 1-2 I report CNAs identified in fresh-frozen and FFPE melanoma 
tumours, and human melanoma cell lines, through whole-genome analysis, and the 
reported associations with histological features or mutation status in a proportion of 
the studies. Frequent CNAs identified by whole-genome studies include losses in 
chromosomes 9 and 10 and gains in chromosomes 6, 7 and 11 (Table 1-2). An 
example of a recurrent focal copy number loss has been reported in 9p21 region 
where the CDKN2A gene is located (Lin et al., 2008, Gast et al., 2010). Studies 
using candidate approaches such as fluorescence in situ hybridisation (FISH) and 
multiplex ligation-dependent probe amplification (MLPA) assays have reported 
supportive information that the 9p21 region is frequently altered in melanoma 
tumour samples (Takata et al., 2005, Rakosy et al., 2008). 
A number of studies have also reported CNAs in different histological subtypes 
(Table 1-2). Bastian et al first identified different somatic copy number changes in 
acral melanomas compared to SSM (Bastian et al., 2000). Two further studies 
supported the view that melanoma is a heterogeneous disease with different 
genetic alterations identified in melanomas arising in sun-exposed sites versus 
those in sun-protected sites (Table 1-2) (Bastian et al., 2003, Curtin et al., 2005). In 
addition, a few studies have provided evidence that different CNAs are seen in 
melanomas with different mutations (Table 1-2). For example, it has been shown 
that BRAF mutation is associated with copy number loss in the 10q region where 
the PTEN gene is located (Jonsson et al., 2007, Gast et al., 2010). 
More recently, whole-exome NGS studies using cell lines or frozen tumours were 
conducted to identify recurrent mutations in melanoma but also reported the 
observed CNAs (Hodis et al., 2012, Krauthammer et al., 2012). For example, both 
studies reported losses in 9p and 10q and gain in 11q in the samples tested 
confirming previous studies (Table 1-2).  
 
 
 Table 1-2: Whole-genome studies reporting copy number alterations in melanoma tumour samples and human melanoma cell lines. 
Studies reporting frequent alterations in distinct histological subtypes and in BRAF/NRAS/PTEN mutated tumours or ulceration are also 
included. Chromosomal changes which were validated using a different method are highlighted in bold. Studies focusing on the identification 
of the heterogeneity or clonal evolution of melanoma are not included. Abbreviations used: MM (metastatic melanoma); FISH (fluorescence 
in situ hybridisation); CGH (comparative genomic hybridisation); SNP (single nucleotide polymorphism); TMA (tissue microarray); LMM 
(lentigo maligna melanoma); SSM (superficial spreading melanoma); CSD (chronic sun-induced damaged). 
Samples Methods Copy number losses Copy number gains Reference 
2 primaries & 15 MM Karyotype 1p, 6p 7q 
(Balaban et al., 
1984) 
8 MM  Karyotype 1p 1q, 6, 7  
(Limon et al., 
1988) 
11 primaries & 43 MM Karyotype 10 7 
(Parmiter et al., 
1988) 
1 primary & 10 MM Karyotype 1, 6, 9 7 
(Cowan et al., 
1988) 
158 MM Karyotype 
In all cases (>20%): 6, 10, 1, 7, 9 
In 49 near-diploid cases (>20%): 9, 10, 19, 22 
In 49 near-diploid cases (>20%): 7 
(Thompson et 
al., 1995) 
172 tumours 
(Data derived from a 
chromosome data bank) 
Karyotype 
(>15%): 1p21-36, 3, 4p35, 6q12-27, 8p10-23, 9p22-
24, 10, 11p15, 11q13, 11q22-25, 12q24, 13p11-13, 
13p34, 14p10-13, 15, 16 
(>15%): 1q10-44, 6p21-25, 7, 8, 20 
(Mertens et al., 
1997) 
3 MM cell lines 
CGH 
FISH (validation) 
In the highly metastatic line: 4, 9p21.3, 10p   
(Adam et al., 
2000) 
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 Samples Methods Copy number losses Copy number gains Reference 
1 primary short-term 
culture 
CGH 
Karyotype 
4q, 5q, 8p (in CGH only), 9p, 10, 11 
In karyotype only: 12p, 12q, 16q, 19 
5p, 8q, 13q (karyotype only) 
(Wiltshire et al., 
2001) 
46 primary and MM 
tumours (short-term 
cultures) 
CGH 
FISH (validation) 
(>30%): 4q, 6q, 9p, 10p/q, 11q 
(>30%): 6p, 7p/q, 17q, 20p/q 
(>20%): 3q26 (hTERC), 5p15.33 
(hTERT), 6p, 7p, 7q, 17q, 20p, 20q 
(Pirker et al., 
2003) 
68 FFPE tumours 
(19 BRAF mutated) 
aCGH 
FISH (validation) 
 
7q in 24 tumours 9 of which were BRAF 
mutated 
(Maldonado et 
al., 2003) 
NCI60 cell lines (8 
melanoma lines)/ 62 
tumours (qPCR)/179 
primary and metastasis 
TMAs (FISH) 
SNP array 
qPCR (validation) 
FISH (validation) 
 
3p13-14 (MITF) in 70.5% of lines 
 
Associated with MITF increased 
expression, metastasis & decreased 
overall survival (tumour samples) 
(Garraway et al., 
2005) 
30 microdissected 
tumours 
(15 AMs, 15 SSMs) 
CGH 
FISH (validation) 
*Tumour to normal 
ratio>1.5 including a 
whole chromosome 
not considered a gain 
In AMs (>40%): 6q  
In both AMs and SSMs (>40%): 9p, 10q 
 
In AMs (>20%): 5p15, 7p, 11q13, 22q11-
13 
 
(Bastian et al., 
2000) 
132 FFPE primaries CGH 
(>20%): 9p, 9q, 10q , 10p, 6q, 11q 
 
Frequent in acral vs non-acral melanomas: 6q23.1, 
15q13, 16q24 
Frequent in LLM vs SSM: 13q21.1, 17pter 
Frequent in non-CSD vs CSD melanomas: 10pter, 
10q22.2 
Frequent in CSD vs non-CSD melanomas: 17pter 
(>20%): 6p, 1q, 7p, 8q, 17q, 20q 
 
Frequent in acral vs non-acral 
melanomas: 5pter, 12q14, 4q11, 11q13.3 
Frequent in LLM vs SSM: 15q21.1, 17qter 
Frequent in CSD vs non-CSD melanomas: 
15q15 
 
(Bastian, 2003) 
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 Samples Methods Copy number losses Copy number gains Reference 
2 frozen tumours (acral 
primary & matched MM) 
SNP array 
WG-NGS 
aCGH 
FISH (validation) 
(In both primary and metastasis): 9p 
(In both the primary and metastasis): 4q12 
(KIT), 11q13, 11q14, 17p11, 20q11 
(Turajlic et al., 
2012) 
17 fresh primaries aCGH 
4q, 6q*, 7q, 9q, 10q* 11p, 14q, 15p, 17q, 20q, 21p 
(frequent in ulcerated tumours) 
*Losses were associated with gene expression in 
these locations 
3p, 6p, 7p/q, 8q, 11p/q, 15q, 16p, 17q, 
18q, 22q 
(frequent in ulcerated tumours) 
(Rakosy et al., 
2013) 
18 FFPE primaries aCGH 
9p & 10q (independent of prognosis),  
frequent focal losses (in patients with bad prognosis 
vs those with good) 
Frequent focal gains (in patients with bad 
prognosis vs those with good) 
(Hirsch et al., 
2013) 
102 FFPE primaries aCGH  
4q12 (c-KIT): (>20% in 
acral/mucosal/chronically sun-exposed 
tumours but not observed in non-
chronically sun exposed tumours) 
 
Associated with increased c-KIT protein 
levels 
(Curtin et al., 
2006) 
9 MM cell lines 
49 lines (PCR) 
CGH 
M-FISH 
Digital karyotyping 
PCR (validation) 
(>30%): 6q, 9p, 10q, Xp21.2 (DMD)* 
 
*Loss was associated with decreased DMD gene & 
protein expression 
(>30%): 1q, 6p, 7p/q, 20p/q, 22q, Xp/q 
 
(Korner et al., 
2007) 
8 primary and MM cell 
lines 
SNP array  
7q (in 6 lines of which 5 were BRAF 
mutated) 
(Spittle et al., 
2007) 
93 FFPE tumours 
aCGH publicly 
available data 
16q24.3 (MC1R) in 12.9% of samples (infrequent) 
16q24.3 (MC1R) in 7.5% of samples 
(infrequent) 
(Kim et al., 2008) 
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 Samples Methods Copy number losses Copy number gains Reference 
83 tumours and  
cell lines (aCGH) 
38 TMA cores from 
primary and metastatic 
tumours (FISH) 
aCGH data available 
(Maser et al., 2007) 
FISH (validation) 
 
5p13 (GOLPH3) (3.4% of samples on 
aCGH and 31.6% on TMA cores) 
Associated with increased GOLPH3 gene 
expression 
(Scott et al., 
2009) 
14 MM tumour cell lines 
SNP array 
qPCR (validation) 
 
7q31-34 (mir-182 cluster, cMET, BRAF) 
(53.8%) 
Associated with increased mir-182 
expression 
 
(Segura et al., 
2009) 
52 patient-derived 
primary and MM cell 
lines/ 43 frozen MM 
tumours 
aCGH data 
(Greshock et al., 
2009) 
 
(>20%) : 6p21.32* (MHC Class I & II 
genes)  
*associated with MHC Class I & II gene 
expression in VGP cell lines only 
(Degenhardt et 
al., 2010) 
18 MM cell lines 
22 FFPE MM (FISH) 
SNP array 
qPCR (validation) 
 
(>40%): 5p13.2* (SKP2) 
*associated with increased SKP2 protein 
expression 
 
(Rose et al., 
2011) 
5 frozen MM (mucosal) 
Whole-genome NGS 
SNP array 
 1q, 8q 
(Furney et al., 
2013) 
150 melanomas (101 
short-term cultures and 
cell lines) (SNP array) 
42 TMAs (FISH) 
SNP array data 
((Beroukhim et al., 
2010)) 
FISH (validation) 
 
(>40%): 1p12* (PHGDH) 
*Gain associated with increased PHGDH 
protein expression 
(Locasale et al., 
2011) 
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 Samples Methods Copy number losses Copy number gains Reference 
101 MM short-term 
cultures (SNP array)/ 
70 FFPE primaries 
(aCGH) 
SNP array 
aCGH (validation 
dataset (Curtin et al., 
2005)) 
Most frequent: 9p21 (CDKN2A), 10q23* (PTEN, 
CUL2, KLF6) 
*Association with PTEN, CUL2, KLF6 gene 
expression 
 
General pattern of losses validated in aCGH tumour 
data 
 
Most frequent: 7q34* (BRAF), 3p13 
(MITF), 11q13 (CCND1)  
*Associated with BRAF mutations 
General pattern of gains validated in 
aCGH tumour data (3p13 gain not 
frequent in tumour data) 
 
(Lin et al., 2008) 
47 cell lines (SNP array) 
130 FFPE primaries 
(aCGH) 
SNP array 
aCGH (validation 
dataset (Curtin et al., 
2005)) 
 
(>20% in tumours but not frequent in 
lines): 7p22 (Epo), 19p13 (EpoR) 
Both associated with acral/mucosal 
melanomas 
(Kumar et al., 
2012) 
60 patient-derived MM 
cell lines 
SNP array 
9p21* (CDKN2A), 10q23** (PTEN), 17p*** (TP53) 
*associated with lack of expression and was 
independent of BRAF/NRAS mutation status 
**associated with BRAF mutation 
***associated with NRAS mutations 
7q* (BRAF), 11q** (CCND1), 12q** 
(CDK4),  
*associated with BRAF mutation 
**associated with wild-type BRAF/NRAS 
 
(Gast et al., 
2010) 
47 cell lines 
(1 primary & 46 MM) 
aCGH 
(>50%): 4p/q, 6q, 8p, 9p*, 10p/q***, 11q** 
*associated with PTEN mutation 
**associated with BRAF mutation 
***associated with both BRAF and PTEN mutations 
(>50%): 1q, 7p/q*, 8q, 17q, 20q 
*associated with BRAF mutation 
(Jonsson et al., 
2007) 
52 patient-derived 
primary and MM tumour 
cell lines/ 43 frozen 
metastatic tumours 
aCGH 
11q24-25*, 16q21-qter** 
*Associated with NRAS mutation 
**Associated with BRAF mutation 
5p15, 7q32-33 
Both associated with BRAF mutation  
(Greshock et al., 
2009) 
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 Samples Methods Copy number losses Copy number gains Reference 
76 primary and MM cell 
lines 
SNP array 
(>40%): 6q, 9p/q, 10p/q, 11q, 17q 
Frequent focal copy number losses (>50%) included 
9p21 (CDKN2A),  10q23 (PTEN) 
(>20%): 2p, 6p, 7p/q, 19q, 20p, 20q, and 
22q 
(>12%): 3p13 (MITF) 
(Stark and 
Hayward, 2007) 
85 frozen tumours 
(23 from sun-protected 
sites)  
aCGH 
FISH (validation) 
 
(6%):4q12 (KIT), (9%): 11q14 (GAB2)* 
Both associated with tumours in sun-
protected sites 
*Independent of BRAF/NRAS/KIT 
mutations 
*Associated with increased protein 
expression 
(Chernoff et al., 
2009) 
126 FFPE primaries aCGH 
3q*, 4q* 8p*, 10**, 11p* 
 
*Associated with mucosal melanomas 
**Associated with acral/mucosal and tumours on 
skin without sun-induced damage  
1q*, 6p**, 11q13**, 17q*** 
 
*Associated with acral tumours 
**Associated with mucosal & acral 
tumours 
Associated with mucosal melanoma 
(Curtin et al., 
2005) 
121 frozen 
tumour/normal blood 
pairs (15 primaries, 30 
MM, 76 short-term 
cultures from MM) 
Whole-exome NGS 
Most frequent: 4q22.1, 4q.35.1, 5p11.2, 9p21.3 
(CDKN2A), 10q23.31 (PTEN) 
Most frequent: 2q21.2, 7q.34, 5p15.33 
(TERT), 7q34, 11q13.2 (CCND1),   
(Hodis et al., 
2012) 
68 primary and MM cell 
lines/31 primaries and 
MM frozen tumours 
Whole-exome NGS (>10%): 9p21, 10p12, 10q11  (>10%): 1q31, 5p13, 11q14 
(Krauthammer et 
al., 2012) 
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The findings reported in Table 1-2 provide support that there are distinct molecular 
pathways in subsets of melanomas driven by different genetic alterations. Relating 
such genetic alterations to prognosis might improve prognostication in melanoma 
and help in the development of new targeted therapies. In the next section, I will 
review the studies addressing the prognostic significance of CNAs in melanoma. 
1.9.1.1 Copy number alterations and prognosis 
Only a small number of studies have explored the prognostic significance of CNAs 
in melanoma. Some studies have reported differences in CNAs between primary 
and metastatic samples, relapsers and non-relapsers, while a couple associated 
CNAs with relapse-free survival (RFS) or overall survival (OS). These studies often 
lacked validation in independent datasets or multivariable analysis which is 
important to identify if the reported marker adds to the current staging system 
(McShane et al., 2005). It has been reported that chromosomes 1 and 7 are often 
gained in metastatic tissue (Udart et al., 2001, Lee et al., 2001) while a more recent 
study reported that CCND1 gain (located in 11q13) and MYC gain (located in 8q34) 
were associated with worse overall survival in 107 primary melanomas (Gerami et 
al., 2011). The EGFR gene, which is located in 7p12, was reported to be amplified 
in relapsers within 5 years of diagnosis compared to non-relapsers within 5 years 
(Rakosy et al., 2007). However, a different study reported that EGFR amplification 
was not associated with RFS or OS (Boone et al., 2011). Chromosome gain in 
3p14 where microphthalmia-associated transcription factor (MITF) is located has 
also been reported to be associated with disease-free survival (DFS) in 104 
metastatic tumours (Ugurel et al., 2007) and worse OS in 160 metastatic tumours 
(Garraway et al., 2005). All studies reporting CNAs associated with melanoma 
prognosis are listed in Table 1-3. 
Most studies have reported the use of candidate molecular cytogenetic assays, 
such as FISH, and studies using whole genome approaches have been limited 
(Table 1-3). In Chapter 4 I describe the use of whole-genome NGS sequencing 
using FFPE melanoma tumours which could be used for the identification of 
somatic genetic alterations associated with prognosis. 
 
 Table 1-3: Copy number alterations and melanoma prognosis. 
Abbreviations used: FISH (fluorescence in situ hybridisation); aCGH (array comparative genomic hybridisation); SNP (single nucleotide 
polymorphism), MLPA (multiplex ligation-dependent probe amplification); RFS (relapse-free survival); OS (overall survival); DFS (disease-
free survival); DSS (disease-specific survival); HD (homozygous deletion). 
Samples Methods Outcome measure Result Reference 
97 FFPE primaries  
FISH (6q25, 6q23, 11q13, 
9p21, 8q24, 20q13) 
Relapse status 
11q13 (CCND1) & 8q34 (MYC) gains were 
associated with tumours who metastasized 
even in multivariable analysis 
(Gerami et al., 
2011) 
104 frozen MM qRT-PCR (MITF) DSS (univariable analysis) MITF gain (>3 copies) associated with DSS   
(Ugurel et al., 
2007) 
20 FFPE primaries Metaphase CGH OS (univariable analysis) 
1q or 6p gains were associated with worse 
OS 
(Namiki et al., 
2005) 
144 FFPE primaries FISH (6p25, 6q23, 11q13) DFS/DSS 
Gain in all three loci was associated with 
worse survival rates (remained independent 
predictors in multivariable analysis) 
(North et al., 
2011) 
20 FFPE primaries aCGH 
Good prognosis (median 
survival 14.5 years) vs bad 
prognosis group (median 
survival 4 years) 
Chromothripsis & focal amplifications were 
associated with the bad prognosis group  
(Hirsch et al., 
2013) 
160 TMA MM FISH OS (5-year follow up) 
MITF gain associated with worse prognosis 
(not significant when analysis adjusted for 
Breslow (missing for some data)) 
(Garraway et 
al., 2005) 
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 Samples Methods Outcome measure Result Reference 
75 FFPE primaries 
MLPA (3 probes for CDKN2A, 
1 for MTAP) 
Relapse status 
(univariable analysis) 
CDKN2A loss associated with relapse status  
(Conway et al., 
2010) 
81 fresh primaries Interphase FISH-7q12 (EGFR) 
Relapse status 
Survival status (within 5 years) 
EGFR gain was associated with relapse 
status but not associated with patients who 
survived within 5 years versus those 
who did not 
(Rakosy et al., 
2007) 
94 FFPE primaries FISH DFS/OS 
EGFR gain was not associated with DFS/OS 
however associated with  thicker tumours & 
positive SNB  
(Boone et al., 
2011) 
18 frozen primaries vs 41 
frozen MM 
FISH Progression 
Chromosome 7 gain was associated with 
progression 
(Udart et al., 
2001) 
21 FFPE melanomas in situ vs 
21 invasive vs 21MM 
Colorimetric ISH-1q12 
microsatellite III DNA 
Progression 
Chromosome 1 gain was associated with 
progression 
(Lee et al., 
2001)  
4 pairs of primary and MM 
tumours and 1 pair of a 
patient-derived cell line 
SNP array Progression 
This study provides evidence for a non-linear 
model for melanoma progression through 
identification of HD found in primaries and not 
in matched MM 
(Swoboda et al., 
2011) 
2
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1.9.2 Gene expression profiling 
With the development of DNA microarrays, several studies have been performed to 
identify gene expression signatures of prognostic significance in melanoma. A 
number of them showed that overexpression of genes involved in DNA repair 
pathways or cell cycle/division correlated with tumour progression and poorer 
outcome (Jaeger et al., 2007, Kauffmann et al., 2008, Winnepenninckx et al., 2006, 
Ryu et al., 2007, Jonsson et al., 2010), and overexpression of genes involved in cell 
adhesion and invasion correlated with tumour progression (Busam et al., 2005, 
Haqq et al., 2005, Jaeger et al., 2007, Mandruzzato et al., 2006, Ryu et al., 2007, 
Talantov et al., 2005). Other studies showed that overexpression of immune-related 
genes are associated with better outcome (Jonsson et al., 2010, Mandruzzato et 
al., 2006). Most of these studies have used small numbers of frozen tumours or cell 
lines. The introduction of the gene expression profiling technology using FFPE 
samples made it possible to study the biology of melanoma. The Leeds group has 
used the cDNA-mediated Annealing, Selection, extension, and Ligation (DASL) 
microarray cancer chip (502 genes), which is specifically designed for FFPE tissue 
in a large dataset, and showed that increased expression of osteopontin and DNA 
repair genes (RAD51, RAD52, TOP2A) is associated with worse relapse-free 
survival and overall survival (Conway et al., 2009, Jewell et al., 2010). In Chapter 4, 
I report the use of the whole genome DASL assay and describe an attempt to 
integrate copy number with gene expression data as a means to corroborate the 
results derived from the copy number data. 
As technology develops, RNA-sequencing where cDNA (synthesized from RNA) is 
sequenced using NGS is likely to become the lead technology to identify altered 
gene expression levels associated with prognosis as it offers the advantage to 
detect alternative splice variants and transcripts from gene fusion events compared 
to traditional microarray approaches (Meyerson et al., 2010). In Chapter 2, I 
describe the successful sample preparation (cDNA libraries) from matched frozen 
and FFPE cell line melanoma samples as a means to evaluate the feasibility to use 
FFPE samples for RNA-sequencing. 
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1.10 Biomarkers in serum and plasma 
As discussed in section 1.7.2.2, serum LDH is elevated in advanced stage patients 
and is the only serum marker which has been included in the AJCC staging system 
(Balch et al., 2009). Serum S100B and melanoma inhibiting activity (MIA), both 
melanocyte lineage/differentiation antigens produced by melanoma cells have been 
implemented in the clinic to monitor disease progression in many European 
countries but not in the UK (Gogas et al., 2009, Palmer et al., 2011). S100B was 
reported to be associated with worse overall survival in a meta-analysis of 22 
studies, however there were issues related to different assays and different cut-off 
values in those different studies (Mocellin et al., 2008). A study comparing S100B, 
LDH, MIA and albumin has revealed that S100B was superior to the other markers 
tested to detect newly diagnosed metastases while MIA provided no additional 
benefit over the other markers (Krahn et al., 2001). The use of S100B and MIA 
have been studied as early indicators of tumour progression or relapse, but neither 
showed prognostic significance in early stage melanoma patients (Stahlecker et al., 
2000, Acland et al., 2002). A number of other potential serum biomarkers have 
been tested but none has been found to be superior to LDH and S100B or add 
prognostic information in early stage disease patients (Gogas et al., 2009, Palmer 
et al., 2011). In the future, serum proteomic profiling may serve as a means to 
identify new prognostic biomarkers in melanoma. Serum Amyloid A (expressed in 
response to inflammatory stimuli) came up as a potential prognostic marker from 
such a study in stage I-III disease (Findeisen et al., 2009). Recently, osteopontin 
was measured in plasma samples from melanoma patients to identify its prognostic 
value (Kluger et al., 2011, Maier et al., 2012). These studies are reviewed in 
Chapter 6, where I also report a study designed to identify if plasma osteopontin 
concentrations are of prognostic value in stage I-III patients from the Leeds 
Melanoma Cohort, which was recently published (Filia et al., 2013). 
 
1.11 Treatment of melanoma 
Patients with no evidence of metastasis (stage I-II) undergo surgical removal of the 
primary lesion. For patients with evidence of nodal disease (stage III) after surgical 
removal of the primary lesion complete lymphadenectomy is performed. For 
patients with thin tumours (stage I-IIA) prognosis is excellent (Balch et al., 2009). 
However patients with thick tumours and nodal disease (stage IIB-III) have a high 
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risk of relapse (5-year survival rates 24-67.4%) (Table 1-1) and they may be 
counselled about adjuvant treatment within a clinical trial. Adjuvant treatment by 
definition is designed to reduce the risk of relapse. For patients with stage IV 
disease the 5-year survival rate is much lower (6.7-18.8%) (Table 1-1) and 
chemotherapy and radiotherapy treatment has been used with very few long-term 
survivors (Lorigan et al., 2008). More recently, more effective drugs have been 
tested in stage IV patients including BRAF inhibitors, and immunotherapies such as 
antibodies to co-inhibitory molecules such as CTLA4 and PDL-1 (Eggermont and 
Robert, 2012). 
 
1.12 Adjuvant therapies  
Most of the adjuvant therapies have been trialled in melanoma patients with not 
very promising results (Molife and Hancock, 2002, Eggermont et al., 2009) except 
for IFN-α and Ipilimumab (anti-CTLA4) (Davar et al., 2012, Eggermont and Robert, 
2011). Anti- PDL-1 treatment is currently being evaluated. 
Interferons (IFN) inhibit proliferation, but also enhance immune recognition of 
tumour cells (Davar et al., 2012). IFN-α is an FDA-approved drug which is used in 
the US and in Europe but not in the UK as the toxicities are perceived to outweigh 
the small survival benefit reported in meta-analyses (Mocellin et al., 2010).  
Expression of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) causes 
inhibition of T cell activation and proliferation (Eggermont and Robert, 2011). In the 
adjuvant setting, a phase-II clinical trial reported survival benefit in resected stage 
III/IV patients (Sarnaik et al., 2011) while an EORTC phase-III clinical trial is on-
going to further assess the use of Ipilimumab in high-risk stage III patients 
(Eggermont and Robert, 2011). 
Identification of new adjuvant therapies is needed and also, biomarkers that could 
predict benefit from them. Vitamin D is a potential new adjuvant therapy on the 
basis of data published that low vitamin D levels at diagnosis are associated with 
thicker tumours and poorer prognosis even if data are adjusted for thickness 
(Newton-Bishop et al., 2009) and predictive biomarkers could identify patients that 
could benefit from it. In the next sections I give an overview of what is known about 
the role of vitamin D in melanoma to justify why it is at least a potential candidate as 
an adjuvant therapy. 
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1.12.1 Vitamin D  
Vitamin D is a fat-soluble hormone which is essential to human health; it plays a 
role in calcium and phosphate intestinal absorption and transport and bone 
homeostasis (Lieben and Carmeliet, 2013). Vitamin D is synthesized in the skin in 
response to UVB irradiation (sun exposure) (Holick, 2003).  
The importance of sunlight and resultant vitamin D in human health was well 
illustrated when vitamin D deficiency was recognised to result in rickets, a disease 
which affects bone development in children (Holick, 2004). Rickets was very 
common among children during the 19th century which resulted in vitamin D food 
fortification. But after World War II the absence of monitoring of the fortification 
process led to hypercalcemia (vitamin D intoxication) in children and as a result 
vitamin D fortification of dairy products was banned in many European countries 
(Holick, 2004). In recent years, there has been an increase in cases of rickets 
especially in dark-skinned people who live in less sunny countries which has fuelled 
the interest to study the effect of vitamin D in bone health and in health in general 
(Field and Newton-Bishop, 2011). 
Epidemiological studies, reviewed by Holick and Field and Newton-Bishop (Holick, 
2004, Field and Newton-Bishop, 2011), have reported evidence that higher vitamin 
D levels are associated with the risk of cardiovascular disease, autoimmune 
diseases, and cancers. Experimental in vitro and in vivo data, reviewed by Mullin 
and Dobs and Deeb et al (Mullin and Dobs, 2007, Deeb et al., 2007), support the 
view that vitamin D has also anti-tumour effects through regulation of proliferation, 
angiogenesis and induction of apoptosis. These effects have been studied in many 
cancers but data are limited in melanoma. 
In this section I will discuss the role of vitamin D and epidemiological studies 
designed to identify an association between vitamin D and melanoma. 
1.12.1.1 Metabolism 
The active form of vitamin D (1α,25(OH)2D3) comes from the diet but mostly is 
synthesized in the skin in response to sun exposure. The vitamin D2 and vitamin D3 
forms also come into blood circulation from the intestinal absorption of food 
(predominantly oily fish but also eggs and fortified foods). The vitamin D3 form is 
also synthesised though conversion of 7-dehydrocholesterol to pre-vitamin D3 
followed by conversion to vitamin D3 in the skin when exposed to sunlight (Holick, 
2003). Vitamin D3 is bound to vitamin D binding protein and transported to the liver 
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where vitamin D3 is converted to 25(OH)D3 through 25-hydroxylase (coded by 
CYP27A1) (Deeb et al., 2007). 25(OH)D3 is then transported to the kidney, and the 
active form of vitamin D (1α,25(OH)2D3) is released by 1α-hydroxylase (coded by 
CYP27B1) (Deeb et al., 2007). The negative regulation of synthesis of the active 
form is mediated though 24-hydroxylase (coded by CYP24A1) which converts 
25(OH)D3 and 1α,25(OH)2D3 to their inactive forms and through the repression of 
parathyroid hormone by 1α,25(OH)2D3, which normally promotes the synthesis of 
the active form (Deeb et al., 2007) (Figure 1-3). 
1.12.1.2 Dual role of 1α,25(OH)2D3 
The genomic effect of 1α,25(OH)2D3 is mediated through binding to the heterodimer 
vitamin D receptor (VDR)-retinoid X receptor (RXR) complex. The 1α,25(OH)2D3-
VDR-RXR complex binds to vitamin D response elements (VDREs), sequences 
located in the promoter of target genes to promote their transcriptional activation or 
repression (Figure 1-4) (Campbell et al., 2010). 
1α,25(OH)2D3 has also a rapid, non-genomic effect through regulation of calcium 
channels and activation of cytoplasmic kinases such as MAPK (Campbell et al., 
2010, Haussler et al., 2011). The activation of pathways through the rapid 
mechanisms of 1α,25(OH)2D3 has been postulated to cross-interact with other 
pathways to affect gene transcription (Figure 1-4)  (Deeb et al., 2007, Haussler et 
al., 2011). 
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Figure 1-3: Vitamin D metabolism and biological effects. 
The vitamin D3 form is synthesised in the skin when exposed to sunlight. The 
vitamin D2 and vitamin D3 forms come into blood circulation from the intestinal 
absorption of food. Vitamin D3 is transported to the liver where vitamin D3 is 
converted to 25(OH)D3 through 25-hydroxylase. 25(OH)D3 is then transported 
to the kidney, and the active form of vitamin D (1α,25(OH)2D3) is released by 
1α-hydroxylase. The negative regulation of synthesis of the active form is 
mediated though 24-hydroxylase which converts 25(OH)D3 and 
1α,25(OH)2D3 to their inactive forms and through the repression of parathyroid 
hormone by 1α,25(OH)2D3, which normally promotes the synthesis of the 
active of form. The main effects of 1α,25(OH)2D3 on different tissues are 
shown. Adapted from (Deeb et al., 2007, Field and Newton-Bishop, 2011). 
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Figure 1-4: Transcriptional regulation in response to vitamin D3. 
The genomic effect of 1α,25(OH)2D3 is mediated through binding to the 
heterodimer VDR-RXR complex. The 1α,25(OH)2D3-VDR-RXR complex binds 
to vitamin D response elements (VDREs), sequences located in the promoter 
of target genes to regulate transcription. The non-genomic effect of 
1α,25(OH)2D3 is postulated to be mediated through an alternative membrane 
or cytosolic VDR or through binding to G-coupled proteins which promote 
regulation of calcium channels and activation of cytoplasmic kinases such as 
MAPK. The activation of pathways through the non-genomic mechanisms of 
1α,25(OH)2D3 may cross-interact with the classical genomic pathway to affect 
gene transcription. 
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1.12.1.3 The epidemiology of vitamin D and cancer 
There has been an interest in the role of vitamin D and cancer risk for many years, 
in particular following an observation of lower cancer risks in individuals living in 
areas of the USA with higher sun exposure than those living in areas with lower 
exposure (Garland and Garland, 1980). That vitamin D has been shown to be anti-
proliferative in vitro fuelled this interest. 
Vitamin D levels are measured as serum 25(OH)D2 or 25(OH)D3 by most 
laboratories as the active form, 1α,25(OH)2D3, has a short half-life (<4 hours). The 
relationship between serum levels and cancer risk or survival in different cancers 
has been extensively studied but data in melanoma are limited. A meta-analysis of 
seven studies performed by Chen et al reported an association of lower serum 
25(OH)D3 levels and increased risk of breast cancer (Chen et al., 2010). An 
association was also reported between higher serum 25(OH)D3 levels and 
decreased risk of colorectal cancer (Jenab et al., 2010) and better prognosis 
(Mezawa et al., 2010).  
1.12.1.4 Vitamin D and susceptibility to melanoma 
There is no doubt that sun exposure is associated with melanoma susceptibility, 
although this relationship has proven complex (Gandini et al., 2005b). Intermittent 
sun exposure related to sunburns but not cumulative sun exposure has been 
reported as a risk factor for melanoma (Newton-Bishop and Randerson-Moor, 2013, 
Field and Newton-Bishop, 2011). It has also been reported that occupational sun 
exposure and regular weekend sun exposure have even shown a protective effect 
(Gandini et al., 2005b). The observation of a possible protective effect of regular 
sun exposure suggests that regular moderate sun exposure might be protective 
because of increased levels of vitamin D or photoadaptation, related to a decreased 
risk of sunburns (Newton-Bishop and Randerson-Moor, 2013, Field and Newton-
Bishop, 2011). The reported association between risk and genetic polymorphisms, 
such as the VDR SNPs, have also shown some support for a relationship between 
vitamin D levels and risk (Randerson-Moor et al., 2009, Newton-Bishop and 
Randerson-Moor, 2013). Further support for that relationship is provided by 
biological studies showing that vitamin D has anti-proliferative effects on melanoma 
cells in vitro (Table 1-4). The anti-proliferative and other anti-tumour effects of 
vitamin D on melanoma and other cancer cells are further discussed in section 
1.12.2.  
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1.12.1.5 Vitamin D and outcome from melanoma 
An association between higher serum vitamin D levels and better survival from 
melanoma and thinner tumours exists as reported by the Leeds group (Newton-
Bishop et al., 2009). This association was supported by a subsequent small study 
which showed that vitamin D levels are protective in stage IV melanoma patients 
(Nurnberg et al., 2009). The lack of large cohort studies with stored serum samples 
means that such associations have not been validated to date. The concern around 
these data is that thinner, healthier and more active people have higher vitamin D 
levels suggesting that high vitamin D levels might depict healthier life styles 
generally (Field and Newton-Bishop, 2011), and that in the 2009 Leeds study higher 
vitamin D levels might be acting as marker of healthier lifestyles rather than being 
causally related to melanoma survival. Biological studies have been performed 
however and demonstrate that vitamin D has anti-tumour effects in vitro and in vivo 
but data on melanoma models are limited (Deeb et al., 2007). As further evidence 
from such studies become available clinical trials could be set up to define the right 
vitamin D dose and identify the effect that vitamin D supplementation could have as 
an adjuvant therapy for melanoma. To date there are only two clinical trials 
currently recruiting patients. Understanding the anti-tumour effects of 1α,25(OH)2D3 
in melanoma could also lead to the identification of predictive biomarkers that would 
show likely benefits to vitamin D supplementation. 
1.12.2 Anti-tumour effects of 1α,25(OH)2D3 
The anti-tumour effects of the active form of vitamin D 1α,25(OH)2D3 or other non-
calcaemic analogues have been reported in different cancers in in vitro and in vivo 
models (reviewed by (Deeb et al., 2007, Fleet et al., 2012). It is reported that 
1α,25(OH)2D3 plays a role in proliferation, apoptosis, angiogenesis, autophagy and 
immune response pathways. The diverse role of 1α,25(OH)2D3 in melanoma still 
needs further elucidation as studies have been limited to its anti-proliferative role 
(summarized in Table 1-4).  
Gene expression experiments after 1α,25(OH)2D3 treatment have been performed 
in different cancers to confirm the anti-tumour effects but also identify the 
mechanisms of these effects. These studies have identified a number of 
1α,25(OH)2D3 target genes (reviewed by (Deeb et al., 2007, Fleet et al., 2012). 
Some of the reported 1α,25(OH)2D3 target genes contained VDREs in their 
promoters but others did not (Deeb et al., 2007, Osborne and Hutchinson, 2002), 
suggesting a VDR independent action. Supportive evidence of a VDR independent 
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action was shown in that 1α,25(OH)2D3 continued to have an anti-proliferative effect 
when VDR was knocked down in breast cancer cells (Costa et al., 2009). 
 
Table 1-4: Summary of in vitro and in vivo experiments to assess potential 
anti-tumour effects of 1α,25(OH)2D3 or other vitamin D-analogue treated 
melanoma cells compared to untreated cells. 
Cell line/xenograft Effect Reference 
MM96 Growth inhibition (Frampton et al., 1983) 
RPMI 7932 xenograft Unaffected growth (Eisman et al., 1987) 
COLO 239F xenograft Growth inhibition (Eisman et al., 1987) 
SkMel28 Growth inhibition 
(Evans et al., 1996, Reichrath et 
al., 2007) 
RPMI7951 Growth inhibition (Evans et al., 1996) 
WM1341 
Unaffected 
growth/small induction 
of apoptosis 
(Danielsson et al., 1998, 
Danielsson et al., 1999) 
MeWo 
Growth inhibition/no 
induction of apoptosis 
(Danielsson et al., 1998, 
Danielsson et al., 1999, Seifert et 
al., 2004, Reichrath et al., 2007) 
ME18 Growth inhibition (Gruber and Anuszewska, 2002) 
SkMel5 Unaffected growth  
(Seifert et al., 2004, Reichrath et 
al., 2007) 
SM Growth inhibition (Reichrath et al., 2007) 
IGR Unaffected growth (Reichrath et al., 2007) 
MelJuso Unaffected growth (Reichrath et al., 2007) 
SkMel188 Growth inhibition 
(Slominski et al., 2011, Li et al., 
2010, Janjetovic et al., 2011) 
A375 Growth inhibition (Ishibashi et al., 2012) 
 
1.12.3 Gene expression studies in response to vitamin D in 
melanoma cells 
Functional and gene expression studies in response to 1α,25(OH)2D3 have been 
relatively limited in melanoma and here I give an overview of these studies. Seifert 
et al have demonstrated that gene expression of VDR and CYP24A1, coding for the 
vitamin D degradation protein, is increased in response to 1α,25(OH)2D3 in vitamin 
D-sensitive cells but not in vitamin-D resistant cells (Seifert et al., 2004), indicating 
a VDR-mediated effect. Evidence that Peroxisome Proliferator-Activated Receptor 
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(PPAR) signalling decreases the metastatic potential of melanoma cells (Grabacka 
et al., 2006), and the fact that both VDR and PPAR form a heterodimer with RXR, 
has led to the investigation of PPAR signalling when cells are treated with 
1α,25(OH)2D3 (Sertznig et al., 2009b). Sertznig et al showed that VDR and PPARα 
gene expression is increased after 1α,25(OH)2D3 treatment in vitamin D-sensitive 
cells compared to the resistant cells (Sertznig et al., 2009b) suggesting a potential 
activation of both the VDR and PPAR signalling pathways in response to vitamin D. 
A further study by the same group showed an increase in expression of the 
1α,25(OH)2D3-induced CYP24A1 gene in MeWo vitamin D sensitive cells when 
treated with both 1α,25(OH)2D3 and PPAR ligand DHA compared to vehicle-treated 
cells. This induction of CYP24A1 was significantly lower compared to cells treated 
with 1α,25(OH)2D3 alone (Sertznig et al., 2009a). They suggested a potential cross-
talk between the VDR and PPAR signalling pathways but not at the level of cell 
proliferation, as similar levels of reduction in cell proliferation were seen in response 
to 1α,25(OH)2D3 alone, or in combination with PPAR ligand DHA (Sertznig et al., 
2009a). Further studies need to be done to investigate the potential cross-talk 
between these two signalling pathways. Sertznig et al also showed that 
1α,25(OH)2D3 might have a pro-apoptotic action when RNA and protein expression 
of CLU (Clusterin), a pro-apoptotic gene, was increased in response to 
1α,25(OH)2D3 in vitamin D sensitive cells compared to resistant cells (Shannan et 
al., 2006). Another study suggested an anti-tumour effect of 1α,25(OH)2D3 through 
repression of cytokine IL-8 at transcriptional level, mediated through NF-κB in 
melanoma cell line A3 (Harant et al., 1997). In 1988, a study showed that mRNA 
and protein levels of HLA-class II DRa are downregulated after 1α,25(OH)2D3 
treatment, showing a role for 1α,25(OH)2D3 in differentiation and immune response 
in melanoma cell lineages (Carrington et al., 1988). A more recent study published 
that 1α,25(OH)2D3 mediates its anti-tumour effects in vitamin D resistant cells 
through the immune system, with enhancement of Fas expression on the surface of 
melanoma cells and increase of caspase sensitivity to Fas-mediated apoptotic 
pathway by natural killer (NK) cells (Lee et al., 2011). Interestingly, a synergistic 
effect of 1α,25(OH)2D3 and trichostatin A (a demethylating agent) was reported in 
vitamin D resistant cells IGR, suggesting that an epigenetic mechanism might be 
involved in vitamin D resistance (Essa et al., 2010). In the same study it was 
reported that micro-RNA mir-125b expression was inversely correlated with VDR 
expression in vitamin D sensitive cells (Essa et al., 2010). It has been shown that 
VDR expression is regulated by mir-125b at a post-transcriptional level (Mohri et al., 
2009).  
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Supportive data that vitamin D has anti-tumour effects through different pathways 
such as proliferation, apoptosis and immune response has been shown in other 
cancers, reviewed by (Deeb et al., 2007). The vitamin D effect in cancer cells 
generally and specifically in melanoma cells however appears diverse, based on 
the above studies, and the information derived generally from a candidate approach 
to understanding the biological events rather than an agnostic one. In Chapter 5 I 
will describe my approach to validate previous findings, and possibly identify novel 
mechanisms of vitamin D anti-tumour effects by generating whole-genome gene 
expression data from two vitamin D responsive melanoma cell lines cultured with 
and in the absence of vitamin D. 
 
1.13 The use of FFPE tumour tissue for genomic and 
transcriptomic analysis 
As previously discussed primary melanomas are small and routinely fixed in 
formalin. Formalin-fixed tumours are then embedded in paraffin wax blocks to allow 
sections to be taken for staining and histological examination to assess features of 
prognostic significance, such as Breslow thickness and mitotic rate. Formalin is a 
fixative which causes chemical modifications of proteins and other tissue 
constituents to preserve the tissue in a close approximation of the in vivo state 
(Frankel, 2012, Srinivasan et al., 2002). The negative effects of formalin which 
affect the quality and quantity of nucleic acids have well been described: formation 
of cross-links between nucleic acids and proteins; addition of methylol groups in 
adenine and thymine in particular; random breaks in the nucleotide sequence 
(Frankel, 2012, Srinivasan et al., 2002). For these reasons the use of FFPE blocks 
for genomics has been limited in the past. Some of the effects of formalin are 
reversible. Cross-links are reversible through thorough proteinase K digestion and 
therefore nucleic acid yields can be improved although they will be lower than those 
from frozen tissue (Frankel, 2012). The addition of methylol groups in adenine in 
particular can prevent effective reverse transcription of RNA caused by alteration of 
the poly-A tail but the use of random instead of oligo(dT) primers in cDNA synthesis 
may overcome this problem (Frankel, 2012, Srinivasan et al., 2002). Nucleic acids 
fragmentation remains an issue, though. The development of new techniques is 
enabling the study of fragmented nucleic acids. This thesis reports use of NGS 
technology for DNA sequencing to identify CNAs and DASL assay to assess gene 
expression in FFPE melanoma samples. DASL is specifically designed for use with 
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degraded RNA and has been shown to produce reproducible results (Bibikova et 
al., 2004, Ravo et al., 2008, Conway et al., 2009). NGS technology utilises DNA 
sequencing of short fragments and recent studies have reported the successful 
generation of NGS data using low yields of DNA extracted from FFPE tumour 
samples (Wood et al., 2010, Belvedere et al., 2012). Using whole-genome NGS, 
Wood et al and Schweiger et al have reported reproducible CNAs between FFPE 
and frozen tumours (Schweiger et al., 2009, Wood et al., 2010). These results are 
promising but further investigation is needed to evaluate the feasibility of NGS 
technology to be used for the identification of prognostic and predictive biomarkers 
in melanoma using stocks of FFPE samples from patients with long-term follow-up 
clinical data. In Chapters 3 and 4, I report such a study.  
 
1.14 Outline of thesis chapters 
To address the major aims of the thesis (section 1.1), I will briefly outline the next 
chapters of this thesis: 
Chapter 2 describes patients, samples, cell lines and methods used throughout the 
thesis. It describes techniques of tumour sampling and methodological work to 
assess the use of new technologies using FFPE samples. The results from the 
authentication of the cell lines used are also presented. 
Chapter 3 presents the evaluation and optimisation of different protocols for sample 
preparation for whole-genome NGS analysis. Chapter 4 describes the feasibility to 
use whole-genome NGS using FFPE primary melanomas. It includes an 
assessment of quality control measures to predict success of sample preparation 
and assay performance. An attempt to identify copy number alterations associated 
with outcome and clinico-pathological characteristics known to predict survival but 
also BRAF/NRAS mutation status is also presented. Finally, an assessment of NGS 
and gene expression data integration is described. 
Chapter 5 reports the effect of vitamin D on the growth of cultured melanoma cells. 
Immunocytochemistry experiments to assess the expression of vitamin D receptor 
and melanocyte markers in the cell lines used are described. This chapter also 
presents whole-genome gene expression data using microarrays technology. 
Differentially expressed genes between vitamin D treated cells and controls are 
identified and gene ontology and pathway analysis using the gene expression data 
generated is assessed. 
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Chapter 6 reports osteopontin plasma concentrations in patients with melanoma to 
identify their prognostic significance. The validation of the enzyme-linked 
immunosorbent assay (ELISA) used to measure plasma levels of osteopontin is 
described. 
Finally, Chapter 7 summarises the main findings of my thesis, discusses limitations 
and describes future work. 
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Chapter 2  
Methodology 
 
2.1 Aims 
Chapter 2 aims to describe: 
• The studies which contributed patient samples and clinical data; 
• The reasons of tissue microarray needle usage to sample the tumours 
• The cell lines studied; 
• The results of cell line authentication and assessment of their mutation 
status; 
• The quality control assessment of WG-DASL HT data derived from FFPE 
samples to ensure that only high quality data are used in work described in 
Chapter 5; 
• The successful preparation of samples for RNA-sequencing although the 
sequencing data are not presented in this thesis; 
• The methods used throughout the thesis (generally statistical analysis 
relevant only to one chapter will be given within that chapter). 
 
2.2 Studies contributing samples and clinical data 
2.2.1 The Leeds Melanoma Cohort 
The Leeds Melanoma Cohort is a population-based cohort of patients with 
melanoma predominantly from a geographically defined area: the Yorkshire and 
Northern region of the UK. In all, 2180 patients have been recruited to this study 
since 2001 and the Leeds group are in the process of retrieving and sampling 
primary tumours from all participants who gave consent to use of their tissues. The 
study was designed to identify genetic and environmental determinants of survival 
from melanoma. 
Patients have been recruited within 6 months of diagnosis wherever possible 
(Newton-Bishop et al., 2009). Detailed questionnaires have been filled in to collect 
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lifestyle indicators and lifetime environmental exposure data. Plasma, serum, DNA 
and lymphocytes have been stored from blood samples collected at the time of 
recruitment. 
Research nurses within our group also collect blood samples and follow-up data 
from annual patient questionnaires and surveys completed by their general 
practitioners every 2 years. Participants in the study have also given consent to 
sample formalin-fixed paraffin-embedded (FFPE) primary tumour blocks stored in 
the referring hospitals.  
Approvals for the study have been granted by the Multicentre Research Ethics 
Committee (MREC) (1/3/057) and the Patient Information Advisory Group (PIAG) 
(3-09(d)/2003). A significant amendment was sought from the Northern and 
Yorkshire Research Ethics Committee (01/3/057) for using the plasma samples for 
biomarker discovery. 
 In Chapter 6 plasma samples from patients who relapsed after recruitment and 
samples from patients who haven’t were selected to test the prognostic significance 
of osteopontin plasma levels. In Chapter 4 FFPE primary blocks from patients with 
tumours thicker than 0.75mm who have died from melanoma and patients who 
have not relapsed for at least 5 years were selected to identify if DNA copy number 
alterations are associated with survival.  
2.2.2 Melanoma metastasis samples 
Melanoma metastasis FFPE blocks from 11 patients were used for nucleic acid 
extraction to assess a number of assays throughout my thesis. These samples 
were used in the methodological work described in Chapter 3. Primary melanoma 
tumours are usually small and therefore we avoided using them in methodological 
assessments. In contrast metastasis samples are usually larger allowing more 
tissue to be used. Also, new targeted therapies have emerged for melanoma 
making primary FFPE blocks precious material which need to be kept for future 
clinical testing. 
These samples were obtained from the Leeds Teaching Hospitals Trust pathology 
department (Dr Sara Edward) from patients who had given written consent to the 
use of their tissue samples at the time of surgery. Also, a number of samples from 
patients recruited in the Predicting Response to Chemotherapy in Malignant 
Melanoma study were used for methodological assessments. Ethical approval for 
this study has been granted by the Yorkshire and Humber Central Research Ethics 
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Committee (10/H1313/72) and the National Information Governance Board for 
Health and Social Care (formerly PIAG) (ECC 8-02 (FT2)/2010). 
 
2.2.3 EDTA plasma and serum samples for validation studies 
In the early phases of the Leeds Melanoma Cohort study, a standard approach to 
preparing blood samples was developed. Samples arrive in the lab at varying 
intervals, as some are taken in St James’s and can be delivered within an hour and 
others are mailed to the laboratory. All samples are therefore processed for storage 
as near to 48 hours after the blood is taken with a proportion processed up to 4 
days after the blood is taken. The assays developed to study these samples must 
therefore be shown to be stable when samples are left “on the bench” for the 
maximum period of 4 days, and thus validation of all test assays must be carried 
out both to look at the assay itself and how stable the protein/constituent is on the 
bench. 
Blood samples were collected for this purpose from 5 patients with melanoma and 4 
healthy volunteers in two 4ml EDTA-containing anticoagulant collection tubes from 
each person. Also, stored EDTA plasma and matched serum samples from 4 
patients with renal cell carcinoma were kindly provided by Professor Rosamonde 
Banks. In all cases plasma was separated by centrifugation of blood samples at 
1,500g for 15 minutes, prior to storage in aliquots at -80oC.  
Patients and healthy volunteers have given informed consent and sampling was 
done under approval of the Local Research Ethics Committee (LREC) 
(07/Q1206/28). 
All samples were used in the validation assays of the osteopontin immunoassay 
described in Chapter 6. 
 
2.3 Management of FFPE tissue 
A standard operating procedure has been developed within our group on how to 
manage and sample tissue from FFPE blocks. Our Human Tissue Act Manager, 
Sandra Tovey was responsible for tracing the FFPE blocks. The blocks are mailed 
to our lab, sectioned, stained, reviewed for sampling, sampled wherever possible 
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and finally returned. Sectioning, staining and sampling were performed by skilled 
histopathologists: Dr Filomena Esteves and Dr Jonathan Laye. 
2.3.1 Tissue sectioning 
The blocks were mounted onto a microtome and 5 micron sections were cut 
allowing the sections to float in a water bath set at 45oC until a clean section was 
achieved. One section from each block then mounted on a Superfrost glass slide 
(Solmedia, UK) and placed in an oven at 36oC overnight to dry. The tissue was 
fixed by putting the slide on a heating block at 60oC for 20 minutes with the tissue 
facing upwards. 
2.3.2 Haematoxylin and Eosin (H&E) staining of slides 
All sections were stained using Mayer’s Haematoxylin and 1% Eosin to allow 
identification of an area for sampling after review.  
Firstly, slides were de-waxed by immersing slides in xylene in a glass slide bath for 
5 minutes. This step was repeated twice by immersing slides in different water 
baths containing fresh xylene. The slides were drained on tissue paper and a 
dehydration step followed by immersing slides in absolute ethanol for 2 minutes, 
repeating twice. The slides were transferred to baths containing 90% ethanol for 2 
minutes and 75% ethanol for 2 further minutes. Then they were placed under 
running water for 30 seconds to 1 minute. For staining, the slides were immersed in 
Mayer’s haematoxyin for 2-3 minutes, moved to a fresh container and then placed 
under running water for 1 minute. Next they were immersed in Scott’s Tap water for 
1 minute, rinsed in tap water for 1 minute, immersed in eosin stain for 3 minutes, 
rinsed under running water for 30 seconds to 1 minute and left to drain on tissue 
paper. The slides were then rehydrated after immersion in absolute ethanol for 1 
minute, repeating two more times. They were air-dried for 1 minute, immersed in 
xylene for 1 minute, and then transferred to fresh xylene for a further minute. A drop 
of Depex mounting medium (VWR International, UK) was placed onto a glass cover 
slip and the slide was lowered onto the cover slip tissue side down, taking care not 
to introduce air-bubbles between the slide and cover slip. The slides were left in a 
fume hood overnight to dry before proceeding to review. 
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2.3.3 Slide review and tumour sampling 
H&E slides were reviewed by Professor Julia Newton Bishop and Dr Jonathan Laye 
using a double headed microscope to identify an area of the tumour suitable for 
sampling (additional details are given in the next section).  
A fine tip permanent marker was used to mark the area on the slide. Sampling was 
performed using Tissue Micro-Array (TMA) Building Apparatus. The needle was 
cleaned between blocks by taking cores from a blank paraffin block to avoid tumour 
contamination between blocks. The marked H&E slide was placed over the tumour 
block. The TMA needle was aligned above the marked spot, the slide removed 
carefully and the needle guided down to the block. A 0.8 x 2mm core was taken 
from the block, placed in a 1.5ml microcentrifuge tube and stored at 4oC prior to 
processing. 
2.3.4 Justification for tumour core sampling using a TMA needle 
In this work, tumours have been sampled as described above using TMA needles 
inserted horizontally ideally through the deepest part of the tumour with high tumour 
cell content and minimal stromal invasion: thus, the intent was to consistently 
sample the deepest part of the primary tumour most likely to contain least stroma or 
inflammatory tissue. The considerable variation in the morphology of primary 
melanomas means that the sample taken might have been close to, and potentially 
include, contaminating stromal epidermis or dermis. 
Where the tumour was too small to allow sampling without removing the majority of 
the tumour sample (which would potentially prejudice the patient’s subsequent 
access to tissue for clinical biomarker testing) no sample was taken at all. 
Other research groups habitually take whole tissue sections from FFPE blocks and 
some additionally perform laser capture microdissection (LCM). The decision to use 
a TMA needle was made by our group after considering that: 
• TMA sampling leaves the block intact so that the area of sampling can be 
subsequently reviewed. This also means that the shape of the tumour and 
its relationship with the stroma in not affected in case clinical re-review of 
the block is needed; 
• Sectioning of the block for LCM wastes tissue as many sections are 
discarded; 
• LCM is a time-consuming method for large-scale studies; 
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• LCM is more likely to avoid stromal contamination. However, Dr Caroline 
Conway, a previous PhD student, showed that the tumour content of cores 
is estimated to be at least 70% (Conway et al., 2009). Briefly, horizontally 
sectioned cores were embedded in wax blocks and blocks were sectioned 
to obtain 5 micron sections throughout the tissue core. H&E sections 
prepared from these sections were reviewed using light microscopy and the 
percentage of tumour content was determined. 
• Much of the work within the group aims to identify biomarkers. The group 
argues that TMA sampling would be appropriate for such work. We have 
consistently sampled the least inflamed part of the tumour and have not 
sampled tumour where inflammation was dominant. Using this approach 
there is a recognisable bias as it is argued that all samples should be 
sampled for biomarker work. However sampling was avoided when tumour 
cell content could be <70%. 
2.3.5 Melanin score 
Some melanoma tumours are highly pigmented while some others are not. Melanin 
is usually co-purified with nucleic acids from pigmented melanoma tumours. 
Melanin binds to the DNA polymerase and inhibits downstream reactions such as 
the polymerase chain reaction (PCR) (Eckhart et al., 2000). A melanin score (0-3) 
was therefore assigned for each tumour core so that technological variation which 
could be attributed to melanin could be investigated. No melanin content was noted 
as 0, and high melanin content was noted as 3. This procedure was performed by 
myself, Dr Rosalyn Jewell, Dr Jonathan Laye, or Minttu Polso before nucleic acid 
extraction. 
2.3.6 Nucleic acid extraction from FFPE tissues 
2.3.6.1 Tissue de-paraffinisation 
1ml xylene was added in the tubes containing the FFPE tissue cores and incubated 
at 37oC for 30 minutes with pulse vortexing at regular intervals. The xylene was 
carefully removed using a pipette and 1ml 100% ethanol was added. The sample 
was mixed by vortexing, quickly microcentrifuged at 13000rpm and the ethanol was 
carefully removed using a pipette. A second wash step with 70% ethanol was 
performed to remove residual xylene. Finally, the tubes were placed at 37oC with an 
open lid to let the tissue dry completely. 
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2.3.6.2 Qiagen QiAamp® DNA FFPE tissue kit 
A proportion of DNA samples extracted with this kit were used for work described in 
Chapters 3 and 4. In the course of my work a newer kit was assessed which proved 
to have higher yields of DNA, and also allowed dual extraction of DNA and RNA, 
and this kit was subsequently abandoned. Samples were processed according to 
the supplied protocol. 
Briefly, the deparaffinised tissue core was resuspended in 180µl buffer ATL and 
20µl proteinase K, vortexed and incubated at 56oC with agitation for up to 48 hours 
to ensure complete tissue lysis. The lysed sample was then incubated at 90oC for 1 
hour. 2µl RNase A (100mg/ml) was then added and the mixed sample was 
incubated at room temperature for 2 minutes. 200µl buffer AL was mixed with the 
sample followed by further mixing after addition of 200µl absolute ethanol. The 
sample was transferred to a QIAamp MinElute column placed in a 2ml collection 
tube. The column was centrifuged at 6,000g for 1 minute. The column was put in a 
new collection tube, 500µl buffer AW1 added and the column was washed by 
centrifugation at 6,000g for 1 minute. A second wash step was performed after 
addition of 500µl buffer AW2. The column was transferred to a new collection tube 
and the column centrifuged at 20,000g for 3 minutes to dry the silica-gel membrane. 
The column was transferred to a new 1.5ml collection tube, 30µl buffer ATE applied 
to the column, and the column incubated at room temperature for 5 minutes. The 
DNA was eluted after centrifugation at 16,000g for 1 minute and stored at -20oC. 
2.3.6.3 Qiagen AllPrep® DNA/RNA FFPE kit 
RNA and DNA extraction was performed using the AllPrep® DNA/RNA FFPE kit 
(Qiagen, Crawley UK) according to the manufacturer’s instructions with a few 
modifications. Using this protocol both RNA and DNA could be extracted using a 
single tissue core. DNA & RNA extracted using this kit was used for work in 
Chapters 3 and 4. 
2.3.6.3.1 Tissue digestion 
The deparaffinised core was resuspended in 150µl buffer PKD. 10µl proteinase K 
(20 mg/ml) was added and the sample was mixed by vortexing. The sample was 
incubated at 56oC overnight and then put on ice for 3 minutes to ensure efficient 
precipitation. The sample was centrifuged for 15 minutes at 20,000g and the 
supernatant transferred to a new tube. The pellet was retained for DNA purification. 
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2.3.6.3.2 RNA extraction  
The supernatant was incubated at 80oC for 15 minutes. 320µl buffer RLT was 
mixed with the sample, followed by the addition of either 720µl or 1120µl ethanol 
(1120µl ethanol was added for total RNA extraction that includes microRNAs). 
700µl of the mixed sample was transferred to an RNeasy MinElute column, and the 
column was centrifuged for 15 seconds at 8,000g. The flow-through was discarded 
and this step was repeated until the entire sample had passed through the column. 
350µl buffer FRN was then added to the column, the column centrifuged for 15 
seconds at 8,000g and the flow-through discarded. The DNase incubation mix of 
10µl DNase I and 70µl buffer RDD was added to the column and left at room 
temperature for 15 minutes. Following the addition of 500µL buffer FRN the column 
was centrifuged for 15 seconds at 8,000g and the flow-through was kept for use in 
the next step. The column was placed in a new collection tube and the flow-through 
from the previous step was re-applied to the column. The centrifugation step was 
repeated for 15 seconds at 8,000g and the flow-through was now discarded. 500µl 
buffer RPE was added to the column, the column centrifuged for 15 seconds at 
8,000g and the flow-through was discarded. The wash step with 500µl buffer RPE 
was repeated and then the column was transferred to a new collection tube. 26µl 
RNase-free water was finally applied to the column and incubated at room 
temperature for 1 minute. The RNA was eluted after centrifugation for 1 minute at 
20,000g and stored at -80oC. 
2.3.6.3.3 DNA extraction 
The pellet retained after the tissue digestion described in section 2.3.6.3.1 was 
resuspended in 180µl buffer ATL and 40µl proteinase K. The mix was incubated at 
56oC overnight and then at 90oC for 2 hours. 4µl RNase (100mg/ml) was added and 
the sample was incubated for 2 minutes at room temperature. 200µl buffer AL was 
added, the sample mixed thoroughly, and then 200µL ethanol was further mixed 
with the sample. The entire sample was transferred to a QIAamp MinElute column 
and the column centrifuged for 1 minute at 8,000g. The column was placed in a 
new collection tube, 700µl buffer AW1 added, the column centrifuged for 15 
seconds at 8,000g, and the flow-through discarded. The same step was performed 
using 700µl buffer AW2 followed by 700µl ethanol. Finally, 30µl buffer ATE was 
applied to the column and left to stand at room temperature for 5 minutes. The DNA 
was eluted after centrifugation at 20,000g for 1 minute and stored at -20oC. 
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2.3.7 cDNA synthesis of RNA extracted from FFPE tissue 
2.3.7.1 The Invitrogen™ High Capacity cDNA Reverse Transcription kit 
Production of cDNA from both FFPE RNA and frozen RNA was carried out using 
the High Capacity cDNA Reverse Transcription kit (Invitrogen™ by Life 
Technologies, USA). This protocol uses random hexamer primers which is 
important for successful cDNA synthesis from fragmented RNA. Oligo-dT 
(Oligodeoxythymidylic acid residues (dT)) primers are usually avoided as they bind 
to the poly-A tail, which is missing in fragmented RNA derived from FFPE blocks.  
In brief, a master mix was prepared by combining 2µl 10x reverse transcriptase 
(RT) buffer, 0.8µl 25x dNTP (deoxyribonucleotide triphosphate) mix, 2µl 10x RT 
random primers, 1µl Multiscribe Reverse Transcriptase, 1µl RNase Inhibitor and 
3.2µl nuclease-free water. 10µl of master mix were combined with 200ng total RNA 
(up to 10µl) in a 96-well plate placed on ice, quickly centrifuged and incubated on 
the Applied Biosystems 9700 Thermal Cycler at 25oC for 10 minutes, 37oC for 120 
minutes, and 85oC for 5 minutes. The prepared cDNA was stored at -20oC. 
 
2.4 Mutation screening 
BRAF and NRAS mutation screening was performed in all tumour samples 
described in Chapter 4 and in all cell lines used throughout this thesis. The assays 
were performed by Dr Philip Chambers, Genomics Facility, Leeds, using 
pyrosequencing. 
2.4.1 Pyrosequencing 
Pyrosequencing is a sequencing method where DNA polymerase initiates the 
synthesis of a single-stranded fragment while deoxynucleotides are added 
sequentially (Ronaghi et al., 1998). When a deoxynucleotide is incorporated 
pyrophospate is released which is converted to adenosine-5’-triphosphate (ATP) by 
ATP sulfurylase. Luciferase oxidises luciferin in the presence of ATP and light is 
generated. The amount of light emitted is proportional to the amount of nucleotides 
incorporated. The unincorporated nucleotides are degraded by apyrase before the 
addition of the next nucleotide (Ronaghi et al., 1998).  
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The assays were performed based on NCBI RefSeq accession number 
NM_004333 for BRAF and NM_002524 for NRAS (Pruitt et al., 2012). Primers for 
PCR amplification and pyrosequencing assays were designed using proprietary 
Pyrosequencing assay design software version 2.0.1.15 (Qiagen, Crawley UK). 
Three PCR reactions were performed; one reaction for BRAF codon 600, one for 
NRAS codon 61 and one for both NRAS codons 12 and 13 (Table 2-1). Each PCR 
reaction was prepared by mixing 20ng genomic DNA or 2µl cDNA, 12.5µl HotStar 
Taq Master Mix (Qiagen, Crawley UK), 2mM magnesium chloride, 200nM each of 
forward and reverse primers and nuclease-free water to make a final volume of 
25µl. Thermal cycling conditions were 94oC for 12 minutes, 40 cycles of 94oC for 10 
seconds, 55oC for 20 seconds and 72oC for 20 seconds. The biotinylated PCR 
product was captured with streptavidin-coated magnetic beads and sequenced on a 
PyroMark ID system (Qiagen, Crawley UK) according to manufacturer’s protocols. 
Data were analysed by visual inspection of pyrograms and by analysis of peak 
height data. 
 
Table 2-1: PCR and pyrosequencing primers for BRAF and NRAS assays 
Region 
of 
interest 
PCR primers 
Pyrosequencing 
primer 
Amplicon 
length 
(bp) 
BRAF 
codon 
600 
F:5’-TGAAGACCTCA 
CAGTAAAAATAGG-3’ 
R: 5’-biotin-
TCCAGACAACTGTTCAAACTGAT-3’ 
5’-
TGATTTTGGTCT
AGCTACA-3’
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NRAS 
codon 
61 
F: 5’-biotin-
GAAACCTGTTTGTTGGACATACTG-3’ 
R:5’-TCGCCTGTCCTCATGTATTG-3’ 
5’-
CTCTCATGGCA
CT GTACT-3’ 
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NRAS 
codons 
12 & 13 
F:5’-CTTGCTGGTGTGAAATGACTGAG-3’ 
R: 5’-biotin-TGGATTGTCAGTGCGCTTTTC-3’ 
5’-
CTGGTGGTGGT
TGGA-3’ 
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Pyrosequencing assays developed previously have shown higher sensitivity than 
Sanger sequencing assay for BRAF exon 15 (Spittle et al., 2007) and comparable 
sensitivity to Sanger sequencing assays for NRAS codons 12, 13 and 61 
(Sivertsson et al., 2002). Also, matched frozen and FFPE melanoma DNA samples 
produced comparable results in a BRAF pyrosequencing assay, showing that FFPE 
DNA is suitable for use in pyrosequencing (Spittle et al., 2007). The percentage of 
the mutated allele compared to the wild-type allele was calculated based on peak 
height data using the formula: peakmutant/(peakmutant/peakwild-type)*100 (Yancovitz et 
al., 2012). Dr Philip Chambers has advised that the sensitivity of the assay is 5% 
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where a peak can be distinguished from background data (based on his previous 
experience with the assay). Therefore, the DNA sample was considered mutated 
when a mutant allele was present in >5% of the cells assessed or >10% if the data 
was of poor quality. Example pyrograms are illustrated in Figure 2-1. 
2.4.2 Sanger sequencing 
Traditional Sanger sequencing was performed on a selection of samples to confirm 
BRAF and NRAS mutations identified by pyrosequencing. Non-biotinylated 
pyrosequencing primers as described previously in Table 2-1 were used as 
sequencing primers and both forward and reverse strands were sequenced. 
To remove any unincorporated dNTPs and primers, 2µl of ExoSAP-IT® (USB, 
Affymetrix, High Wycombe, UK) was added to 5µl of the PCR product, mixed and 
incubated at 37oC for 15 minutes, followed by 80oC for 15 minutes and finally 
cooled to 15oC. The sequencing reaction comprised of 0.5µl of 3.2pmol/µl primer, 
1µl of purified PCR product, 4.5µl of molecular biology grade water, 3.5µl of ABI 5x 
Sequencing Buffer (Applied Biosystems, UK) and 0.5µl of 2.5x Ready Reaction Mix 
v1.1 (from Applied Biosystems BigDye® Terminator Cycle Sequencing kit v1.1). 
Thermal cycling conditions were 25 cycles of 96oC for 10 seconds, 60oC for 5 
seconds and 60oC for 4 minutes, and finally the mixture was cooled to 15oC. 
Sequencing products were concentrated and purified using ethanol precipitation. 
Precipitation was achieved by adding 1µl of 3M sodium acetate and 25µl of 95% 
ethanol to the product and the mixture incubated at room temperature for 15-30 
minutes. The samples were centrifuged at 2250g for 30 minutes so that the product 
forms a pellet. The supernatant was removed by inverting the 96-well plate onto 
absorbent paper and the plate was centrifuged again at 180g for 1 minute. 70µl of 
70% ethanol was added to wash away residual sodium acetate and the mixture 
centrifuged at 1650g at 4oC for 15 minutes. Supernatant was discarded by inverting 
the plate onto absorbent paper and centrifugation at 180g for 1 minute followed. 
The plate was heated to 95oC for 1 minute to dry the pellet. The sequencing 
product was suspended in 20µl of Hi-Di™ formamide (Applied Biosystems), heated 
to 95oC for 1 minute and then immediately cooled on ice water prior to 
electrophoresis. Products were separated using the Applied Biosystems PRISM 
3130xl Genetic Analyzer with a 36cm length 16-capillary array and POP-7™ 
polymer. Sequence analysis was performed using Sequencing Analysis 5.2 
(Applied Biosystems) and Mutation Surveyor 3.2 (Soft Genetics, State College, PA). 
  
Figure 2-1: Pyrograms for BRAF codon 600. 
A) An example of a sample with a wild-type allele, and B) an example of a sample with a V600E (c.1799T>A). 
5
5
 
56 
2.5 Cell lines 
The SkMel5 (ATCC), MelJuso (ATCC) and SkMel28 (courtesy of Professor Alan 
Melcher, Leeds CRUK cell line bank) melanoma cell lines were used to for RNA-
sequencing as described below in section 2.9.2. The MeWo (courtesy of Professor 
Alan Melcher, Leeds CRUK cell line bank) cell line was used for a number of 
methodological assessments but not elsewhere as, following cell line 
authentication, it appeared to be contaminated with the MM96 cell line (results 
shown in Appendix A.1.1). 
Cell culture experiments described in Chapter 5 were performed in collaboration 
with Professor Jorg Reichrath, Saarland University, Homburg, Germany. The 
melanoma cell lines MeWo, SkMel28, MelJuso and SkMel5, which were used in 
this project, were alternatively sourced and kindly provided by Professor Reichrath. 
These lines were also subjected to cell line authentication in Leeds (results shown 
in Appendix A.1.2). 
2.5.1 Cell line authentication 
Cell line authentication was performed using the PowerPlex® 16 System (Promega, 
USA). This system detects 16 loci, including Penta E, D18S51, D21S11, TH01, 
D3S1358, FGA, TPOX, D8S1179, vWA, Penta D, CSF1PO, D16S539, D7S820, 
D13S317 and D5S818, which are short tandem repeat (STR) loci and the sex 
marker Amelogenin. STR loci are repetitive sequences of 3-7 base pairs and are 
distributed throughout the human genome. All STR loci are amplified in a single 
reaction for each sample using PCR. The alleles of each locus are differentiated by 
the number of copies of the repeat sequence using fluorescence detection following 
electrophoretic separation. This work was carried out by Dr Claire Taylor. 
2.5.1.1 PCR amplification  
The PCR Amplification mix was prepared by combining 2.5µl Gold STR 10x 
buffer, 2.5µl PowerPlex® 16 10x Primer Pair Mix, 0.8µl AmpliTaq Gold® DNA 
Polymerase (4u), up to 19.2µl of 0.5ng DNA and nuclease-free water up to a final 
volume of 25µl. A positive and a negative control reaction were prepared using the 
controls supplied with the kit. The mix was vortexed and pipetted into a 96-well 
plate. The plate was then loaded onto a GeneAmp® PCR System 9700 thermal 
cycler, being set up at 95oC for 11 minutes, 96oC for 1 minute and then: ramp 100% 
to 94oC for 30 seconds, ramp 29% to 60oC for 30 seconds, ramp 23% to 70oC for 
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45 seconds for 10 cycles, then: ramp 100% to 90oC for 30 seconds, ramp 29% to 
60oC for 30 seconds, ramp 23% to 70oC for 45 seconds for 22 cycles and then at 
60oC for 30 minutes. The programme was run in the 9600 ramp mode. The 
reactions were stored at -20oC prior to proceeding to the next step. 
2.5.1.2 Detection of amplified products and data analysis 
A loading cocktail was prepared by mixing 0.5µl Internal Lane Standard 600 and 
9.5µl Hi-Di™ (highly deionized) formamide for each sample. The mix was vortexed 
and pipetted into each well of a 96-well plate. 1µl amplified sample was then added 
to each well and sample denaturation performed at 950C for 3 minutes. The 
cocktail/sample mix was placed on ice for 3 minutes and then loaded onto the 
Applied Biosystems 3130xl Genetic Analyser instrument using a 36cm capillary 
array and POP-7™ polymer. Data analysis was performed using the GeneMarker 
version 1.95 software (SoftGenetics, USA). A reference profile for each cell line was 
sought from either the DSMZ (German Collection of Microorganisms and Cell 
Culture), Cell Line Integrated Molecular Authentication (CLIMA) or Cancer Genome 
Project (CGP) STR databases and matched against the profile retrieved after 
analysis.  
An example can be seen in Figure 2-2, where the locus D3S1358 is shown in two 
MeWo cell line samples, one pure and one mixed with MM96 cell line. For this locus 
MeWo sample has allele 17 and MM96 sample has allele 16. The pure sample 
clearly carries allele 17 and has lost allele 16 whereas the mixed sample has a 
small peak of allele 17 and large peak of allele 16 which is the contribution of MM96 
contamination. STR profiles of all cell lines can be found in Appendix A.1. 
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Figure 2-2: D3S1358 locus is shown in two MeWo samples, one pure and one 
mixed with a different cell line. 
 
2.5.2 Cell line authentication results 
The SkMel28, SkMel5 and MelJuso cell lines available in Leeds were correctly 
authenticated. Unfortunately, cell line authentication in the German cell lines was 
performed at a later time when the experiments using these cells had already been 
done. I went to work on the German cell lines in Homburg and DNA samples were 
subsequently sent to Leeds from the German collaborators to do the authentication 
test. The MeWo melanoma cell line was correctly authenticated, however SkMel5 
appeared to be SkMel28, SkMel28 appeared to be MeWo and the MelJuso cell line 
did not match any reference sample. A second DNA sample was requested from a 
passage of frozen cells close to the ones I grew up while I was there. The second 
authentication showed the same results except that SkMel28 cells were this time 
correctly authenticated. Looking at the SkMel28 cells under the microscope whilst 
the cells were being cultured in Germany they had the expected appearance of 
SkMel28 cells and were very different to the MeWo cells. So, we decided to 
investigate further whether the cells in my hands were the correct ones. We 
performed BRAF and NRAS mutation screening using cDNA derived from the 
stored RNA from these cells. cDNA from the Leeds cell lines was tested as a 
positive control. Table 2-2 shows the mutation status identified. The mutation status 
of the German cell line MeWo, and the Leeds cell lines SkMel28 and MelJuso 
agrees with the literature (all 3 correctly authenticated). The German SkMel28 
which was correctly authenticated the second time appeared to have a p.V600E 
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BRAF mutation, which agrees with both the Leeds SkMel28 sample and the 
literature. If it was a MeWo sample as the first authentication results suggested we 
would expect to observe wild type alleles for both genes tested. So, we 
demonstrated support for the view that the SkMel28 cells in my hands were the 
correct cells and not contaminated. The mutation status of the German and Leeds 
MelJuso sample did not match, which further confirmed that the German MelJuso 
cells are not MelJuso.  
 
Table 2-2: Mutation screening using cDNA generated from the Leeds versus 
the German cell lines 
Cell line 
German cDNA Leeds cDNA 
BRAF NRAS BRAF NRAS 
MeWo Wt Wt Wt Wt 
SkMel28 p.V600E Wt p.V600E Wt 
MelJuso p.V600E Wt Wt  p.Q61L 
 
In summary, we showed evidence that the queried German SkMel28 sample was 
correct and as a result RNA from this cell line was used in further experiments. The 
overall conclusions of the cell line authentication for the cell lines from both Leeds 
and Germany are summarised in Table 2-3. RNA from SkMel5 was not used in 
further experiments, as it appeared to be a SkMel28 sample in both authentication 
tests. The German line labelled as MelJuso (henceforth referred in quotes, 
‘MelJuso’) was stained for melanocyte markers to identify whether this cell line is of 
melanocytic origin, as its profile did not match any reference profile at both 
authentication tests (see Chapter 5). 
 
Table 2-3: Identity of cell lines as determined by cell line authentication 
against a reference profile 
Cell Line Leeds Germany 
MeWo Contaminated with MM96 Authenticated 
SkMel28 Authenticated Authenticated 
MelJuso Authenticated Unknown profile 
SkMel5 Authenticated SkMel28 
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Thus, the need to authenticate experimental cell lines attributed to previously 
extensively characterised lines in the literature has been clearly demonstrated. 
2.5.3 Cell culture 
SkMel28, SkMel5, MeWo and MelJuso lines were grown in RPMI-1640 medium 
(Sigma-Aldrich, UK) supplemented with 10% foetal calf serum (FCS) (Sigma-
Aldrich, UK) and L-glutamine (2mM) (Sigma-Aldrich, UK) added fresh to the 
medium for experiments on the effect of adding vitamin D to cultures (described in 
Chapter 5). Cells were detached from the surface of the flask when they were 80-
90% confluent. The medium was removed, cells washed with phosphate buffered 
saline (PBS) to remove excess serum and 1ml trypsin added. The cells were 
incubated with trypsin at 37oC until the cells detached from the surface. 5-10ml 
medium was added; the cells were collected in 50ml conical tubes and pelleted 
after centrifugation at 400g for 4 minutes. The cells were resuspended in 10ml 
medium and counted using trypan blue exclusion and a haemocytometer prior to 
1α,25(OH)2D3 treatment as described in section 2.5.5. Otherwise, pellets were 
frozen at -80oC for later DNA/RNA extraction or fixed in formalin as described in 
section 2.5.4. 
2.5.4 Embedding of cells in paraffin wax blocks 
Cultured SkMel28, MelJuso and SkMel5 cells in FFPE blocks were prepared and 
used for nucleic acids extraction and subsequent RNA-sequencing as described in 
section 2.9.2. Four 150 cm2 sized flasks of confluent cells for each cell line were 
pelleted as described in section 2.5.3. Each cell pellet was resuspended in PBS; 
the cells were split into two 50ml conical tubes and pelleted again. One pellet was 
frozen at -80oC for later RNA extraction and one pellet was resuspended in 10ml 
10% neutral buffered formalin and fixed overnight at room temperature. The next 
day the cells were centrifuged at 1500rpm for 5 minutes and washed twice with 
10ml PBS. At this stage the cells were transferred into a 1.5ml tube and centrifuged 
at 8000rpm for 5 minutes. After centrifugation the supernatant was discarded, 
leaving only a small meniscus of PBS. The cell pellets were put at 45oC on a 
heating block for 2 minutes. A 2% agar solution in deionised water was prepared 
and allowed to cool to about 55oC. 500µl agar solution was added to the cells and 
resuspended. The cells/agar mixture were kept at 45oC for 15 minutes and then 
rapidly pelleted at 8000rpm for 2 minutes before the agar was set. After 
centrifugation the agar was left to become solid and the tube containing the agar-
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embedded cells was filled up with 70% ethanol and subsequently stored at 4oC until 
processing. The agar-embedded pellets were processed and paraffin-embedded by 
Dr. Mike Shires (Histopathology team, Leeds University) by routine overnight 
method. 
2.5.5 1α,25(OH)2D3 treatment 
MeWo, SkMel28, MelJuso and SkMel5 melanoma cells were treated with 
1α,25(OH)2D3 (Sigma-Aldrich, UK) to study the anti-proliferative effects of 
1α,25(OH)2D3 that has been reported previously in various cell lineages (Deeb et 
al., 2007).  Vitamin D is a fat soluble hormone and the approach usually described 
in the literature has been to dissolve in ethanol. It is also sensitive to light. I looked 
at a variety of approaches in Leeds but had technical difficulties and subsequently 
decided to travel to Homburg, Germany to carry out the experiments in the 
laboratory of Professor Reichrath. 
The methodology described here is therefore that used and published by the 
German research group. 5000 cells were seeded in 24-well plates and left to grow 
for 24 hours as described in section 2.5.3. 1α,25(OH)2D3 was first dissolved in 
ethanol in the glass bottle provided and mixed well. Then the 1α,25(OH)2D3 solution 
was further diluted in dark plastic tubes (due to the light sensitive nature of the 
vitamin D). The final dilution was performed in treatment medium to reach the 
concentration required. The medium was replenished after 24, 48, 72, and 96 hours 
and the cells were left to grow for a total of 144 hours. The treatment medium was 
RPMI-1640 supplemented with 1% bovine serum albumin (BSA), 1% 
penicillin/streptomycin and 1α,25(OH)2D3 at a final concentration of 10
-10M or 10-8M 
or 10-7M. Control cells were treated with medium only, medium supplemented with 
1% BSA and medium supplemented with 1% BSA and 0.01% ethanol. Three 
independent experiments were performed, and 4 replicates per treatment/control 
group were included in each experiment. 
2.5.6 Proliferation assay using crystal violet dye 
Proliferation was measured using crystal violet dye as described previously 
(Sertznig et al., 2009a). Professor Jorg Reichrath suggested the use of this assay 
as being the most reproducible compared to superior assays such as WST-1 (work 
carried out in his lab previously but not reported in the literature). Crystal violet is a 
deep purple dye which is absorbed by DNA stoichiometrically and therefore 
absorbance measurement directly correlates with the number of the cells. Crystal 
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violet addition to the cells and absorbance measurement was done after 24, 48, 72 
and 144 hours of 1α,25(OH)2D3 treatment. A working solution was prepared (1% 
w/v in 20% ethanol). The medium was removed from the 24-well plates and the 
cells were washed twice with 500µl cold PBS. The cells were then fixed by addition 
of 500µl 70% ethanol and incubation at 4oC for 1 hour. The ethanol was removed, 
500µl crystal violet working solution added in each well and the plate incubated at 
room temperature on a shaker for 30 minutes. The plate was then washed using 
distilled water until the running water was clear. The plate was placed upside down 
to dry completely. 400µl 70% ethanol was added to each well and the plate 
incubated at room temperature on a shaker for 30 minutes. The crystal violet dye 
was solubilized in the ethanol solution and the absorbance at 550nm was measured 
using a microplate reader (Titertek Multiskan Plus MK II, Labsystems, Finland). 
2.5.7 1α,25(OH)2D3 treatment for subsequent RNA extraction 
500,000 melanoma cells were seeded in petri dishes and treated with 1α,25(OH)2D3 
as described in section 2.5.5 for 6, 24 and 48 hours. After these time points, the 
cells were pelleted and kept frozen for later RNA extraction. Three independent 
experiments were performed. 
2.5.8 Immunocytochemistry (ICC) 
Immunocytochemical staining was performed by Alexandra Stark at the Department 
of Dermatology at Saarland University in Homburg, Germany. The German cell 
lines SkMel28, MeWo and ‘MelJuso’ were stained for the vitamin D receptor (VDR) 
(Table 2-4). 
The cell line of unknown origin, ‘MelJuso’, was also stained for the following 
melanocytic markers: Melan-A, S100, HMB45, Pan Melanoma cocktail (HMB45, 
Melan-A, Tyrosinase) to identify if these cells are of melanocytic origin (Table 2-4). 
The results from this work are presented in Chapter 5. 
Immunocytochemistry (ICC), the staining of cultured cells, or immunohistochemistry 
(IHC), the staining of tissue sections, offers the direct visualization of specific 
antigens within the examined cells using specific antibodies (Ramos-Vara, 2005). 
An unlabelled primary antibody specifically binds to the cells followed by a 
biotinylated IgG secondary antibody which binds to the constant fragment (Fc) of 
the primary antibody. Then, streptavidin conjugated enzymes bind to biotin on the 
secondary antibody and generate an insoluble substrate which can be visualised by 
light microscopy (Ramos-Vara, 2005). 
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Table 2-4: Primary antibodies used for ICC 
Antibodies used are reported with manufacturer details and dilutions used for 
ICC staining. Anti-VDR was a new antibody tested in the laboratory and a 
titration experiment was performed showing that 1:500 is the optimal dilution 
(details in Chapter 5). 
Antibody Staining Manufacturer Dilution 
Monoclonal mouse anti-
VDR(D-6) 
Cytoplasmic, nuclear Santa-Cruz Biotechnology 
1:500 
1:1000 
1:2000 
Monoclonal mouse anti-
Melan-A Clone A103 
Cytoplasmic Dako, Germany 1:100 
Polyclonal rabbit 
anti-S100 
Cytoplasmic Dako, Germany 1:1000 
Monoclonal mouse 
anti-Melanosome 
Clone HMB45 
Cytoplasmic Dako, Germany 1:100 
Monoclonal mouse anti-Pan 
Melanoma Cocktail 
Cytoplasmic 
Diagnostic Biosystems, 
Germany 
1:50 
 
S-100 is a very sensitive marker for melanoma but its specificity is somewhat 
limited as it is expressed in other cell types (such as myoepithelial cells and 
Langerhans cells) (Ohsie et al., 2008). Therefore, its use in combination with more 
specific melanocyte lineage markers such as HMB45, Melan-A and tyrosinase is 
recommended (Ohsie et al., 2008). The latter three markers are less sensitive than 
S100 but their specificity is 97-100% (Ohsie et al., 2008). The use of IHC for the 
diagnosis of metastasizing melanoma cells in the excised lymph nodes using some 
or all of the mentioned markers is now routine practice in the clinic (Marsden et al., 
2010, Balch et al., 2009). 
ICC was performed using the Dako REAL™ Detection System, Alkaline 
Phosphatase/RED,Rabbit/Mouse kit on the Autostainer (Dako, Germany). Briefly, 
1x104 cells were seeded on a glass slide and left to grow overnight. The next day, 
the cells were fixed using 4% paraformaldehyde in PBS for 15 minutes and then 
washed with PBS. Slides to be stained with HMB45 were pre-treated with 
proteinase K while slides to be stained with the rest of the antibodies were 
subjected to heat-induced epitope retrieval using a microwave. Diluted primary 
antibodies were incubated with the cells for 30 minutes, then the biotinylated 
secondary antibody was added for 15 minutes followed by streptavidin alkaline 
phosphatase for 15 minutes and the substrate working solution was added for 7 
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minutes. The slides were then counterstained with haematoxylin, dehydrated and 
finally mounted with Entellan® (Merck Millipore) mounting medium. Pictured of the 
stained cells are presented in Chapter 5. The staining was evaluated semi-
quantitatively by Dr Jonathan Laye and myself by estimating the staining intensity 
where 0 represents no staining and 3 strong staining.  
2.5.9 Nucleic acids extraction and purification from cell lines 
2.5.9.1 Ambion mirVana™ microRNA isolation kit 
This kit was used for both total RNA and microRNA isolation from cultured 
melanoma cell lines used for work in Chapter 5. The supplied organic extraction 
protocol, as described in brief below, was followed for both total RNA and 
microRNA isolation.  
Cells were trypsinised to detach them and centrifuged at 300g for 4 minutes to form 
a pellet. The pellet was then washed by resuspension in 1ml PBS and pelleted 
again. The PBS was discarded and the pellet stored at -20oC for up to a month for 
later RNA extraction. The pellet was removed from the freezer, put on ice and 
resuspended in 600µl lysis/binding solution. The sample was then vortexed to 
ensure complete lysis of the cells. Then 60µl microRNA homogenate additive was 
added to the lysate, mixed well and left on ice for 10 minutes. 600µl 
Acid:Phenol:Chloroform (Ambion by Life Technologies, USA) was added and mixed 
well by vortexing. The sample was centrifuged at 10,000g for 5 minutes at room 
temperature to separate the aqueous and organic phases. The aqueous phase 
(upper) was carefully transferred to a fresh tube without disturbing the lower organic 
phase which contained the proteins and the volume was measured. The aqueous 
phase was mixed with ⅓ volume of absolute ethanol; 700µl sample was transferred 
to a filter cartridge applied to a collection tube and the cartridge was centrifuged at 
10,000g for 15 seconds. The flow-through was transferred to a new tube as it 
contained the small RNAs. This step was repeated until all the lysate-ethanol 
mixture was passed through the filter and the final volume of the flow-through was 
measured. The total RNA depleted of microRNAs was bound to the filter and it was 
recovered as described below in section 2.5.9.1.2. 
2.5.9.1.1 miRNA isolation 
A ⅔ volume of absolute ethanol was added to the flow-through retained in the 
previous step and mixed well. The mixed sample was transferred to a new filter 
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cartridge applied to a collection tube and the cartridge was centrifuged at 10,000g 
for 15 seconds. The flow-through was discarded and the step was repeated until 
the entire sample had passed through the filter. A wash step was then performed by 
addition of 700µl Wash 1 buffer and centrifugation at 10,000g for 15 seconds. Two 
more wash steps were performed by adding 500µl Wash 2 buffer to the cartridge. 
After discarding the flow-through from the last wash step the cartridge was 
centrifuged at 10,000g for 1 minute to remove residual fluid. The cartridge was 
transferred to a new collection tube, 100µl nuclease-free water was applied to the 
cartridge and it was left stand at room temperature for 1 minute. After centrifugation 
at 10,000g for 1 minute the eluate contained the microRNAs. This sample was 
stored at -80oC.  
2.5.9.1.2 Total RNA isolation 
700µl microRNA Wash buffer 1 was applied to the cartridge from the last step 
described in section 2.5.9.1. The cartridge was centrifuged at 10,000g for 15 
seconds and the flow-through was discarded. Two more wash steps were 
performed after addition of 500µl Wash buffer 2/3. After the last wash step the 
cartridge was centrifuged at 10,000g for 1 minute to remove residual fluid and then 
it was transferred to a new collection tube. Then, 100µl nuclease-free water was 
added and the cartridge was left at room temperature for 1 minute. Total RNA was 
eluted after centrifugation at 10,000g for 1 minute. The RNA was stored at -80oC 
2.5.9.2 Qiagen RNeasy® mini kit 
Total RNA was extracted using this kit according to the supplied protocol and was 
further used for RNA-sequencing (section 2.9.2). 
Briefly, cells were harvested as a pellet and stored at -80oC prior to processing. 
600µl RLT Plus buffer was added to each pellet and mixed well by vortexing for 30 
seconds. Then 600µl 70% ethanol was mixed well with the sample by vortexing and 
up to 700µl of it was transferred to an RNeasy spin column placed in a 2ml 
collection tube. The column was centrifuged for 15 seconds at 8,000g and the flow-
through was discarded. This step was repeated until the entire sample had passed 
through the column. The column was washed by addition of 350µl RW1 buffer to 
the column, and centrifugation, after which the flow-through was discarded. 80µl 
DNase I incubation mix (70µl RDD buffer and 10µl DNase I; Rnase-free DNase set, 
Qiagen, Crawley UK) was added to the column and incubated for 15 minutes at 
room temperature. Another wash step was performed by addition of 350µl RW1 
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buffer and then two more wash steps by addition of 500µl RPE buffer to the 
column. After the last wash step, the column was transferred to a new 2 ml 
collection tube, and centrifuged at full speed for 1 minute to dry the membrane. The 
column was then placed in a new 1.5ml microcentrifuge tube, 100µl RNase water 
added and the column left to stand at room temperature for 1 minute. The column 
was centrifuged for 1 minute at 8,000g and the eluted RNA was stored at -80oC. 
2.5.9.3 Qiagen AllPrep® DNA/RNA FFPE kit 
RNA and DNA was extracted from cells embedded in FFPE blocks using the 
AllPrep® DNA/RNA FFPE kit and RNA was subsequently used for RNA-
sequencing (section 2.9.2). Three cores were taken from each block and 
deparaffinised as described in section 2.3.6.1. The Qiagen AllPrep® kit was used 
as described in section 2.3.6.3 with the following modification: the RNA was eluted 
in 100µl RNase-free water and the DNA in 100µl elution buffer. 
2.5.9.4 Ambion Turbo™ DNase-free kit 
DNase treatment was essential to remove contaminating DNA from RNA samples 
used on the Affymetrix gene expression array. RNA extracted using the Ambion 
miRvana kit was DNase treated consequently using the Turbo™ DNase-free kit 
(Ambion by Life Technologies, UK). 
A DNase treatment was performed on the eluted RNA by addition of 0.1 volume 
10x Turbo™ DNase buffer and 0.02x volume Turbo™ DNase. The sample was 
mixed gently and incubated at 37oC for 30 minutes. Then 0.1x volume of 
resuspended DNase Inactivation reagent was added and the sample incubated for 
5 minutes at room temperature, mixing occasionally. The tube was then centrifuged 
at 10,000g for 15 minutes and the RNA transferred to a new tube without disturbing 
the pellet formed by the DNase Inactivation Reagent.  
2.5.9.5 Qiagen RNeasy® MinElute® Cleanup kit 
DNase treated RNA with the Turbo™ DNase kit was immediately cleaned up using 
the RNeasy® MinElute® CleanUp kit (Qiagen, Crawley UK) to ensure no 
contaminants were left in the RNA sample. The RNA sample was adjusted to a 
volume of 100µl with RNase-free water, 350µl RLT buffer added and the sample 
mixed well. Then 250µl absolute ethanol was added, mixed well and up to 700µl of 
sample was transferred to an RNeasy® MinElute® column placed in a 2ml 
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collection tube. The column was centrifuged at 8,000g for 15 seconds, the flow-
through was discarded and the step was repeated until the entire sample had 
passed through the column. The column was then transferred to a fresh 2ml 
collection tube, and two wash steps were performed by addition of 500µl RPE 
buffer followed by 500µl 80% ethanol. After the last centrifugation, the column was 
placed in a new 2ml collection tube and centrifuged at full speed for 5 minutes to 
dry the membrane. The column was then placed in a new 1.5ml microcentrifuge 
tube. 15µl RNase-free water was added to the centre of the column, left at room 
temperature for 1 minute and centrifuged at full speed for 1 minute. The eluted RNA 
was stored at 80oC prior to processing.  
2.5.10 cDNA synthesis of RNA extracted from cell lines 
Production of cDNA from RNA extracted from cell lines was carried out using the 
High Capacity cDNA Reverse Transcription kit (Invitrogen™ by Life Technologies, 
USA) as described in section 2.3.7.1. 
 
2.6 Nucleic acid quantification and fragment size 
assessment 
2.6.1 DNA/RNA quantification using the ND-8000 
The concentrations of DNA and RNA extracted from FFPE or frozen samples was 
measured using the ND-8000 (Nanodrop, Thermo Scientific, USA), a 
spectrophotometer measuring absorbance in a spectrum of 220nm-750nm. 1.5µl 
nucleic acid was used and absorbance was measured at the appropriate 
wavelength. Single-stranded DNA, double-stranded DNA and RNA absorb at 
260nm. Sample quality was also determined by calculation of the A260/A280 and 
A260/A230 ratios, indicative of sample contamination as organic compounds absorb 
UV light at 230nm and protein at 280nm. DNA is considered pure when the 
A260/A280 ratio is 1.7-1.9 and RNA when the A260/A280 ratio is 1.9-2.1.  
2.6.2 DNA quantification using Picogreen 
The concentration of DNA used for next-generation sequencing was measured 
using picogreen as an accurate measurement of double-stranded DNA was 
required. Picogreen is a dye which binds and intercalates with DNA meaning that 
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only double-stranded DNA is measured. This is in contrast with spectrophotometers 
which measure both single and double-stranded DNA. The Quant-iT™ broad range 
ds-DNA assay kit (Invitrogen by Life Technologies, USA) was used. 198µl 
picogreen mix (197µl reagent buffer and 1µl picogreen reagent) was mixed with 2µl 
of standard DNAs of known-concentration (kit-supplied) or 2µl DNA to be quantified 
and loaded onto a black flat-bottom 96-well plate. The plate was loaded onto the 
FLUOstar Galaxy spectrofluorometer (BMG Labtech, Germany) and intensity was 
measured using an excitation filter at 480nm and an emission filter at 520nm. The 
standard curve using the 8 DNAs of known concentration and the concentration of 
the unknown samples were calculated by the FLUOStar Galaxy software.  
2.6.3 DNA/RNA fragment size assessment  
DNA/RNA fragment size was determined during preparation of samples for next-
generation sequencing described in section 2.9.1 and 2.9.2. RNA fragment size 
was checked to determine the quality of RNA samples before running them on the 
Affymetrix microarray described in section 2.7 and before proceeding to library 
preparation for RNA-sequencing described in section 2.9.2. Both Agilent 2100 
Bioanalyser and 2200 Tapestation automated electrophoretic systems were used.  
The assay on 2100 Bioanalyser is in a chip format and uses micro-fluidics 
technology to enable electrophoretic nucleic acid fragment separation (Mueller et 
al., 2000). The assay on the most recent Agilent 2200 Tapestation instrument is in a 
tape format and contains acrylamide gel and integrated electrodes to enable nucleic 
acid separation. The fragment sizes were evaluated by looking at the 
electropherograms. 
2.6.3.1 Agilent 2100 Bioanalyser 
2.6.3.1.1 DNA 1000/High Sensitivity kit for DNA analysis 
The Agilent DNA 1000 kit was used for the detection of DNA fragments after 
shearing or the detection of DNA library size and the manufacturer’s protocol was 
followed. The gel-dye matrix was prepared by adding 25µl DNA blue dye 
concentrate to a DNA gel matrix vial (both equilibrated at room temperature), mixed 
well by vortexing. This was transferred to the spin column provided and centrifuged 
at 2240g for 15 minutes. 9µl DNA gel-dye mix was added to the appropriate well of 
the chip. The chip was placed in the priming station, the syringe was plunged down 
and the chip left in place for 1 minute. Then the chip was taken out of the priming 
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station and 9µl DNA gel-dye mix, 5µl DNA marker, 1µl DNA ladder and 1µl sample 
were added to the appropriate wells. The chip was vortexed for 1 minute and finally 
loaded onto the instrument. Most FFPE libraries were of low concentration and for 
these the High Sensitivity version of the kit was used, especially when comparisons 
were done between samples prepared using different methods. The manufacturer’s 
protocol was followed (similar to the DNA 1000 kit). The data from both chips were 
analysed using the 2100 Expert software. 
2.6.3.2 Agilent 2200 Tapestation 
2.6.3.2.1 Standard D1K/High Sensitivity HD1K Tape for DNA analysis 
The Agilent 2200 Tapestation was also used for the detection of DNA fragments 
after shearing or the detection of DNA library size when it replaced the Agilent 2100 
Bioanalyser in the laboratory. The Standard D1K kit or the High Sensitivity HD1K kit 
was used and the manufacturer’s protocol was followed. 16 samples can be run on 
each tape, usually comprising a ladder and 15 DNA samples. The samples are 
prepared in 8-well strip tubes and then specialist loading tips transfer the samples 
from the tubes to the tape in the instrument. 3µl D1K ladder was placed into the first 
well of the 8-well strip, with 3µl sample buffer and 1µl DNA or 2µl sample buffer and 
1µl DNA being prepared for the D1K kit or the HD1K kit respectively. The tubes 
were quickly vortexed and centrifuged, and loaded onto sample cradle of the 
instrument, together with the loading tips and appropriate tape. The data were 
analysed using the supplied 2200 Tapestation Controller software. 
2.6.3.2.2 R6K kit for RNA analysis 
Total RNA fragment size assessment was done using the R6K kit and the 
manufacturer’s protocol was followed. 4µl R6K sample buffer was mixed with 1µl 
RNA. Sample denaturation was achieved by heating the samples at 72oC for 3 
minutes and then placing them on ice for 2 minutes. The samples, loading tips and 
R6K tape were loaded onto the instrument and the data analysis was performed 
using the 2200 Tapestation Controller software. A software ladder was assigned to 
each run and the sizes were assessed. The RNA Integrity Number (RIN) was 
calculated by the software and used as a quality assessment measure. RIN values 
start from 0 indicating totally degraded RNA to 10 indicating totally intact RNA. The 
algorithm that calculates the RIN takes into account several features of the 
electrophoretic curve as described previously (Schroeder et al., 2006).  
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2.7 Affymetrix GeneChip® Human Genome U133 plus 2.0 
Array 
The Affymetrix GeneChip® Human Genome U133 plus 2.0 platform array was used 
for the gene expression work described in Chapter 5. 500ng total RNA was sent to 
the Affymetrix service provider at the Patterson Institute, University of Manchester, 
UK. The Human Genome U133 plus 2.0 array is a high-density probe-based array 
(Lockhart et al., 1996) currently comprised of 54,120 probe sets, translating into 
47,401 gene transcripts. A probe is a 25-mer oligonucleotide which targets a 
specific gene transcript and millions of copies of a specific probe are immobilised 
on the solid surface of the array in a specific region called a probe cell. Each 
transcript is represented by multiple probe sets and each probe set is comprised of 
a perfect match (PM) and a mismatch probe (MM) (Lockhart et al., 1996, Lipshutz 
et al., 1999). The mismatch probe has the same sequence as the perfect match 
probe except for a non-complementary nucleotide in its 13th position. Theoretically, 
the mismatch probes can be used to remove non-specific hybridisation (Lipshutz et 
al., 1999). Sample preparation and array scanning were performed according to 
Affymetrix guidelines (Affymetrix, 2009) at the Patterson Institute. Briefly 40ng high 
quality RNA (RIN>7) was converted to double-stranded cDNA. Only one RNA 
sample had a RIN<7 and was therefore not processed further. The double-stranded 
cDNA was purified using a column-based step, amplified and then repurified. The 
clean, double-stranded cDNA was converted to biotin-labelled cRNA using in vitro 
transcription, purified and fragmented to produce fragments of 35-200 bases in 
length. A hybridisation cocktail was prepared containing the clean biotin-labelled 
cRNA fragments and the mixture was transferred to the array where the cRNA 
fragments were hybridised to the complementary oligonucleotides present on the 
array for 16 hours. After hybridisation, unbound cRNA was removed and a number 
of washing and staining steps were performed resulting in the fluorescent agent 
streptavidin-phycoeryhtrin being bound to the biotin-labelled cRNA (Figure 2-3). 
The array was then placed in the GeneArray® laser scanner where the intensity of 
the fluorescent agent was recorded and an image of the entire chip was taken. 
Using a control probe a grid is aligned on the image and a raw intensity probe value 
for each probe cell is calculated. The raw intensity values are stored in CEL files 
which is the format that the data were received and used for subsequent analysis.  
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Figure 2-3: Affymetrix GeneChip array. 
RNA is converted to double-stranded cDNA, which is then converted to biotin-
labelled cRNA using in vitro transcription and fragmented to produce 
fragments of 35-200 bases in length. The cRNA fragments are hybridised to 
the complementary oligonucleotides present on the Affymetrix GeneChip® 
Human Genome U133 plus 2.0 platform array. 
 
2.7.1 Data pre-processing and quality control 
Data pre-processing is always performed before statistical analysis of array-based 
gene expression data to subtract technical variation from biological variation 
(Bolstad et al., 2003). Technical variation usually arises from differences in sample 
preparation, processing or scanning of the arrays. A number of different methods 
have been compared for their performance so far (Irizarry et al., 2003a, Giorgi et 
al., 2010). Here, the Robust Multi-Chip Analysis (RMA) algorithm (Irizarry et al., 
2003b) was used to pre-process the data described in Chapter 5 using 
BioConductor software (Gentleman et al., 2004) in R programming environment (R 
Development Core Team, 2012). RMA uses only the PM probe values and totally 
ignores the MM probe values while the originally proposed algorithm for Affymetrix 
array data, MAS5, uses both PM and MM probe values (Hubbell et al., 2002). It has 
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been shown that subtracting the MM probe values from PM values mathematically 
does not always correct for non-specific hybridisation (Irizarry et al., 2003a, Irizarry 
et al., 2003b, Naef et al., 2002). Furthermore, MAS5 does not take into account 
across-array normalisation while RMA does (Irizarry et al., 2003b). Briefly, RMA 
pre-processing includes three steps: background adjustment to remove non-specific 
intensities, quantile normalisation across arrays to make them comparable, and 
summarisation using a log scale linear additive model to calculate a single 
expression measure for each probe set. Density plots of log-intensity distribution of 
each array before and after data pre-processing were used to identify arrays with 
abnormal distributions. The density distributions of raw probe-set log-intensities are 
not expected to be identical but still well correlated while the distributions of 
normalized probe-set log-intensities are expected to be more identical. 
After data pre-processing quality control assessment was performed using the 
affyPLM package (Bolstad et al., 2005) available from BioConductor software in R 
which uses probe-level models. Chip pseudo images of the residuals of the models 
were produced to help us identify any artefacts on the arrays. Box plots of the 
Relative Log Expression (RLE) values for each probe set were also produced by 
comparing the expression value of each array against the median expression value 
across the arrays for the given probe set. The box plots should be centred to zero 
assuming that most of the expression values across arrays remain the same. 
Normalised Unscaled Standard Errors (NUSE) for each probe set on the array were 
also plotted. Standard error estimates for each probe set on each array were 
calculated and standardised across arrays so that the median standard error for 
that probe set is 1. Elevated standard errors relative to the other arrays are usually 
of lower quality. Finally, the average intensity of each probe across all probe-sets, 
ordered from the 5‘ to the 3’ end was calculated and plotted as a curve (RNA 
degradation plot) for each sample. Since degradation starts from the 5’ end of the 
RNA molecule, we would expect probe intensities to be lower at that end of a probe 
set compared to the 3’ end. An RNA sample that is too degraded will have a very 
high slope from 5' to 3'. The slope of the curves was thus used as a quantitative 
indicator of the RNA degradation. Two samples which did not perform as expected 
in most of the quality control plots were excluded from further analysis. The density 
distributions of log-intensities before and after pre-processing are included in 
Appendix A.2. Data pre-processing and quality control was performed by Dr Alastair 
Droop who is a bioinformatician in the Leeds Cancer Research UK Centre.  
  
73 
2.8  Illumina whole-genome cDNA-mediated annealing, 
selection, extension and ligation (WG-DASL HT) assay 
The Illumina WG-DASL HT assay, which uses the HumanHT-12 v4 Expression 
BeadChip, was used for the gene expression work using FFPE samples described 
in Chapter 4. Two hundred nanograms total RNA (whenever possible) was sent to 
the Illumina service provider, ServiceXS (Leiden, Netherlands). The 12-sample 
HumanHT-12 v4 Expression BeadChip platform is composed of individual 40,000 
probe-based bead arrays on a microscope slide surface. Three-micron beads 
assembled into the micro wells of the BeadChip substrate have probes attached to 
them. Each bead has thousands of copies of one type of probe and is present in 
multiple copies on the array. Each array has a 12-sample format enabling multiple 
samples assayed using a single array.  
Sample preparation and array scanning were performed according to the Illumina 
guidelines (Illumina, 2012) by ServiceXS (Leiden, Netherlands). The WG-DASL HT 
assay can be used for partially degraded RNAs as it uses random priming in cDNA 
synthesis and a target sequence of only 50 nucleotides is required for probe groups 
to anneal (described below). RNA quality was measured using qRT-PCR of the 
housekeeping gene RPL13a as described in the Illumina manual (Illumina, 2012), 
by ServiceXS. Mean cycle threshold (Ct) values were determined for all samples. 
Previous DASL data within the group have demonstrated that this quality control 
step does not correlate with performance on the array and therefore all samples 
were used in the assay irrespective of this quality control step (Conway et al., 2009, 
Jewell et al., 2010). 
The assay begins with conversion of total RNA to cDNA using biotinylated oligo(dT) 
and random nonamer primers. The biotinylated cDNA is then annealed to the DASL 
Assay Pool (DAP) probe groups. The DASL Assay Pool probe groups consist of 
29,285 unique probes. The assay probe group consists of two 50-mer 
oligonucleotides; an upstream which contains a transcript-specific sequence and a 
universal PCR primer 1 at the 5’ end and a downstream which contains a transcript-
specific sequence and a universal PCR primer 2 at the 3’ end. The oligos are 
hybridised to the targeted cDNA sites and non-hybridised oligos are washed away 
using streptavidin-conjugated paramagnetic particles. A polymerase is added and 
the upstream oligo extends and ligates to its corresponding downstream oligo to 
create a PCR template which is amplified with universal PCR primers 1 and 2. The 
PCR primer on the strand that is complementary to the array is fluorescently 
labelled. After amplification the labelled single-stranded product is hybridised to the 
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HumanHT-12 v4 Expression BeadChip (Figure 2-4). After hybridization, HumanHT-
12 v4 Beadchips are scanned using the Illumina HiScan, iScan System or 
BeadArray Reader which measures fluorescence intensity at each bead location. 
The intensity of the signal corresponds to the quantity of the respective transcript in 
the original sample. The intensity values are stored in data files (*.bgx) and are 
analysed using Illumina’s GenomeStudio® software. 
 
 
Figure 2-4: WG-DASL HT assay. 
RNA is converted to cDNA using biotinylated primers. The biotinylated cDNA 
is then annealed to the DASL Assay Pool (DAP) probe groups. Correctly 
annealed oligos are extended, ligated and amplified using PCR. The PCR 
primer on the strand that is complementary to the array is fluorescently 
labelled. After amplification the labelled single-stranded product is hybridised 
to the HumanHT-12 v4 Expression BeadChip. 
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2.8.1 Control and replicate samples 
To ensure the reproducibility of the assay, technical replicates (RNA samples from 
the same extraction) and biological replicates (RNA samples derived from different 
FFPE blocks of the same tumour) were assessed. To further monitor the 
performance of the assay MelJuso cell line RNA samples and Stratagene Universal 
Human Reference RNAs (Agilent Technologies, Edinburgh, UK) were also included 
on the array.  
2.8.2 Data pre-processing and quality control 
As discussed in section 2.7.1 data pre-processing is an important step before 
statistical analysis of array-based gene expression data (Bolstad et al., 2003). Data 
were pre-processed using Lumi package (Du et al., 2008) downloaded from 
BioConductor (Gentleman et al., 2004) in R (R Development Core Team, 2012).  
The number of genes detected in each sample represents the genes for which 
target sequence signal is distinguishable from negative controls on the array at 
threshold p value<0.01. Previously published data have reported the number of 
genes detected as a measure of the array performance (Ravo et al., 2008). In this 
experiment the average number of genes detected was 13572 (range 6848-16194, 
Figure 2-5). 
Data were background corrected to remove non-specific intensities and normalised 
using Robust Spline Normalisation (RSN), a method which is unique in the Lumi 
package (Du et al., 2008). Briefly, RSN includes features of quantile normalization 
(preservation of the rank order of genes) and loess method (continuous intensity 
data transformation) (Du et al., 2008). 
Quality control (QC) plots including density plots of log-intensity distribution and 
boxplots of each sample before and after data pre-processing were used to identify 
samples with abnormal performance. These QC plots highlighted a few samples 
that did not perform well. Therefore, we explored the possibility that samples with 
low number of genes detected have not performed well on the array. The number of 
genes detected in each sample was found to be inversely correlated with both RNA 
concentration (Spearman’s rho=-0.20, p=0.002) and Ct value of the housekeeping 
gene RFLP13a (Spearman’s rho=-0.20, p=0.002) but not with melanin score or age 
of the block (data not shown). This finding shows evidence that a low number of 
genes detected might be due to a combination of low input material and low RNA 
quality. Consequently, data normalisation was rerun after exclusion of samples with 
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<9000 genes detected (2.5% of the samples). Log-intensity plots after normalisation 
showed three further outlier samples and we excluded them as well. Two of these 
samples had the number of genes detected in the lower bracket (respectively 9674 
and 10021), which further supports the view that the number of genes detected is a 
good diagnostic tool. Based on the above observation the threshold applied for 
sample exclusion was <10021 genes detected. The number of genes detected for 
the third sample (14362) could not explain its abnormal behaviour after pre-
processing. However, this sample was also excluded from the analysis as it was an 
outlier (possibly due to contamination or signal saturation). The cell line samples 
expressed more genes than tumour tissues (see Figure 2-5) and their log-intensity 
distributions were outlying before and after the pre-processing. For this reason we 
excluded them from the dataset prior to the final pre-processing. 
 
 
 
Figure 2-5: Number of genes detected (p<0.01) for each sample on the WG-
DASL HT assay. 
The red dots represent the number of genes detected for the cell line 
samples. All other samples were FFPE-derived. 
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In summary, data pre-processing was finally performed after exclusion of 5 samples 
with <10021 genes detected, 1 outlier sample and all cell line RNA samples. QC 
plots after sample exclusion before and after data pre-processing can be found in 
the Appendix A.2.3. The correlation between replicate samples after pre-processing 
is shown in Table 2-5. The correlation coefficients between normalised probe 
signals of replicate cell line RNAs are presented separately as they were before 
their exclusion to demonstrate the performance of the assay. Correlation 
coefficients across technical replicates are high, with slightly higher correlation 
across cell line RNA technical replicates, as expected (Table 2-5). The mean 
correlation coefficient for biological replicates was smaller which could be attributed 
to tumour heterogeneity (Table 2-5). 
In summary, the data were of sufficiently good quality, and subsequently the 
replicate signals were averaged before log transformation and statistical analyses 
described in Chapter 5. 
 
 
Table 2-5: Correlation coefficients between RSN transformed probe signal 
intensities of replicate samples. 
Correlation coefficients for technical cell line replicates are presented as they 
were before cell line samples were finally excluded from the data. 
Replicates (number 
of pairs) 
Νumber of replicate 
pairs with failed samples 
Mean of correlation 
coefficients (Range) 
Technical FFPE 
replicates (22) 
2 0.96 (0.81-0.99) 
Biological FFPE 
replicates (5) 
0 0.91 (0.84-0.93) 
Technical cell line 
replicates (4) 
0 0.98 (0.98-0.99) 
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2.9 Next-generation sequencing 
A number of different next-generation sequencing platforms have been developed 
so far (reviewed by (Zhang et al., 2011, Ross and Cronin, 2011, Mardis, 2008)). 
These are: a) the Roche GS-FLX/454 Genome Sequencer; b) the Illumina Genome 
Analyzer HiSeq2000; c) the ABI SOLiD system; d) the Danacher/Dover/Azco 
Polonator G.007; and e) the Helicos HeliScope. All platforms use slightly different 
technology to perform massively parallel sequencing differing in accuracy, error-
rate and read-length (Zhang et al., 2011). Here in Leeds the Illumina Genome 
Analyzer platforms have been used. Initially there was a Genome Analyzer IIx 
installed, however more recently a HiSeq2000 instrument replaced the Genome 
Analyzer IIx. 
The Illumina system uses a sequencing-by-synthesis technology. The template 
requires amplification, through solid-phase amplification (Metzker, 2010), before 
sequencing, as this system cannot detect single fluorescent events. Double-
stranded DNA, the input material, is fragmented mechanically or enzymatically and 
adapter sequences are ligated to the sample. A PCR step follows to amplify the 
ligated template which is then called a library and further attached to a glass slide, 
the flow cell. Oligos complementary to the adapters are attached to the surface of 
the flow cell. A flow cell consists of 8 lanes and thus 8 samples can be run 
simultaneously (7 test samples and 1 control). Each cluster is generated through 
bridge amplification by the addition of non-fluorescent nucleotides and a DNA 
polymerase (Metzker, 2010). In the end each fragment consists of millions of 
clones. The clusters provide free ends and a universal sequencing primer is 
hybridised and sequencing initiates. All four fluorescently-labelled nucleotides with 
3’ blocked reversible terminators are added simultaneously but only the 
complementary one is incorporated at each position. When the first nucleotide is 
added to each sequence, the unincorporated nucleotides are washed away and 
imaging is performed. Then, the terminating group and the fluorescent dye are 
removed and the second incorporation takes place. This is called cyclic reversible 
termination (Metzker, 2010). The steps from DNA fragmentation to imaging are 
shown schematically in Figure 2-6. 
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Figure 2-6: Illumina sequencing technology.  
DNA is fragmented and adapters are ligated to each fragment, followed by 
PCR amplification. The amplified product is immobilised on the flow cell and 
each sequence is further amplified to form clusters comprised of millions of 
copies of that sequence. Sequencing is performed using sequencing-by-
synthesis technology and imaging is performed. (More details are provided in 
the text) Adapted from (Metzker, 2010). 
 
2.9.1 Whole-genome library preparation protocols using DNA for 
Illumina next-generation sequencing on the HiSeq2000 
instruments 
In the course of my thesis I attempted to generate next generation sequencing data 
from tiny formalin-fixed tumours, some of which were very old (and likely therefore 
degraded) and heavily contaminated with melanin. Library preparation was 
therefore potentially a serious issue both in terms of efficiency and time taken and 
therefore five different protocols were evaluated for the preparation of DNA libraries 
from FFPE derived DNA (Chapter 3). Protocols number 1, 2 and 5 as listed below 
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were performed by myself while protocols 3 and 4 by a service provider, Source 
Biosciences, UK. 
All are based on the same principle except for the NEXTERA™ protocol which is 
described in detail in section 2.9.1.4. DNA is first fragmented into small fragments 
mechanically resulting in the formation of blunt ends. An end-repair reaction 
corrects the blunt ends and adenine addition follows to prepare DNA for adapter 
ligation. During ligation, adapters containing a 6-nucleotide barcode at the 5’ end or 
indexed adapters are ligated to the DNA and a PCR step follows to amplify the 
ligated sample. Only one protocol (see section 2.9.1.5) used a different method to 
tag the samples where non-barcoded adapters were ligated to the DNA and 
indexed primers during PCR amplification were used to tag the sample. The 
indexed adapters/primers contain a 6-nucleotide barcode in the middle of the 
adapter/primer molecule, thus a different sequencing primer is used to read the 
barcode in an independent sequencing run. The barcodes are useful to identify 
samples when multiplexing more than one sample. The amplified sample is loaded 
onto the flow cell and cluster generation and sequencing are performed as 
described in section 2.9. 
The concentration of the input DNA and the final library was measured using 
Picogreen (section 2.6.2). The size of the libraries was evaluated on either a 
standard or a high sensitivity chip on the Agilent Bioanalyser or the Tapestation 
System (section 2.6.3). 
2.9.1.1 Library preparation protocol number 1 using 5’-end barcodes 
(manual protocol) 
DNA in a final volume of 250µl (TE added) was sheared on the Covaris S2 
sonicator (KBiosciences, UK) to produce an average fragment size of 200bp. 
After shearing, DNA was cleaned up using the MinElute purification kit (Qiagen, 
Crawley UK). Briefly, 5x volume of the PB binding buffer was added to the sheared 
DNA, the solution was processed through a MinElute column, then a wash step of 
750µl of PE wash buffer followed and the elution was done in 10µl of the elution 
buffer (EB) provided within the kit. 1µl of sheared sample was checked on the 
Bioanalyser or Tapestation system (Agilent Technologies, USA) using a standard or 
a high sensitivity chip. 
The blunt DNA ends formed after shearing were repaired using the End-It DNA End 
Repair kit (Epicentre, USA). The reaction was prepared as shown in Table 2-6 and 
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the mix was incubated at room temperature for 45 minutes. The reaction was then 
purified using the QiaQuick purification kit (Qiagen, Crawley UK) using the same 
protocol when the MinElute purification kit was used but a QiaQuick column used 
instead of a MinElute. The elution was done in 34.45µl EB or 30µl EB if BSA was 
used. 
 
Table 2-6: End-repair reaction 
 Volume without BSA (µl) 
Volume with BSA 
(µl) 
DNA 9 9 
End-it Buffer 5 5 
dNTP mix 5 5 
ATP 5 5 
End-it Enzyme mix 1 1 
BSA - 5 
dH2O 25 20 
 
The A-Addition reaction followed where adenine is added at the repaired DNA ends 
to prepare the molecule for the adapter ligation. The reaction was prepared as in 
Table 2-7 using 9 U/µL DNA polymerase I Large (Klenow) fragment, exonuclease 
minus (Promega, USA) and dATP (Promega, USA). 
 
Table 2-7: A-Addition reaction 
 Volume without BSA (µl) 
Volume with BSA 
(µl) 
DNA 34.45 30 
DNA Pol (Klenow) Buffer 5 5 
1mM dATP 10 10 
Klenow  0.55 0.55 
BSA - 4.45 
 
The ligation mix prepared as described in Table 2-8 and the mix was incubated at 
room temperature for 15 minutes followed by 20 minutes at 65oC for to inactivate 
the ligase. The adapter sequences are listed in Appendix A.3. 
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Table 2-8: Ligation reaction 
 
Volume without BSA 
(µl) 
Volume with BSA 
(µl) 
DNA 10 9 
Liga-fast reaction buffer 15 15 
Adapter 0.5 0.5 
T4 DNA Ligase 3 3 
dH2O 2 - 
BSA - 3 
 
After ligation, size selection was performed using the AgenCourt Ampure XP Beads 
(Beckman Coulter, USA). The beads were added (0.9x of the reaction volume) and 
the sample mixed thoroughly by pipetting. The mixed sample was left at room 
temperature for 3-5 minutes and then placed on a magnetic separator rack 
(Invitrogen, UK) for 5-10 minutes and the beads were separated from the solution. 
The supernatant was aspirated and discarded. Two wash steps with 200µl 70% 
ethanol followed and after the last wash step the beads were air-dried for 15-20 
minutes and the DNA was finally eluted in 30µl EB. All the steps were performed on 
the magnetic rack. 
A PCR enrichment step was performed to enrich the ligated sample. The reaction 
was prepared as described in Table 2-9 and placed on a thermocycler at 98oC for 
30 seconds, 15 or 18 cycles of 98oC for 10 seconds, 65oC for 30 seconds and 72oC 
for 30 seconds, and finally 72oC for 5 minutes. The forward and reverse primers 
used were 5'-CAA GCA GAA GAC GGC ATA CGA GAT CGG TCT CGG CAT TCC 
TGC TGA ACC GCT CTT CCG ATC T-3’ and 5'-AAT GAT ACG GCG ACC ACC 
GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC T-3’ 
respectively. 
 
Table 2-9: Enrichment reaction 
 Volume without BSA 
(µl) 
Volume with BSA 
(µl) 
DNA 20 20 
Phusion HF Master Mix 25 25 
PE-PTO-F primer(25uM) 1 1 
PE-PTO-R primer(25uM) 1 1 
BSA - 5 
dH2O 13 8 
83 
The reaction was finally purified using the AgenCourt Ampure XP Beads (1.8x of 
reaction volume) as described previously. 
2.9.1.2 Library preparation protocol number 2 using 5’-end barcodes 
on the SPRIworks system (Beckman Coulter, USA) 
Libraries were prepared using the SPRIworks automated system (Beckman 
Coulter, USA). The DNA was sheared using the Covaris S2 sonicator and it was 
placed straight on the SPRIworks instrument. The steps performed on the 
instrument were: DNA purification using beads; end-repair; purification with beads; 
A-addition; purification with beads; adapter ligation; and beads size selection. The 
5’-end barcoded adapters were used in this system but were diluted first in 1:20. 
The enrichment and the final clean-up steps were manually performed as described 
in section 2.9.1.1. 
2.9.1.3 Library preparation protocol number 3 on the Agilent Bravo 
robot using the TruSeq™ protocol (indexed adapters) (Illumina 
Inc., USA) 
This is a semi-automated method where 96 libraries can be prepared in each run 
and requires manual intervention. The Truseq™ DNA sample preparation kit 
(Illumina Inc., USA) containing indexed adapters was used. Test FFPE DNA was 
sheared using a Covaris S2 sonicator with an average fragment size of 350bp. 50µl 
fragmented DNA was then mixed with 10µl End Repair Control and 40µl End 
Repair Mix and incubated for 30 minutes at 30oC. The reaction was cleaned-up 
using 160µl AMPure XP Beads (Beckman, Coulter, USA) and eluted in 15µl 
Resuspension Buffer. 2.5µl A-Tailing Control and 12.5µl A-Tailing Mix were mixed 
with 15µl of clean end-repair reaction to perform the A-addition step. The reaction 
was incubated for 30 minutes at 37oC. Adapter ligation was immediately performed 
by mixing 2.5µl Ligation Control, 2.5µl Ligation Mix and 2.5µl DNA Adapter Index 
with 15µl end-repaired fragments and incubating for 10 minutes at 30oC. The 
ligation reaction was stopped by the addition of 5µl Stop Ligation Buffer. The 
ligation reaction was cleaned-up using 42.5µl AMPure XP Beads and eluted in 50µl 
Resuspension Buffer. A second clean-up step followed by adding 50µl AMpure XP 
Beads and the final elution was done in 20µl Resuspension Buffer. Size selection of 
the ligation products were performed after running them on a 2% agarose gel 
stained with 1x SyBR Gold. Gel bands were cut at 350bp. The bands were 
extracted from the gel using MinElute Gel Extraction kit (Qiagen, Crawley UK) 
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eluting in 25µl Qiagen EB buffer. 5µl PCR Cocktail Mix and 25µl PCR Master Mix 
were mixed with 20µl purified ligated fragments and put on a thermal cycler at 98oC 
for 30 seconds, 10 cycles of 98oC for 10 seconds, 60oC for 30 seconds and 72oC 
for 30 seconds, and 72oC for 5 minutes. The PCR reaction was cleaned-up using 
50µl AMPure XP Beads and eluted in 30µl Resuspension Buffer. The Truseq™ 
libraries on the Agilent robot were prepared by Source BioScience, UK. 
2.9.1.4 Library preparation protocol number 4 using the NEXTERA™ 
kit (indexed adapters) (Illumina Inc., USA) 
This protocol uses an engineered transposome to randomly fragment the DNA and 
add adapter sequences to the ends in a single step called tagmentation. 25µl of 
tagment DNA buffer and 5µl of the tagment enzyme were added per 20µl of DNA 
sample at a 2.5ng/µl concentration (50ng in total). The reaction was incubated in a 
thermal cycler at 55oC for 5 minutes. Then the tagmented DNA was purified using 
the column-based Zymo purification kit. 180µl Zymo DNA binding buffer was mixed 
with the 50µl reaction, transferred to the Zymo-Spin I-96 plate and centrifuged at 
1,300xg at 20oC for 2 minutes. The plate was washed twice after the addition of 
300µl wash buffer and centrifugation at 1,300g for 2 minutes. The tagmented DNA 
was eluted in 25µl resuspension buffer. Then the PCR amplification step was 
performed by mixing 20µl cleaned tagmented DNA with 5µl of index 1 primers, 15µl 
of the NEXTERA™ PCR master mix and 5µl PCR primer cocktail. The reaction was 
put on a thermocycler at 72oC for 3 minutes, 98oC for 30 seconds and 5 cycles of 
98oC for 10 seconds, 63oC for 30 seconds and 72oC for 3 minutes. Finally, the 
library was purified and the correct size fragments were selected using AMPure XP 
beads. The average size of libraries prepared with this protocol should be 500bp. 
The NEXTERA™ libraries were prepared by Source BioScience, UK. 
2.9.1.5 Library preparation protocol number 5 using the NEBNext® 
Ultra DNA Library Prep kit for Illumina (indexed primers) (New 
England BioLabs, UK) 
The NEBNext® kit was also considered for DNA library preparation from FFPE 
samples as it was optimised for as little as 5ng fragmented DNA. DNA 
fragmentation and purification steps were performed as described previously (see 
2.9.1.1) except that the elution after purification was done in 14µl buffer EB. 55.5µl 
fragmented DNA (50ng maximum) was mixed with 3µl End Prep Enzyme Mix and 
6.5µl End Repair Reaction Buffer (10x) and incubated on a thermal cycler at 20oC 
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for 30 minutes and 65oC for 30 minutes. The End Prep product was then mixed with 
15µl Blunt/TA Ligase Master Mix, 2.5µl 1:10 diluted NEBNext Adaptor for Illumina 
and 1µl Ligation Enhancer and incubated at 20oC for 15 minutes in a thermal cycler. 
3µl of USER™ Enzyme was immediately added to the ligation mixture and 
incubation at 37oC for 15 minutes followed. The ligated product was cleaned up 
using 86.5µl AMPure XP beads with three 80% ethanol washes and elution in 28µl 
of 0.1x TE. 23µl of clean ligated product was mixed with 25µl NEBNext High Fidelity 
2x PCR Master Mix, 1µl Universal Primer and 1µl Index Primer (provided in 
NEBNext Multiplex Oligos for Illumina, Index Primers Set 1). The PCR amplification 
was performed using the following thermal cycler conditions: 98oC for 30 seconds, 
12 or 15 cycles of 98oC for 10 seconds, 65oC for 30 seconds and 72oC for 30 
seconds, and 72oC for 5 minutes. The PCR product was then purified using 50µl 
AMPure XP beads with 2 80% ethanol washes and eluted in 33µl 0.1x TE. 
2.9.2 Whole-genome library preparation using total RNA for RNA-
sequencing using the Illumina HiSeq2000 
The aim of the work described in this section was to assess the feasibility to use 
RNA-sequencing technology using FFPE material. As a result RNA extracted from 
matched frozen and FFPE primary melanoma cell lines (SkMel28, MelJuso and 
SkMel5) was used to prepare libraries using the newly available TruSeq Stranded 
Total RNA Sample Preparation kit (Illumina Inc., USA). This protocol was chosen as 
it has been optimised to prepare libraries both from intact and fragmented RNA, i.e. 
RNA extracted from FFPE tissue. The quality of the RNA samples extracted from 
the cells was analysed on the Agilent Tapestation to determine fragmentation time 
as described below. 
2.9.2.1 rRNA-removal 
100ng total RNA measured by Nanodrop was used. Ribosomal RNA (rRNA) was 
depleted and the remaining RNA was purified, fragmented and primed for cDNA 
synthesis. The lid was pre-heated to 100oC during all thermal cycler programs and 
all incubations during this protocol were done at room temperature except 
otherwise stated below. The total RNA was first diluted with nuclease-free water up 
to a final volume of 10µl. 5µl rRNA Binding Buffer was added to the diluted RNA 
sample and mixed well. The addition of 5µl Ribo-Zero rRNA Removal Mix-Gold 
followed and the sample was mixed thoroughly. The sample was then placed on a 
thermal cycler at 68oC for 5 minutes to denature the RNA. Then, the sample was 
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left at room temperature for 1 minute. 35µl rRNA Removal Beads were mixed well 
with the sample for 1 minute. The tube was put on a magnetic stand for 1 minute 
and the resulting supernatant transferred to a new tube. The old tube was 
discarded and the new tube was then placed on the magnetic stand for 1 minute, 
repeating once more to ensure complete removal of all magnetic beads. After the 
third clean-up on the magnetic stand the supernatant was transferred to a new 
tube. 193µl RNAClean XP beads were added to a fresh tube and the rRNA-
depleted RNA was transferred and mixed with the beads. The tube was incubated 
at room temperature for 15 minutes, then placed on the magnetic stand and 
incubated for a further 5 minutes. The supernatant was discarded. Two 200µl 70% 
ethanol washes were performed and rRNA-depleted RNA was finally eluted in 11µl 
Resuspension Buffer. 8.5µl clean rRNA-depleted RNA was transferred to a new 
tube. 
2.9.2.2 RNA fragmentation 
8.5µl rRNA-depleted RNA sample was fragmented after mixing with 8.5µl Elute, 
Prime, Fragment High Mix and put on a thermal cycler at 94oC. The fragmentation 
time differs based on RIN scores and Agilent RNA traces by matching the sample 
profiles to example profiles illustrated in the protocol. Therefore the fragmentation 
time for intact frozen RNA samples was 8 minutes and for FFPE RNA was 7 
minutes. After fragmentation the thermal cycler was set at 4oC and on reaching 
temperature the sample was removed and briefly centrifuged.  
2.9.2.3 First and second cDNA strand synthesis 
SuperScript II was mixed with First Strand Synthesis Act D Mix at a ratio of 1:9 and 
8µl of the mix was added to the fragmented RNA sample. The first cDNA strand 
synthesis was performed on a thermal cycler at 25oC for 10 minutes, 42oC for 15 
minutes and 70oC for 15 minutes. The second cDNA strand was then synthesized 
by adding 5µl Resuspension Buffer and 20µl Second Strand Marking Master Mix to 
the tube containing the RNA:cDNA sample. The reaction was performed on a 
thermal cycler at 16oC for 1 hour having pre-heated the lid to 30oC. The double-
stranded cDNA reaction was purified by addition of 90µl AMPureXP beads. Two 
washes with 200µl 80% ethanol were performed and the double-stranded cDNA 
was eluted in 17.5µl Resuspension Buffer. 15µl clean double-stranded cDNA was 
transferred to a fresh tube. 
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2.9.2.4 3’ end adenylation, adapters ligation and enrichment 
The rest of the procedure includes 3’end adenylation, adapter ligation and PCR 
enrichment for the completion of the library preparation. 2.5µl Resuspension buffer 
and 12.5µl A-Tailing Mix were added to the 15µl double stranded (ds)-cDNA and 
mixed well. The adenylation was performed on a thermal cycler at 37oC for 30 
minutes and 70oC for 5 minutes. The adenylated ds-cDNA was then mixed with 
2.5µl Resuspension buffer, 2.5µl Ligation Mix and 2.5µl Indexed Adapter. The 
adapter ligation was performed on a thermal cycler at 30oC for 10 minutes. Then 
the tube was removed from the thermal-cycler and 5µl Stop Ligation Buffer was 
mixed with the sample. The ligated sample was cleaned with 42µl AMPure XP 
beads as described in paragraph 2.9.2.3 and eluted in 52.5µl Resuspension buffer. 
The 50µl eluted cleaned ligated sample was cleaned again using 50µl AMPure XP 
bead and eluted in 22.5µl Resupension buffer. 20µl eluted clean ligated sample 
was transferred to a fresh tube. The enrichment of the DNA fragments was 
performed after addition of 5µl PCR Primer Cocktail and 25µl PCR Master Mix to 
the sample. The mixed sample was put on a thermal-cycler for 15 cycles of 98oC for 
10 seconds, 60oC for 30 seconds and 72oC for 30 seconds, finishing at 72oC for 5 
minutes. The resultant library was cleaned with 50µl AMPure XP beads and eluted 
in 32.5µl Resuspension buffer. 30µl of the clean eluted library was transferred to a 
fresh tube and was stored at -20oC before proceeding to cluster generation and 
sequencing.  
2.9.3 Results and future work 
Here I present the successful library preparation using matched frozen and FFPE 
cell line RNA. The Agilent traces of the libraries and the concentrations are 
presented in Figure 2-7. These libraries were sequenced as 1 per lane but due to 
time limitations the data have not been analysed and therefore not presented in this 
thesis. The intent was to explore the feasibility of RNA-sequencing using FFPE 
material. To identify the reproducibility of the data generated from fragmented RNA, 
libraries were also prepared from matched frozen cells. Also, microarray data are 
available from the same frozen cell line RNA to compare the data generated from 
the two platforms. Quality control of the sequencing data, correlation between 
matched samples within the same platform and across platforms should be 
performed. If this analysis shows evidence that good quality data can be generated 
from FFPE cell line RNA then the RNA-sequencing platform could be tested using 
RNA from FFPE melanoma samples. 
  
Figure 2-7: Libraries prepared from matched frozen and FFPE cell line RNA.  
All libraries were prepared successfully even when the starting material was fragmented as indicated by the RIN number for each sample. 
The concentration of libraries generated using FFPE samples were lower compared to those from frozen samples, but were sufficient for 
sequencing. 
8
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2.9.4 Cluster generation and sequencing 
Prior to sequencing, enriched libraries are clonally amplified through bridge 
amplification to form clusters of millions of copies of each DNA fragment on the flow 
cell as described in section 2.9. Cluster generation was performed on the cBOT 
instrument prior to sequencing on the HiSeq2000. 
The DNA library was first diluted to 2nM using Tris-Cl 10mM, pH 8.5 with 0.1% 
Tween 20. Then, 10µl 20pM DNA library was mixed with 10µl 0.1N NaOH, 
centrifuged to 280g for 1 minute and incubated at room temperature for 5 minutes 
to denature the DNA into single strands. The 20µl denatured DNA was transferred 
to a tube containing 980µl pre-chilled Hybridization Buffer, mixed well, pulse 
vortexed and kept on ice. The fourth lane of the flow cell is the control lane for the 
12pM PhiX library which was diluted and denatured in a similar manner. Denatured 
libraries were loaded onto an eight-tube strip. The eight-tube strip, the flow cell and 
the thawed reagent plate provided within the appropriate cluster kit version were 
placed on the cBot and v1.4 software was used. The Truseq PE Cluster Kit v3 with 
flow cell v3, Truseq SBS Kit v3-HS and HCS v1.4/RTA v1.12 were used for whole 
genome sequencing on the Illumina HiSeq2000 instrument. Paired-end runs were 
performed on the HiSeq2000 (2x100bp reads) according to Illumina standard 
protocols. 
The NGS facility team, University of Leeds, performed both cluster generation and 
sequencing runs. 
 
2.10 Bioinformatics analysis of whole genome next-
generation sequencing paired-end data generated using 
the manual protocol 
A pipeline generated by bioinformatician Dr Alastair Droop was used for aligning the 
sequencing data to a reference genome (Figure 2-8) and decisions made after 
discussion. Because the data sizes are so large the high performance computing 
facility at Leeds University (Arc1) was used. 
Two files per lane in FASTQ format were collected from the Illumina Hiseq2000 
sequencer; one file for read 1 and one for read 2. Each FASTQ file was uploaded to 
the FASTQC publicly available software (Babraham Bioinformatics, 2010). The 
FASTQC software generates plots used to assess data quality including quality 
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score per base, frequency of each base per cycle, GC content per base and 
overrepresented sequences. The Phred-based quality score represents the error 
probability for each base (Ewing and Green, 1998). A quality score of 30 is 
equivalent to the probability of an error base 1 in 1000 times (99.9% base 
accuracy). Typically, a quality score of greater than 28 is taken to indicate high 
quality data (Babraham Bioinformatics, 2010). A trimming procedure was followed 
to ensure that high quality data were used for alignment. Trimming bases with low 
quality scores has been proposed in the literature to reduce errors in the alignments 
(Minoche et al., 2011). Also, adapter sequences were removed if sequenced. Each 
sample was determined by the 6-base barcode (5 unique bases and a T at the 6th 
position). The sequencer needs a high diversity at each position and therefore 2 
different 6-base tags were added to each sample and a total number of 10 
barcodes were present in each lane.  
The reads were then aligned to the human reference genome using BWA (Burrows-
Wheeler transform) (Li and Durbin, 2009). The reference used was from Phase 2 of 
the 1000 genomes project. This reference is based on GRCh37 patch 4 (hg19) 
(Church et al., 2011), but with an updated mitochondrial sequence (NC_012920), 
herpes simplex sequences (NC_007605) and decoy sequences covering known 
repetitive regions. The repetitive decoys prevent reads mapping to repetitive 
elements from being included. The read count data were binned in 10kb regions 
before further processing. 
PCR replicates were removed from the data using SAMtools (Li et al., 2009) based 
on the fact that reads that start and end at the same genomic coordinates must be 
PCR replicates.  
A study in 2011 reported that multicopy regions due to incorrect assembly in the 
human reference genome lead to false positive CNV peaks in ChIP-sequencing 
data (Pickrell et al., 2011). These regions were listed as problematic by Pickrell et al 
and removed from further analysis (more details in Chapter 4). 
GC content can cause uneven coverage of reads in next generation sequencing 
data (Chen et al., 2013). Therefore, base content per window was defined and an 
analysis of variance (ANOVA) test was run to identify the explained variance by GC 
content for each sample. For each sample log read counts were modelled as a 
linear function of chromosome and base content. The read counts were corrected 
for base content bias based on that model.  
Finally the data were median normalised to make the samples comparable. 
Normalised read count data in 10kb regions were used for further analysis. 
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Decisions made on removal of PCR replicates, removal of problematic regions and 
GC correction are discussed in more detail in Chapter 4.  
 
 
Figure 2-8: Next-generation sequencing data pre-processing workflow. 
 
2.11 Human Osteopontin Immunoassay (Quantikine®, R&D 
systems) 
The Human Osteopontin Immunoassay is a quantitative sandwich enzyme 
immunoassay and was used for work described in Chapter 6. Samples are added 
to a 96-well microplate coated with a monoclonal antibody specific for osteopontin. 
The plate is washed and anything that has not been bound is removed. A substrate 
solution is added and colour develops the intensity of which is proportional to the 
amount of osteopontin bound to the antibody.  A dilution series of samples with 
known osteopontin concentrations are used to create a standard curve and from 
this the concentration of unknown samples is calculated. 
The stored EDTA plasma samples from the Leeds Melanoma Cohort were used. In 
addition samples from 5 patients with melanoma, 4 patients with renal cell 
carcinoma and 4 healthy people were used to assess assay performance in the 
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stored plasma samples and make a comparison between plasma and serum 
osteopontin levels. The methodological work performed is described in more detail 
in Chapter 6.  
A 25-fold dilution of EDTA plasma samples was prepared by combining 10µl 
sample and 240µl Calibrator Diluent RD5-24.  A dilution series of the osteopontin 
standard sample (starting from 20ng/ml to 0.312ng/ml) was prepared. Low and high 
level control samples with known concentrations were used to ensure the assay 
performed as expected (Quantikine® osteopontin ELISA Kit controls, R&D 
systems). All samples, controls and standards were assayed in duplicate. 100µl of 
Assay Diluent RD1-6 was added to each well of the microplate and 50µl of 
standard, control or sample was added per well. The plate was covered with an 
adhesive film and incubated for 2 hours at room temperature. The content of each 
well was aspirated and washed by adding 400µl wash buffer, repeating the process 
three times for a total of four washes using a microplate Wellwash 4 Mk 2 
autowasher (Thermo Scientific, USA). After the last wash, any remaining wash 
buffer was aspirated and the plate was inverted and blotted against clean paper 
towels. 200µl osteopontin conjugate was added to each well, the plate covered and 
incubated for 2 hours at room temperature. The aspiration/wash step was repeated 
as described above and 200µl Substrate Solution was added to each well. The 
plate was incubated for 30 minutes at room temperature protected from light. Next, 
50µl Stop Solution was added to each well and thorough mixing was ensured. The 
colour in the wells changed from blue to yellow. The optical density of each well 
was determined within 30 minutes using a microplate reader set to 450nm. 
Wavelength correction was used when the optical density was measured at 570nm. 
2.11.1 Data analysis of output from the osteopontin 
immunoassay 
Standard curves were created by fitting the standard concentrations to a 4 
parameter logistic model. Each standard curve was assessed for accuracy and 
precision of the back calculated standard concentrations. For a curve to be 
acceptable, precision and accuracy should be ≤20% at the limits of the assay and 
≤10% throughout the remaining standards. ≥80% of standards must pass the 
criteria. Once standard curves have passed the above criteria, unknown 
concentrations of samples are calculated. As each sample is run twice, the mean 
concentration of the two replicates is calculated. Precision of the duplicates should 
be ≤10%. The average of the duplicates was used for statistical analysis which is 
described in Chapter 6. 
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2.12 Summary 
In this chapter I presented methods used in this thesis. Statistical analysis relevant 
to a single chapter is presented in the relevant chapter. Here, I also reported the 
cell line authentication results derived from various cell lines used throughout the 
thesis, which highlight the importance of cell line authentication to avoid generation 
of misleading data. Finally, I presented the successful preparation of samples for 
RNA-sequencing using RNA from matched frozen and FFPE cultured melanoma 
cells with the intent to explore whether FFPE melanoma tumours can be assessed 
using this technology in the future. 
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Part II 
Results and Discussion 
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Chapter 3  
Evaluation of whole-genome library preparation 
techniques using DNA from formalin fixed paraffin 
embedded (FFPE) melanoma samples for next 
generation sequencing (NGS) 
 
3.1 Aims 
The aims of the work described in this chapter were: 
• to evaluate the performance of different whole-genome library preparation 
techniques using DNA from FFPE melanoma samples; 
• to assess if experimental DNA fragmentation is essential before library 
preparation considering that the FFPE samples might already be 
fragmented as a result of degradation in formalin; 
• to assess the use of bovine serum albumin (BSA) during library preparation 
as a means of improving the generation of data from highly pigmented 
samples by comparing libraries prepared with and without BSA 
 
3.2 Background 
High-throughput DNA sequencing using NGS technology is a powerful tool to study 
the complex cancer genome. It can be used to detect copy number alterations, 
mutations and translocations (Meyerson et al., 2010). Most NGS studies report 
usage of high quality DNA extracted from cell lines or fresh-frozen tumours. Frozen 
primary melanomas would inevitably be biased as only rare (large) selected 
tumours are cryopreserved. However, FFPE tumours which are routinely stored in 
pathology archives potentially could be a powerful source of genomic material for 
experimental studies. FFPE tissue available in pathology archives is potentially 
linked with long term follow-up data enabling the identification of prognostic and 
predictive biomarkers. For example predictive biomarkers might be identified from 
stored samples from mature clinical trials. The majority of genomic studies 
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performed in order to understand the genomics of melanoma have by necessity 
been carried out using metastatic tumours, but my aim was to identify genomic 
prognostic biomarkers for primary disease, therefore my intent was to develop 
methodologies to study FFPE melanoma primaries which are usually small in 
volume. 
In Chapter 1 it was discussed how formalin fixation impedes the use of FFPE 
samples in various assays. Briefly, formalin affects the quality and quantity of 
nucleic acids by: the formation of cross-links between nucleic acids and proteins; 
the addition of methylol groups in adenine and thymine in particular; the introduction 
of random breaks in the nucleotide sequence (Frankel, 2012, Srinivasan et al., 
2002). Recent studies have shown that DNA from FFPE tissue can be used 
successfully for next generation sequencing (Schweiger et al., 2009, Adams et al., 
2012, Menon et al., 2012, Wood et al., 2010). Wood et al first demonstrated 
comparable results between NGS and aCGH technologies for copy number 
analysis (Wood et al., 2010). Two studies have illustrated that NGS data from FFPE 
tissue were comparable to data from matched fresh-frozen tissue (Wood et al., 
2010, Schweiger et al., 2009). These studies report the use of 1-3µg DNA, which is 
not available from most FFPE melanoma samples as the majority of them are 
small. However, Wood et al also reported that lower amounts of FFPE-derived DNA 
from lung squamous cancer cell lines and oral tumours can be used to successfully 
generate NGS data to identify copy number alterations (Wood et al., 2010). This 
study showed similar patterns of copy number changes using sequencing data 
generated from serial dilutions of FFPE-derived DNA (Wood et al., 2010). Array 
CGH has been the leading technology for the identification for copy number 
alterations, but it is difficult to use with FFPE tissue (larger amounts are usually 
required) and an amplification step is needed when the amount of starting material 
is low (Little et al., 2006). 
The data reported by Wood et al were encouraging but considering that primary 
melanomas are small, and DNA extracted from FFPE samples is limited in volume, 
a feasibility study was designed where DNA from 10 FFPE metastatic melanoma 
tumours was used for whole-genome NGS. I extracted the DNA from the samples 
but they were then processed, multiplexed and sequenced by the NGS facility team 
at Leeds University and the data were analysed by Dr Henry Wood using published 
techniques (Wood et al., 2010). All ten samples were sequenced twice in one lane 
on the Illumina GAIIx system using 75bp single-end reads. Dr. Henry Wood 
analysed the data using tumour:reference ratio where pooled data from the 1000 
Genomes project from 10 healthy individuals were used as reference (Wood et al., 
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2010). Successful generation of data from 90% of the samples as well as the 
observation of previously described CNAs in melanoma such as gains in 
chromosomes 6 and 7 and losses in chromosomes 9 and 10 in this feasibility study 
suggested that generation of reliable NGS data from FFPE melanomas (Figure 3-1) 
would be possible. 
Based on the successful results of the feasibility study, a large-scale study using 
FFPE primary melanomas was designed to identify recurrent copy number 
alterations which could be linked to prognosis and driver mutation status. In this 
chapter I first explored the performance of the whole-genome library preparation 
technique used in the study by Wood et al using 21 DNA samples from primary 
melanoma tumours.  
The process of library preparation has been described in Chapter 2. Briefly, DNA is 
fragmented, adapters are ligated and a PCR amplification step is performed to 
enrich the yield of the library. I explored a number of aspects of library preparation.   
• DNA extracted from FFPE samples might already be sufficiently fragmented 
to allow library preparation and therefore I tested the hypothesis that further 
fragmentation during library preparation might be unnecessary and might be 
associated with loss of material during the consequent purification step. In 
the experiment therefore a comparison was performed between samples 
which were fragmented according to the protocol and others in which this 
fragmentation step was omitted. 
• Melanin has been shown to co-purify with DNA and inhibit downstream 
applications such as PCR through binding to DNA polymerase (Eckhart et 
al., 2000). The inhibitory effect of melanin on DNA polymerase has however 
been shown to be reversible when BSA was added in the reaction (Eckhart 
et al., 2000). Leeds Genomics Facility had explored this in DNA from 
melanomas and showed KIT amplification to be successful when 5mg/ml 
BSA is added in the PCR reaction compared to reactions without BSA using 
samples enriched with synthetic melanin (data not shown). Here, I describe 
an investigation of the effects of BSA addition in all the enzymatic reactions 
during library preparation to prevent the inhibitory effects of melanin by 
comparing libraries prepared with and without BSA. 
• Finally, in this chapter I also explore the comparative performance of a 
number of alternative library preparation techniques marketed at the time, 
including automated methods, as manual library preparation is a labour 
intensive and time consuming process for large-scale studies. 
  
Figure 3-1: Frequency plot of copy number alterations in 9 FFPE metastatic melanoma samples (feasibility study). 
The NGS data generated from the FFPE melanoma metastases confirmed copy number alterations such as gains in chromosomes 6 and 7 
and losses in chromosomes 9 and 10, known to be altered in melanoma. The feasibility study was considered successful and enabled the 
design of a large-scale study. 
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3.3 Methodology  
DNA from primary (Leeds Melanoma Cohort) and metastatic samples (details in 
section 2.2.2) was used to for the evaluation of the different protocols. DNA from 
21/116 primary melanomas available in the lab was used to assess the 
performance of the manual library production protocol described by Wood et al 
(Wood et al., 2010). DNA was extracted from metastatic samples for the evaluation 
of the rest of the protocols using the Qiagen All Prep® FFPE RNA/DNA kit (section 
2.3.6.3). 
The protocols for each technique evaluated in this chapter were described in detail 
in section 2.9.1. In summary, the techniques used to test their performance using 
FFPE-derived DNA were:  
a) Library preparation protocol using 5’-end barcodes (manual);  
b) Library preparation using 5’-end barcodes on the Beckman Coulter 
SPRIworks system (SPRIworks);  
c) Library preparation on the Agilent Bravo robot using the Illumina TruSeq™ 
protocol (indexing) (TruSeq);  
d) Library preparation using the Illumina NEXTERA™ kit (indexing) (Nextera);  
e) Library preparation using the New England BioLabs NEBNext® Ultra DNA 
Library Prep kit for Illumina (indexing) (NEB).  
The protocols and the quality control checkpoints are summarised in Figure 3-2. To 
optimise the protocols, adapter concentrations and PCR cycles were adjusted 
according to the DNA input. The performance of the protocols was judged by 
looking at the size range of the libraries on the Agilent 2100 Bioanalyser or 2200 
TapeStation and the concentration of the library, measured using the Quant-iT™ 
broad range ds-DNA assay kit (Invitrogen by Life Technologies, USA), as described 
in section 2.6. Fifty nanograms of each library are needed for sequencing. 
Henceforth, libraries with concentration greater than 2ng/µl in an elution volume of 
30µl are considered successful. Examples of libraries judged to be good or 
contaminated by adapters are shown in Figure 3-3.  
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Figure 3-2: Whole-genome library preparation techniques and quality control 
(QC) checkpoints. 
  
 
 
Figure 3-3: Agilent profiles of: a) a pure library free of adapters; b) a library contaminated with adapters; and c) adapters without library 
amplification. 
If the ratio of adapters:DNA input during the ligation step is high, then adapter dimers are formed. Adapter dimers will bind to the flow cell, 
form clusters and be sequenced reducing the sequencing depth of the tested sample. 
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3.4 Results and discussion 
3.4.1 Library preparation protocol using 5’-end barcodes for 
Illumina SPRI size selection (manual) 
DNA from 116 primary FFPE melanoma samples was available in the lab from 
previous studies. The median DNA concentration measured using picogreen was 
5.73ng/µl (range 0-125ng/µl). DNA is eluted in 30µl buffer and 60ng are used for 
BRAF/NRAS mutation screening routinely in the lab. Therefore, the average volume 
left from these samples was 20µl and the average DNA yield available for library 
preparation was 114ng.  
Wood et al have illustrated that the manual protocol produced sufficient libraries 
with as little as 5ng FFPE-derived DNA (Wood et al., 2010) and therefore I tested 
this protocol using melanoma samples. First, 21/116 DNA samples with a wide 
range of concentrations (5.4-42.3ng/µl) were used to test if the manual protocol 
could produce libraries from small primary melanoma samples. All 21 samples were 
fragmented according to protocol and their profile was checked on the Agilent 
Bioanalyser. Seven of the 21 samples were considered unsuitable for library 
preparation as DNA was not visible on the Agilent profiles. Libraries were 
successfully prepared from the remaining 14 samples. 
3.4.2 BSA addition using the manual protocol 
The addition of BSA in PCR reactions can reverse the inhibitory effect of melanin 
on DNA polymerase. To test the effect of BSA addition during library preparation, 5 
metastatic samples were identified, each with 2 highly pigmented cores (assigned 
melanin score of 3) available from each sample. The DNA extracted from the first 
core was used to prepare a library by adding 5mg/ml BSA to all enzymatic reactions 
of the manual protocol and the DNA from the second core was used to prepare a 
library using the manual protocol without BSA as described by Wood et al. The 
libraries produced with and without BSA are illustrated in Figure 3-4. Due to the 
presence of adapter dimers the library concentration was not used as a measure of 
library success. For samples 4 and 5 higher DNA input was used in the presence of 
BSA and therefore the better performance of the protocol could be either attributed 
to higher starting material or BSA or a combination of both. For samples 1 and 2 
where similar or lower DNA input was used in the presence of BSA however, a 
library was generated only in the presence of BSA. For sample 3, where lower DNA 
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input was used in the presence of BSA higher library yield was obtained based on 
the Agilent trace in the presence of BSA. From this experiment, I concluded that 
BSA might improve the performance of the library preparation protocol. As a result, 
I decide to use BSA in all subsequent library preparations using the manual 
protocol even if samples were not visibly highly pigmented. 
I then attempted to make libraries from the 7 out of the original set of 21 samples, 
where no DNA had been seen on Agilent profiles and I had therefore not attempted 
to make a library, but this time adding BSA during library preparation. I was able to 
generate successful libraries from 5 of these 7 samples. The samples that failed 
had very low DNA yield (18ng and 4ng) compared to the others (30-260ng). The 
fact that some of these samples prepared successful libraries even if DNA was not 
visible on the Agilent traces could be in part attributed to BSA addition (2/5 DNAs 
generated successful libraries had melanin score of 3). However, it is also likely that 
the standard Agilent kit failed to detect the low amount of fragmented DNA before 
library preparation as its sensitivity is low and as a result they were erroneously 
considered as unsuitable. It was therefore considered that the Agilent high 
sensitivity kits would be more reliable to check the fragmented DNA before library 
preparation in the next runs. 
 
 
 
 
 
Figure 3-4 (following page): Libraries prepared in the presence or absence of 
BSA. 
Library concentration is overestimated when there is adapter contamination 
and therefore library yields were determined based on the Agilent traces. For 
samples 1 and 2 libraries were only prepared successfully when BSA was 
used. For sample 3 a library with higher yield was observed in the presence of 
BSA. For samples 4 and 5 no conclusion for the effect of BSA could be made 
due to higher DNA input used in the protocol with BSA addition. 
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Figure 3-4: Libraries prepared in the presence or absence of BSA. 
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3.4.3 Adapter contamination 
Some libraries were contaminated with adapters (Figure 3-3, Figure 3-4) and after 
discussion with other colleagues preparing libraries it was decided that the adapters 
concentration should be diluted proportionally according to the DNA input (Table 
3-1).  
 
Table 3-1: Adapter concentration based on the DNA input. 
DNA input Adapters 
1µg Undiluted 
500ng 1:2 
250ng 1:5 
120ng 1:10 
60ng 1:20 
 
3.4.4 DNA library preparation using 5’-end barcodes on the 
Beckman Coulter SPRIworks system (SPRIworks) 
Library preparation using the manual protocol is time consuming. Samples could be 
prepared in batches of 15 over 2 days. Therefore the semi-automated protocol on 
the Beckman Coulter SPRIworks system was explored as a faster option for a 
large-scale project. The adapters used in the SPRIworks protocol are the same 
used in the manual technique. The standard SPRIworks protocol suggests diluting 
the adapters 1:10, and recommends 1µg DNA input. In the trial runs <150ng DNA 
input was used to test if this protocol is useful for low DNA yield from primary 
melanoma samples. 
3.4.4.1 First and second SPRIworks trial runs designed to identify the 
feasibility of the standard protocol using FFPE samples 
Ten libraries were prepared using different concentrations of DNA extracted from 2 
samples and different dilutions of adapters. Successful libraries were prepared 
when the standard 1:10 adapter dilution was used but libraries with low yield were 
prepared when further diluted adapters were used for sample 1 (25ng; Figure 3-5). 
Notably, better libraries were produced from lower DNA concentrations derived 
from sample 2 (Figure 3-5). The standard adapter dilution (1:10) was judged 
necessary and a second experiment was performed to validate this finding. In the 
second run, no libraries were generated from any of the samples tested (data not 
shown). 
  
Figure 3-5: Libraries from the first SPRIworks trial run. 
Libraries were successfully prepared when the standard 1:10 adapter was used. For sample 1 (25ng DNA input), library preparation was 
successful when the standard adapter concentration was used while it was unsuccessful when diluted adapters were used. For sample 2, 
lower library yields were observed when higher DNA input was used. 
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3.4.4.2 Third SPRIworks trial run designed in an attempt to produce 
libraries despite the inconsistent results seen in previous runs 
Considering that the second run failed due to an experimental error a further trial 
run was designed to validate the initial finding. Two samples were tested using 
different dilutions of adapters and a DNA sample derived from a cell line was used 
as a positive control. Also, matched libraries were generated using the manual 
protocol to allow direct performance of the two protocols. In contrast with the initial 
run, here it was clear that the standard 1:10 dilution of adapters resulted in adapter 
dimers for less than 150ng DNA input. For sample 5 there was no library produced 
when a 1:10 dilution of adapters was used, a library with a huge adapter peak for a 
1:50 dilution of adapters, a library with no adapter peak for a 1:100 dilution and 
unexpectedly a library with a small adapter peak for 1:200. The libraries from this 
trial run are shown in Figure 3-6. The manual protocol produced better libraries than 
the SPRIworks. 
In this run libraries were produced using the SPRIworks technique at least for most 
of the samples but adapter dimers were present when the standard concentration of 
adapters was used. The technique failed to show a consistent pattern of lower 
adapter peaks when higher dilutions of adapters were used. We therefore 
contacted the company to seek advice and a fourth trial run was designed. 
 
 
 
 
 
 
Figure 3-6 (following page): Third SPRIworks trial run. 
Libraries were prepared from the majority of the samples using SPRIworks 
but the corresponding libraries using the manual protocol were always of 
higher yield with no adapter dimers except for one sample. The different 
colours of the small legends above the Agilent traces represent the pairs of 
matched libraries using both protocols. For sample 5 the SPRIworks 
technique failed to show a consistent pattern of lower adapter peaks when 
higher dilutions of adapters were used. 
  
 
Figure 3-6: Third SPRIworks trial run. 
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3.4.4.3 Fourth SPRIworks trial run to assess both adapters 
concentration and fragmentation effects due to the inconsistent 
results on the previous assays 
In the fourth trial run, both experimentally fragmented and non-fragmented samples 
were used. This run was designed with the help of a representative from Beckman 
Coulter, when we sought advice regarding the inconsistent results between runs. 
Generally, a very small library was prepared when non-fragmented samples were 
used compared to the fragmented samples. This suggests that fragmentation 
before library preparation is essential. For samples 8 and 9 a consistent lower peak 
was seen when higher dilution of adapter was used but the opposite was seen for 
fragmented sample 10. Libraries with higher yield were produced with the manual 
protocol. The Agilent profiles of the libraries in the fourth run are shown in Figure 
3-7.  
 
 
 
 
 
 
 
 
 
Figure 3-7 (following page): Fourth SPRIworks trial run.  
Generally, a very small library was prepared when non-fragmented samples 
were used compared to fragmented samples. For samples 8 and 9 a 
consistent lower peak was seen when higher dilution of adapter was used but 
the opposite was seen for fragmented sample 10. Libraries with higher yield 
were produced with the manual protocol. The different colours of the small 
legends above the Agilent traces represent the pairs of matched SPRIworks 
libraries starting with fragmented and non-fragmented DNA using the same 
adapter dilution.  
 
  
Figure 3-7: Fourth SPRIworks trial run. 
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3.4.4.4 Summary of the experiments with the SPRIworks technique 
The SPRIworks protocol showed inconsistent results across the trial runs and the 
manual protocol always produced better libraries in terms of less adapter 
contamination and library yield. Some libraries prepared with the manual protocol 
still contained adapter peaks and therefore henceforth more diluted adapters were 
used for the low DNA input (Table 3-2). 
 
Table 3-2: Adapter concentration for <100ng DNA input (updated table). 
DNA input Adapters 
85-100ng 1:25 
65-85ng 1:30 
45-65ng 1:35 
30-45ng 1:40 
20-30ng 1:50 
10-20ng 1:60 
<10ng 1:70 
 
3.4.5 DNA library preparation on the Agilent Bravo robot using 
the Illumina TruSeq™ protocol (indexing) (TruSeq) 
The third technique which was tested was the Truseq protocol on the Agilent Bravo 
robot. Using the Agilent Bravo robot, up to 96 samples can be processed in one 
batch. The libraries using this technique were prepared by a service provider, 
Source Bioscience (Manchester, UK). Ten DNA samples were mailed to the 
company while some DNA was kept in the lab to prepare libraries using the manual 
protocol for comparison. 
Using the SPRIworks system it was identified that smaller libraries were produced 
using non-fragmented compared to experimentally fragmented DNA (section 
3.4.4.3). The DNA samples mailed to the company were run on the Agilent 
Bioanalyser to identify the degree of fragmentation present in each sample before 
experimental fragmentation. The Agilent traces showed that the DNA samples were 
not totally fragmented, although degraded (Figure 3-8). This means that 
experimental fragmentation is essential to produce a uniform pool of fragments 
before library preparation. 
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Libraries were prepared using a 1:100 dilution of adapters following the standard 
Truseq protocol on the Agilent Bravo robot. This technique uses a tight size 
selection step and therefore the average length of the libraries was higher 
compared to the average length of the libraries using the manual protocol (350bp vs 
220bp). The Truseq protocol produced libraries without adapter dimers but of lower 
yield compared to the manual protocol (Figure 3-9). The number of PCR cycles 
used in the Truseq protocol was lower (10 compared to 18 cycles used in the 
manual protocol) and therefore could explain the very low library yields observed. A 
further trial run could be performed by preparing libraries of smaller length and 
increasing the number of PCR cycles. However, the technique was not further 
optimised due to limited time available. 
 
 
Figure 3-8: Agilent traces of FFPE-derived DNA samples. 
Representative examples of DNA samples run on a high sensitivity chip. The 
fragment size of a high quality genomic DNA sample is usually 15-30kb. The 
120s peak represents a length of 10kb. It is shown that samples 11 and 12 
were less fragmented than samples 13 and 14. However, experimental 
fragmentation is needed to produce a uniform pool of fragments before library 
preparation. 
 
  
Figure 3-9: Truseq protocol on the Agilent Bravo compared to manual protocol. 
The Truseq protocol produced libraries without adapter dimers but of lower yield compared to the manual protocol.  The lower number of 
PCR cycles used in the Truseq protocol is the main reason of the lower library yields but this technique was not further optimised due to time 
limitations.
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3.4.6 DNA library preparation using the Illumina NEXTERA™ kit 
(indexed) (Nextera) 
Libraries using the Nextera protocol were also prepared by Source Bioscience. This 
protocol is performed in a 96-well plate and therefore 96 samples can be processed 
simultaneously. Nextera protocol requires only 50ng DNA input and appeared 
therefore to be a good option, considering the limited amount of DNA available from 
primary melanomas. Using this technique however 7/8 samples failed to generate 
libraries and only 1 sample generated a low yield library in both runs, (Figure 3-10). 
Nextera protocol uses transposase enzymes to fragment the DNA as it was 
described in section 2.9.1.4. The use of these enzymes can lead to over-
fragmentation of the FFPE DNA and might therefore explain the poor results 
observed but I did not explore this further. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10 (following page): Nextera trial runs using 50ng DNA input. 
Using this technique 7/8 samples failed to generate libraries and only 1 
sample generated a low yield library in both runs (sample 14). A positive and 
a negative control sample were included in run B. The transposases 
(enzymes used to randomly fragment the DNA in Nextera protocol) might lead 
to over-fragmentation of the FFPE DNA which might therefore explain the 
poor results observed but I did not have the opportunity to explore this further. 
 
  
Figure 3-10: Nextera trial runs using 50ng DNA input. 
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3.4.7 DNA library preparation using the New England BioLabs 
NEBNext® Ultra DNA Library Prep kit for Illumina (indexing) 
(NEB) 
The NEB protocol recently became available, and it is reported to be optimised for 
as little as 5ng fragmented DNA. It is quicker than the manual protocol as the End-
repair and A-addition steps are performed in a single reaction. Three trial runs were 
performed using DNA from melanoma samples. Run A was performed by Sally 
Harrison from the NGS team in Leeds. Good library yields were produced from all 6 
samples that were tested using 12 PCR cycles (Figure 3-11). I performed a second 
run (B) to validate the first result but low library yields were produced. Therefore, 
run C was performed using 6 more samples with 15 PCR cycles by Helen Snowden 
from the Genomics Facility in Leeds. In run C high library yields were obtained 
(Figure 3-11). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-11 (following page): Libraries prepared using the NEB protocol. 
Run A: Good library yields were produced from 2 samples (samples 21 and 
22) using different DNA input using 12 PCR cycles; Run B: Low library yields 
were produced when different DNA input of sample 22 was used; Run C: Six 
more samples were tested with 15 PCR cycles and sufficient library yields 
were obtained. 
 
  
Figure 3-11: Libraries prepared using the NEB protocol. 
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3.5 Conclusion  
Whilst NGS studies represent major developments in cancer research, analysis of 
FFPE tumours would enable studies using larger numbers of less selected 
samples, including primary melanomas, with mature follow-up data to allow 
identification of potential prognostic biomarkers.  
Here, I have evaluated different protocols for library preparation for whole genome 
NGS including comparative performance of alternative library preparation 
techniques marketed at the time, including automated techniques, useful for large-
scale studies. 
The concentration of DNA extracted from FFPE primary melanoma samples is low 
(range 0-125ng/µl) even if TMA cores are used and most available library 
preparation protocols require large amounts of high quality DNA. Here, I have 
described the evaluation of the manual protocol for library preparation, which has 
previously been shown to produce successful libraries from FFPE samples of other 
tissues (Wood et al., 2010, Belvedere et al., 2012). I showed that the manual and 
subsequently the NEB protocol produced libraries successfully from melanoma 
samples. Optimisation of these protocols included adjustment of adapters 
concentration according to the DNA input to reduce adapter dimers in the libraries. 
Finally, it was shown that BSA might improve the performance of the library 
preparation protocol when libraries with and without BSA were compared and 
therefore BSA was used in all subsequent library preparations using both the 
manual and the NEB protocols even if samples were not visibly highly pigmented. 
The SPRIworks protocol showed inconsistent results across runs and therefore it 
was considered unsuitable for samples with low DNA yield. However, it helped us 
conclude that experimental fragmentation might be essential as smaller libraries 
were generally generated when experimentally non-fragmented samples were used 
compared to matched experimentally fragmented samples. This was further 
confirmed when DNA traces before experimental fragmentation showed that FFPE-
derived DNA was insufficiently fragmented, although degraded. 
The Truseq protocol on the Agilent Bravo robot produced low yield libraries and 
further optimisation was needed to prove the good performance of this protocol 
using low DNA input. Unfortunately, further optimisation using this technique was 
not performed due to time limitations. Finally the Nextera protocol was proven 
unsuitable for FFPE samples. This protocol has not been tested using FFPE 
samples (Illumina technical support). A possible explanation could be that the 
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transposase enzymes used to fragment DNA in this protocol might result in over 
fragmentation resulting in failure to generate libraries, however this hypothesis has 
not been tested.  
In conclusion, the manual and the NEB protocols produced higher library yields 
without adapter contamination compared to the other protocols tested. In Chapter 4 
the manual and NEB protocols were used for library preparation from primary 
melanoma samples that were used for NGS to identify copy number alterations. In 
the next chapter I report a comparison between the two as both have been used in 
the preparation of the whole sample set. 
 
120 
Chapter 4  
Identification of DNA copy number alterations in 
FFPE primary melanoma samples 
 
4.1 Aims 
The aims of the work described in this chapter were: 
• To evaluate the feasibility of whole-genome next generation sequencing 
(NGS) technology using FFPE-derived DNA from primary melanoma 
samples. Specific aims were to investigate: 
o the characteristics of the sample associated with successful DNA 
library preparation; 
o the quality of sequencing data, using the FASTQC quality control 
tool; 
o the effect of PCR replicates in the data and their removal at analysis; 
o the relationship between previously identified regions in the 
reference genome reported to be “problematic” and sequencing 
data; 
o data quality in relation to GC-rich areas of the genome; 
o the characteristics of the sample associated with sequencing 
coverage. 
• To explore the data and copy number alterations using an agnostic 
approach. Specific aims were to investigate: 
o the association between copy number alterations and survival or 
factors known to predict survival, such as Breslow thickness, using 
regression models; 
o the association between BRAF/NRAS mutation status and DNA copy 
number alterations using regression models; 
o if a correlation could be demonstrated between copy number and 
gene expression data generated from the same tumours. 
• To explore the validity of the data by looking for copy number alterations 
previously reported in melanoma, for example evidence consistent with 
deletion of the 9p21 region of the genome where the tumour suppressor 
gene CDKN2A is located.  
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4.2 Background 
In the previous chapter I have described the evaluation of different library 
preparation protocols in order to identify the best method to prepare FFPE 
melanoma samples for whole-genome next generation sequencing. I reported 
optimisation of the manual and the NEB protocol for small amounts of DNA. 
Reproducible results were obtained using the above protocols compared to other 
protocols tested.  
Libraries with higher yield were obtained when BSA was added to all enzymatic 
reactions during library preparation in an attempt to reduce the adverse effect of 
melanin, a previously reported PCR inhibitor (Eckhart et al., 2000).  
Finally, libraries prepared using DNA which was not experimentally fragmented 
were smaller than libraries prepared using experimentally fragmented DNA derived 
from the same samples, implying that the DNA samples derived from FFPE 
melanoma samples are not sufficiently fragmented per se. The Agilent traces of 10 
FFPE DNA samples confirmed that the DNA was not sufficiently fragmented, 
although degraded. 
Sequencing data from a small feasibility study using 10 FFPE metastatic samples 
suggested that NGS could be used to study copy number alterations in melanoma. 
In this chapter I describe a consequent evaluation of the NGS platform for 
melanoma samples in a large-scale-study using FFPE primary melanomas from the 
Leeds Melanoma Cohort. 
The Leeds Melanoma Cohort is the largest melanoma cohort in the world 
(consisting of data and samples collected from 2180 patients with a median follow 
up of 7.2 years). This cohort is powered to identify determinants of outcome. A 
study was designed to identify CNAs in melanoma and explore their prognostic 
implication. Libraries from 269 samples have been generated to date (as of 
September 2013) and sequencing data from the first 75 samples have now been 
analysed, and I describe the analysis of these samples here. I have worked on 
developing a pipeline for analysis using these initial 75 samples and will be able to 
work on the whole data set after submission of this thesis. 
In this chapter, then, 
• I report an investigation of sample characteristics as potential determinants 
of successful library preparation.  
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• I describe an investigation of the quality of the sequencing data and explore 
the effect of previously reported biases/problematic areas in the reference 
genome sequence that affect NGS data quality.  
• I describe approaches to data analysis. The method used to identify copy 
number alterations was based on the read depth in pre-specified 10kb 
regions (otherwise known as windows). The concept is that lower numbers 
of reads indicate copy number loss while increased numbers of reads 
indicate copy number gain (Teo et al., 2012, Duan et al., 2013). This method 
is known as the depth of coverage (DOC) method (Teo et al., 2012, Duan et 
al., 2013). Several tools are available to analyse NGS data using this 
method and most of them are based on the presence of a reference sample 
where test:reference ratio is calculated to estimate the number of copies in a 
region (Teo et al., 2012, Duan et al., 2013). In this study no matched normal 
reference sample was sequenced and therefore the estimation of the exact 
copy number was not possible. Instead, the idea was to identify differences 
in copy number associated with samples with distinct characteristics. DOC 
methods rely on the assumption that the sequencing process is uniform 
(read depth is proportional to the number of copies) (Teo et al., 2012, Duan 
et al., 2013). However, previously reported factors, such as GC content, 
have been shown to be associated with sequencing coverage, suggesting 
that the above assumption is not always correct (Dohm et al., 2008, Aird et 
al., 2011, Chen et al., 2013). I report here attempts to reduce error 
associated with variation such as GC content using computational or 
statistical models. The analysis was performed by Dr Alastair Droop and Dr 
Helen Thygesen in an attempt to develop a pipeline for copy number 
analysis based on the needs of our dataset. Whilst aware that algorithms 
exist for analyses of this sort, we felt that these are in a state of evolution 
and we did not wish to assume that the published approaches were optimal. 
• Here, I decribe an exploration of the effect of two biases related to GC-
content and PCR amplification. Uneven coverage has been reported in GC-
rich regions (Dohm et al., 2008, Chen et al., 2013). A potential explanation 
of GC-bias could be the different melting behaviour of double-stranded 
DNA: AT-rich DNA fragments denature at lower temperatures than GC-rich 
fragments. PCR amplification is thought to be the main cause of GC-bias 
where amplification of GC-rich regions is less efficient due to their ability to 
denature at higher temperatures (Dohm et al., 2008, Aird et al., 2011). 
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Potential denaturation of AT-rich fragments before adapter ligation has also 
been suggested to be a source of GC-bias (Dohm et al., 2008).  
• PCR amplification has also been reported to have an additional effect, 
irrespective of GC-bias. PCR replicates occur when multiple copies of a 
single fragment hybridise on different locations in the flow cell, and therefore 
multiple clusters of the same original molecule are formed while the goal is 
to generate 1 cluster per fragment.  If too low DNA input is used a higher 
number of PCR cycles is required to generate sufficient library for 
sequencing. This results in low-complexity libraries: greater amounts of 
amplified DNA from fewer areas of the genome: a likely source of bias. 
Library preparation protocols therefore suggest the use of a limited number 
of PCR cycles in the enrichment step to reduce PCR replicated sequences 
in the sequencing data. The number of samples sequenced on a single lane 
has an effect on the visibility of this problem. For example a low-complexity 
library run with many other samples on a single lane will result in less PCR 
replicates sequenced while a low-complexity library run on its own would 
result in a higher level of PCR replicates sequenced. It seems likely that to 
avoid PCR replicated sequences there will be an optimal balance between 
DNA quantity and sequence depth. In this chapter I have attempted to 
describe efforts to explore this balance, which would be necessary if NGS 
was to be used for biomarker discovery using small DNA input. 
• NGS is a technology under development and possibly more biases or on the 
other hand better solutions will be identified in the near future. In this 
chapter I describe the approach we followed to minimise GC-bias and PCR 
replication and then the statistical analysis performed in an attempt to 
identify the validity of the data. Both an agnostic approach and a candidate-
gene approach were taken to identify previously reported copy number 
alterations in melanoma.  
• Although individual datasets (genomic, transcriptomic, epigenomic, and 
proteomic) are able to provide useful information, data integration offers a 
potential advantage to answer complex biological questions (Hawkins et al., 
2010). Whole-genome DASL gene expression data from 47 of the 75 
samples with NGS data were generated and here I describe an attempt to 
integrate copy number and gene expression data from matched samples to 
identify if a correlation could be established. Copy number change is only 
one cause of variation in gene expression but for some genes at least one 
would expect reasonable correlation.  
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4.3 Detailed methodology 
4.3.1 Patient samples 
Patients from the Leeds Melanoma Cohort Study were selected for the work 
described in this chapter, which was intended to identify NGS associations with 
death from melanoma. Samples were chosen for my work in a case control design, 
where cases were participants who had died, and controls were sex and Breslow 
thickness matched participants who have not died.  
First, all patients who have died from melanoma were identified and were grouped 
into the following six categories: a) males with a tumour Breslow thickness 0.75-
2mm; b) males with a tumour Breslow thickness 2-4mm; c) males with a tumour 
Breslow thickness >4mm; d) females with a tumour Breslow thickness 0.75-2mm; 
e) females with a tumour Breslow thickness 2-4mm; and f) females with a tumour 
Breslow thickness >4mm. Then, samples matched to those from participants in the 
above groups who have not died from melanoma and were recruited to the study at 
least 5 years ago were identified. Patients were excluded if: the primary block was 
not yet available from the local hospital (82/878); the primary block could not be 
cored (either the tumour was too small or there was an excessively mixed 
population of cells) (369/878) and DNA was not available (the limited amount of 
DNA had been used in other assays) (65/878). Out of the 878 samples, 362 (41%) 
were eligible for inclusion in the study including 15 samples with DNA concentration 
<1ng/µl which were judged too poor to generate libraries but we wished to test that 
assumption. The number of patients in each of the above groups after patient 
exclusion is shown in Figure 4-1. 
Two metastatic samples from the Chemotherapy study with sufficient DNA were 
selected to generate five libraries using different DNA input. These libraries were 
sequenced but not used for statistical analysis using the clinical variables (only 
primaries from the Cohort study were analysed). 
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Figure 4-1: Patients included in the study. 
The diagram shows the number of patients in each survival group (alive or 
dead), gender and Breslow thickness group with DNA sample available to 
use. In brackets the Breslow thickness (mm) group is indicated. 
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4.3.2 Sample processing 
DNA already available in the lab (generated for other experiments) had been 
extracted using either the Qiagen QiAmp® FFPE DNA micro kit or the Qiagen 
Allprep® FFPE DNA/RNA kit by a previous PhD student called Rosalyn Jewell as 
described in sections 2.3.6.2 and 2.3.6.3 respectively. For the rest of the samples, 
DNA was extracted using the Qiagen Allprep® FFPE DNA/RNA kit either by me, 
histopathology technician, Minttu Polso, Dr Jonathan Laye or the service provider, 
GenProbe, Manchester, UK.  
Whole-genome library preparation protocols were evaluated and this is described in 
Chapter 3. Libraries from 71 DNA samples were prepared using the manual 
protocol as described in section 2.9.1.1. The NEB protocol became available during 
my PhD and libraries from the rest of the samples were prepared using that 
protocol as described in section 2.9.1.5. 
Samples were sequenced using the Illumina Hiseq2000 instrument by Sally 
Harrison or Christopher Watson from the NGS facility in the University of Leeds as 
described in section 2.9.4. 
4.3.3 Sequencing data pre-processing 
The data outputted from the sequencer were pre-processed by bioinformatician Dr 
Alastair Droop and statistician Dr Helene Thygesen in conjunction with myself 
according to the pipeline described in section 2.10. The last 3 steps of the pipeline 
(removal of problematic regions from downstream analysis, removal of PCR 
replicates and GC correction) are discussed in this chapter.  
4.3.4 Quality control of library preparation 
I performed the statistical analysis in this section using Stata (StataCorp., 2011). 
Library preparation is critical for the successful generation of sequencing data. 
Therefore, I also explored if DNA yield, degree of pigmentation of the tumour 
(melanin score), age of the block, and day of the week that the block was received 
in the NHS histopathology laboratory are determinants of successful library 
preparation. The day of the week was considered as a potential determinant of 
successful library preparation as a block processed at the end of the week is likely 
to be left in formalin for the weekend before processing and this could have led to 
lower DNA yield extraction from that block as a result of greater degradation of 
DNA. A successful library was considered present when the concentration of the 
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library was >2ng/µl and the amplified library was visible on the Agilent profile. 
Kruskal-Wallis and Spearman’s correlation tests were used where appropriate to 
identify if any of the above tumour or block characteristics determined successful 
library preparation. In Chapter 3 I have described work in which I established that, 
library preparation using both the manual and NEB protocols was successful and in 
this chapter I report a comparison between the two using DNA from 16 samples. 
Library concentration was compared between the matched samples using the 
Wilcoxon matched pairs signed rank test. 
4.3.5 Quality control of sequencing data 
Libraries from 61 unique samples from the Cohort study and 14 replicate pairs were 
sequenced in the first batch and I will report here my analyses of this batch. 
Subsequent batches are being processed currently and I intend to analyse the 
whole data set after submission of this thesis. The FASTQC software (Babraham 
Bioinformatics, 2010) was used to assess quality of the sequencing data as 
described in section 2.10.  
One of the steps during data pre-processing that we considered as a means to 
avoid bias was removal of PCR replicates. PCR replicates are defined as 
sequences with the same start and end coordinates (Li et al., 2009). Normally, only 
a single replicate read would be included in the final dataset. I first investigated 
whether the frequency of the PCR replicates removed for each sample was 
associated with DNA yield, melanin score, age of the block, and day of the week 
that the block was processed using Spearman’s correlation and Kruskal-Wallis tests 
where appropriate, to identify if any of the tumour characteristics predict the 
frequency of PCR replicates observed. To assess if removal of PCR replicates is 
uniform across the genome, the frequency of the reads removed per chromosome, 
divided by the total number of reads for that chromosome was plotted for all 
samples. The decision we ultimately made to remove PCR replicates before final 
analysis is based on the work described here. 
4.3.6 Technical replicate samples 
Technical replicates were sequenced to assess the reproducibility of NGS 
technology using FFPE-derived DNA. Here, different technical replicates were 
assessed: a) replicates of the same libraries derived from 4 patient samples; b) 5 
libraries which were generated using different DNA input from 2 patients (3 libraries 
using 250ng, 100ng and 25ng DNA from patient 1; 2 libraries using 100ng and 25ng 
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DNA from patient 2); and c) 10 libraries derived from 5 patients of which 1 library 
was prepared using 15 PCR cycles and 1 using 18 cycles. Spearman’s correlation 
tests were performed between the read counts for each replicate pair. 
4.3.7 Genome-wide statistical analysis of sequencing data 
Linear, logistic and Cox regression models were constructed to identify if read 
counts from single 10kb windows were associated with the following variables: 
Breslow thickness (mm); mitotic rate (per mm2); presence of tumour ulceration; 
AJCC stage (I/II/III); melanoma-specific survival; tumour site (Head/Neck/Trunk or 
Limbs/Acral); primary subtype (superficial spreading/lentigo maligna or nodular 
melanoma); and mutation status (BRAF versus NRAS versus none). Multiple 
testing correction was performed by applying false discovery rate (FDR) to the p-
values (Benjamini and Hochberg, 1995). A threshold of FDR<0.1 was used. Median 
smoothing (using a bandwidth of 501 windows) of the coefficients was performed to 
reduce the noise. The threshold applied to the smoothed coefficients was selected 
so that the number of selected windows was equal to the number of windows with 
an FDR<0.1 prior to smoothing. The statistical analysis was performed by Dr 
Helene Thygesen using the statistical package R (R Development Core Team, 
2012) although I was intimately involved in the process. 
4.3.8 Integration of sequencing and gene expression data 
Gene expression data using the Illumina whole-genome DASL array were 
generated from 47 of the 61 unique samples from the Cohort study with NGS data 
available. Gene expression and NGS data were both used on a log base 2 scale. 
Gene expression DASL data were pre-processed at the probe level and, as 
described before, multiple probes on the array target a specific gene. In the rest of 
the chapter I have used the words probe and gene interchangeably.  
First, the DASL probes were merged with the NGS data only for the 10kb regions 
significantly associated with tumour mitotic rate (based on the smoothed 
coefficients). A Spearman’s correlation coefficient between the signal of a DASL 
probe and the read count of the corresponding NGS 10kb window where the probe 
was located was calculated. Multiple testing correction was performed and a 
threshold of FDR<0.1 was applied. 
Secondly, to reduce noise, median smoothing (using a bandwidth of 501 windows) 
of the NGS read counts was performed and the DASL data were merged with the 
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NGS data which were significantly associated with tumour mitotic rate. Here, 
Spearman’s correlation coefficients between the signal of a DASL probe and the 
smoothed read count of the NGS 10kb region where the probe was located were 
calculated. 
Third, 15 genes reported previously to be associated with melanoma/melanoma 
prognosis in terms of gene expression or DNA copy number alterations/mutations 
were selected (SPP1, RAD52, TOP2A, RAD54B, RAD51, CDKN2A, EGFR, PTEN, 
TERT, BRAF, NRAS, MITF, CKIT, CMYC, MC1R). The DASL probes targeting 
each one of the above genes and the NGS 10kb region where they were located 
were identified. The correlation(s) between the read count of the window and the 
probe(s) targeting the gene were calculated using the Spearman’s correlation test. 
I recently identified that the DASL file including probe coordinates provided by 
Illumina was incorrect. Some coordinates were based on the human reference 
genome version hg18 while some others were based on version hg19. This means 
that a proportion of DASL probes have not mapped against the correct 10kb NGS 
window. Therefore, the data presented here must be treated with caution. The data 
will be re-analysed using the correct probe coordinates after the submission of this 
thesis. 
4.3.9 Pathway analysis 
The DASL probes significantly correlated with the smoothed read counts from NGS 
windows associated with tumour mitotic rate were used to identify significantly 
overrepresented pathways using MetaCore™, a commercially available pathway 
database and data analysis tool (Thomson Reuters, USA). MetaCore™ offers a 
supervised and informed meta-data collection that was reported to out-perform 
other publicly or commercially available pathway databases in terms of 
completeness and accuracy when compared with experimental standards 
(Shmelkov et al., 2011). 
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4.4 Results 
4.4.1 DNA concentrations, failure of library preparation and 
associations with tumour characteristics 
Both DNA concentrations and rate of failure of library preparation (as defined in 
section 4.3.4) were assessed in relation to tumour characteristics.  
DNA concentration was inversely correlated with melanin score (borderline 
statistical significance, Spearman’s rho=-0.14, p=0.06; Table 4-1). There was no 
significant effect of age of the block or day of the week which the sample was 
received by the NHS laboratory on the likelihood of successful library preparation. 
The median DNA input used for library preparation was 100ng/µl (range 0.00-
1000.00ng/µl) as measured using picogreen. Library preparation was successful in 
92% (247/269) of the samples processed up to the presentation of this thesis. 
Associations between library status (successful or failed) and tumour characteristics 
are shown in Table 4-2. The median DNA yield used for samples which failed 
library preparation (26.98ng/µl) was significantly lower compared to the median 
DNA yield used for samples which prepared libraries successfully (100ng/µl) 
(Mann-Whitney, z=-5.06, p<0.001; Table 4-2). DNA input was the only statistically 
significant predictor of library preparation failure although age of the block showed a 
borderline association (Mann-Whitney, z=1.90, p=0.06; Table 4-2,) 
 
.  
 Table 4-1: Associations between DNA concentrations and tumour characteristics. 
 Samples 
Median DNA concentration, 
(range) 
Associations between measure and 
DNA concentration 
DNA concentration (ng/µl) 269 7.30 (0.00-89.40)  
Melanin score 
0 
1 
2 
3 
172 
42 
38 
46 
46 
 
11.45 (1.00-124.69) 
12.75 (0.10-116.09) 
15.91 (0.00-77.49) 
5.54 (0.00-57.48) 
Spearman’s rho=-0.14, p=0.06 
Age of block, years 267  Spearman’s rho=-0.07, p=0.28 
Day of the week block processed 
Monday 
Tuesday 
Wednesday 
Thursday 
Friday 
Saturday 
Sunday 
267 
49 
66 
55 
43 
52 
1 
1 
 
8.20 (0.60-89.40) 
7.57 (0.00-47.23) 
6.20 (0.72-124.69) 
9.13 (0.00-116.09) 
7.40 (0.26-57.48) 
9.19 
39.98 
Kruskal Wallis, χ2=5.18, p=0.52 
 
  
1
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 Table 4-2: Associations between library status and tumour characteristics. 
 Failed libraries Successful libraries 
Association between measure 
and library success 
Libraries, n (%) 22 (8.18) 247 (91.82)  
DNA input (ng), median (range) 26.98 (0.00-287.48) 100 (0.00-1000.00) Mann-Whitney, z=-5.06, p<0.001 
Protocol, n (%) 
Manual 
NEB 
 
6 (27.27) 
16 (72.73) 
 
74 (29.96) 
173 (70.04) 
χ2=0.07, p=0.79 
Melanin score, n (%) 
0 
1 
2 
3 
For 10 samples 
2 (20.00) 
3 (30.00) 
2 (20.00) 
3 (30.00) 
For 162 samples 
40 (24.69) 
35 (21.60) 
44 (27.16) 
43 (26.54) 
Fisher’s exact=0.92 
Age of block, years, median (range) 11.19 (4.89-14.27) 10.02 (2.63-20.38) Mann-Whitney, z=1.90, p=0.06 
Day of the week block processed, n (%) 
Monday 
Tuesday 
Wednesday 
Thursday 
Friday 
Saturday 
Sunday 
 
3 (13.64) 
8 (36.36) 
4 (18.18) 
4 (18.18) 
3 (13.64) 
0 (0.00) 
0 (0.00) 
 
46 (18.78) 
58 (23.67) 
52 (21.22) 
38 (15.51) 
49 (20.00) 
1 (0.41) 
1 (0.41) 
Fisher’s exact=0.62 
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4.4.2 Manual versus NEB protocol 
In Chapter 3 I have reported experiments which suggested that both the manual 
and NEB protocols generated libraries which met my criteria for adequacy. The 
NEB protocol was identified to be more efficient as less PCR cycles were needed 
compared to the manual protocol. It also uses the new barcoding system (indexing) 
as described in section 2.9.1.5 the advantages of which are discussed later (in 
section 4.5.3). As it was expedient for me to change to the NEB protocol I report 
here an experiment to test consistency between libraries generated from the same 
tumour block using the two protocols. Sixteen samples that had generated a 
successful library using the manual protocol for which a second tumour core was 
available were used. The second core was used to extract DNA and libraries were 
also generated using the newer NEB protocol. Similar DNA yields were used for 
library preparation using both protocols except for two samples where less DNA 
was used for the NEB library preparation by chance as less DNA could be extracted 
from the second core. We failed to prepare a library using the NEB protocol from 
one sample. The manual protocol uses 18 PCR cycles while the NEB protocol uses 
15 PCR cycles. The libraries generated using both protocols were free of adapters 
and therefore library concentrations from the matched samples were compared. 
Higher library concentrations were observed when the NEB was compared to the 
manual protocol (median library concentration 13.90ng/µl, 17.10ng/µl for the 
manual and the NEB protocol, respectively) although the difference was not 
statistically significant. 
 
Table 4-3: Matched libraries using the manual and NEB protocols 
 Manual protocol  NEB protocol Test statistic 
Successful 
libraries, n (%) 
16 (100%) 15 (93.75) Fisher’s exact=1.00 
DNA input, ng, 
median (range) 
100.00  
(44.5-100.00) 
100.00 
 (23.19-100.00) 
Mann-Whitney signed 
rank test,  z=1.99, 
p=0.05 
Library 
concentration, 
median (range) 
13.90 (4.52-
25.90) 
17.10 (0.00-
36.81) 
Mann-Whitney signed 
rank test,  z=-0.93, 
p=0.35 
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4.4.3 Sequencing data using the manual protocol only 
As above, and as presented in Chapter 3, the NEB protocol performed better than 
the manual. Therefore, although 75 libraries (61 unique samples and 14 replicates) 
were prepared using the manual protocol of which sequencing data are presented 
in this thesis, subsequent samples were prepared using the NEB protocol. 
4.4.4 Quality control of the sequencing data 
FASTQC software (Babraham Bioinformatics, 2010) was used to assess the quality 
of the sequencing data, looking at the quality score per base, sequence content per 
base and overrepresented sequences. The quality score for each base is assigned 
by the Illumina base-calling software and represents the probability that a base has 
been called incorrectly. For example a quality score of 30 is equivalent to the 
probability of an error base 1 in 1000 times (99.9% base accuracy). Typically, a 
quality score of greater than 28 is taken to indicate high quality data, whilst a quality 
score of less than 20 indicates very low quality (the background colouration in the 
figures generated by FASTQC show this consensus). First, the quality control of the 
sequencing data from each lane was assessed. In Figure 4-2, a number of issues 
observed have been highlighted. The first 6 bases represent the barcodes used to 
identify each sample where a T is always present at the 6th position. The T at the 
end of the barcode (part of the adapter) is needed for the adapter to ligate to DNA 
fragments. Low quality scores were observed at the 6th base of pair 2 where the T 
is present and at the subsequent 4 bases. Interestingly, low quality scores were not 
assigned to the first 10 bases of read pair 1. Bases from both read pairs were also 
assigned lower quality scores towards the end of the run.  
One hundred base pair fragments are sequenced, so if fragments are shorter than 
100bp then the end of the sequencing read will contain Illumina adapter sequences. 
We therefore removed adapter sequences at the 3’ end of the sequences as 
described in section 2.10. This was highlighted by the FASTQC software where 
Illumina adapter sequences were shown to be overrepresented in the data. 
Based on the above observations, the pre-processing pipeline was adjusted to 
include a trimming procedure of: the bases at the 3’ end of the fragments 
representing Illumina adapters; the bases after the 90th cycle; and the first 10 bases 
including the 6-base barcode. In Figure 4-2, we can see that sequencing failed 
during 60th-75th cycles in a single run due to an air conditioning failure, affecting 10 
samples and therefore bases after the 50th position were trimmed from these 
samples. 
  
Figure 4-2: Quality scores and base frequency per position using the data from a single lane containing 5 samples. 
 FASTQC software was used to assess the quality of the sequencing data. Here, the lower quality scores at the 3’ end of the sequences and 
the low quality score at the 6th base of pair 2 where the T is present (last base of the barcode used) are illustrated. The considerable dip in 
quality score during sequencing failure associated with loss of air-conditioning during 60th-75th cycles is shown (low quality scores in these 
cycles). The base frequency at a given cycle is expected to reflect the base frequency in the input sample. This holds when the quality score 
is high, but at low quality we can see a marked deviation in base frequency. 
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After adopting the above procedure, quality control was performed for each sample 
separately to reassure good quality data per sample. A high frequency of replicated 
sequences (>25% is assigned as high by the FASTQC software) was observed, an 
issue I therefore investigated. 
4.4.5 PCR replicates 
Sequencing data from eight out of 75 samples (11%) contained greater than 25% 
replicated sequences. Generally, more PCR cycles are used to produce enough 
library yield from low DNA input. PCR replicates arise when multiple copies of the 
same original molecule bind onto different positions on a flow cell. Therefore, it was 
considered that removal of PCR replicates should be performed from all samples 
using Samtools (Li et al., 2009) as described in section 2.10. The median proportion 
of replicated sequences removed was 9.90% (range, 5.24-63.69%). The frequency 
of PCR replicates was inversely correlated with DNA input (Spearman’s rho=-0.34, 
p=0.003) and positively correlated with the age of the block (Spearman’s rho=0.33, 
p=0.004) as illustrated in Figure 4-3 and Figure 4-4 respectively and therefore very 
much was related to sample quality.  
 
 
Figure 4-3: The correlation between frequency of PCR replicates and DNA 
input used for library preparation.  
Replication was seen predominantly where DNA input was less than 200ng. 
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Figure 4-4: The correlation between PCR replicate frequency and age of the 
block. 
Replicates were significantly associated with increased block age but 2 
samples which were relatively recent (under 8 years) had high levels of PCR 
replicates. 
 
Neither melanin score nor day of the week that the block was processed was 
associated with the frequency of PCR replicates (Spearman’s rho=-0.08, p=0.48 for 
mitotic rate and x2=7.21, p=0.13 for day of the week, data not shown). To 
investigate further what was removed using Samtools, the percentage of the 
number of PCR replicate sequence reads removed in each chromosome was 
plotted. The plot showed that similar numbers of replicate reads were removed 
across all chromosomes for each sample. There were significantly more PCR 
replicates seen however for chromosome 16 (Figure 4-5). Approximately 5% more 
reads were consistently removed from chromosome 16 compared to all other 
chromosomes in all samples (Figure 4-5). Work reported in section 4.4.6 suggests 
that this was because of “problematic” regions in this chromosome. 
  
138 
 
Figure 4-5: The frequency of the fraction of PCR replicate reads removed per 
chromosome for each sample. 
It is illustrated that more reads aligned at chromosome 16 were consistently 
removed from all samples. Work reported in section 4.4.6 suggests that this 
was because of “problematic” regions in this chromosome. 
 
4.4.6 Problematic regions 
Raw data before and after removal of PCR replicates (dereplicated data) were used 
to assess the effect of regions reported by others as “problematic” (Pickrell et al., 
2011). 
In 2011, Pickrell et al observed that errors in the human reference genome 
sequence cause copy number false-positive peaks in the ENCODE (Encyclopaedia 
of DNA Elements) NGS datasets (Pickrell et al., 2011). The errors in the reference 
sequence are caused by collapsed repeats where a sequence in the reference is 
present in a single copy while in reality there are multiple copies of this sequence 
(Pickrell et al., 2011). They observed a high read depth in these regions. The 
location of these regions is publicly available and different thresholds are used to 
define them as problematic (based on the distribution of sequencing coverage in 
the 1000 Genomes data, 0.1% right tail, 0.05% right tail, 0.01% right tail, 0.005% 
right tail, and 0.001% right tail) (Pickrell et al., 2011). I therefore investigated how 
these problematic regions affect my data. The read counts of windows which 
belong to non-problematic and problematic regions based on the different 
thresholds are shown in Figure 4-6 for raw data and in Figure 4-7 for dereplicated 
data. Generally, increased numbers of reads were seen in the problematic regions. 
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There is no de novo rationale for choosing a particular threshold for data cleaning. 
However, we noted that the 0.1% threshold seem to reject too many regions and a 
decision to remove the problematic regions from subsequent analysis based on the 
0.05% threshold was made. 
 
 
Figure 4-6: The medians of normalised read counts for non-problematic and 
problematic regions using raw data (before removal of PCR replicates). 
Increased coverage was observed in the problematic regions i.e. that 
coverage was proportionally greater for the regions identified by Pickrell et al 
using more stringent criteria. The percentages in brackets represent the 
number of windows in our data that fall in each category. The most stringent 
threshold was the 0.001% right tail of the distribution of coverage in the data 
analysed by Pickrell et al (more details in the text). 
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Figure 4-7: The medians of normalised read counts for non-problematic and 
problematic regions using dereplicated data. 
Again in the dereplicated data, increased coverage was observed in the 
problematic regions: that coverage was proportionally greater for the regions 
identified by Pickrell et al using stringent criteria. The most stringent threshold 
was the 0.001% right tail of the distribution of coverage in the data analysed 
by Pickrell et al (more details in the text). The percentages in brackets 
represent the number of windows in our data that fall in each category. A 
decision to mask the problematic regions based on the 0.05% threshold was 
made. 
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The percentage of the number of PCR replicate reads removed in each 
chromosome was plotted again using the data after removal of problematic regions, 
Figure 4-8. For each sample the frequency of the reads removed was equal across 
all chromosomes suggesting that the consistent increased percentage of reads 
removed from chromosome 16 across samples (as shown in Figure 4-5) was due to 
one or more problematic regions located at that chromosome. 
 
 
Figure 4-8: The frequency of the fraction of PCR replicate reads removed per 
chromosome after removal of problematic regions.  
The increased percentage of reads aligned to chromosome 16 that were 
removed was due to false positive regions defined as problematic by Pickrell 
et al. 
 
4.4.7 Coverage and tumour characteristics 
The median number of reads after removal of PCR replicates and problematic 
regions for chromosomes 1-22 was 40,497,890 (range, 13,064,103-58,284,709). 
The median coverage was 1.01x (range, 0.33x-1.46x) if 80bp is considered the 
average read length (as the first and the last 10 bases were consistently removed 
from all samples).  
Total read counts were associated with the DNA yield used for library preparation 
(Spearman’s rho=0.29, p=0.01, Table 4-4). Neither melanin score, age of the block 
or day of the week that the block was processed were associated with total read 
counts (Table 4-4). 
 Table 4-4: Associations between total read counts and tumour characteristics 
 Samples Median read counts (range) (x107) 
Association between 
measure and total read count 
DNA input (ng) 75 4.05 (1.31-5.83) Spearman’s rho=0.29, p=0.01 
Melanin score 
0 
1 
2 
3 
 
23 (30.67) 
15 (20.00) 
20 (26.67) 
17 (22.67) 
 
4.35 (1.31-5.83) 
4.10 (2.02-5.64) 
3.66 (2.14-5.68) 
3.82 (2.02-5.13) 
Spearman’s rho=-0.16, p=0.17 
Age of block, years, median (range) 75  
Spearman’s rho=-0.0004, 
p=0.99 
Day of the week block processed, n (%) 
Monday 
Tuesday 
Wednesday 
Thursday 
Friday 
75 
14 (18.67) 
18 (24.00) 
15 (20.00) 
8 (10.67 
20 (26.67) 
 
3.26 (2.02-4.83) 
4.33 (2.02-5.59) 
4.15 (1.31-5.20) 
3.62 (2.49-5.83) 
4.34 (2.14-5.64) 
Kruskal-Wallis, χ2=9.24, p=0.06 
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4.4.8 Technical replicate samples  
Spearman’s correlation coefficients between read counts for each sample pair were 
calculated. We distinguished between pairs that were replicates of the same 
sample and pairs of unrelated samples (non-replicates). If the data are of high 
quality a high correlation between replicates compared to non-replicates is 
expected. 
Table 4-5 shows that the correlation coefficients between non-replicates were much 
lower for non-problematic regions than for the problematic regions. This observation 
provides further evidence that the previously identified problematic regions by 
Pickrell et al are indeed questionable and data generated from them should 
probably be removed. There was no difference in correlations between raw and 
data from which PCR replicates had been removed (dereplicated data) (Table 4-5). 
 
Table 4-5: Spearman’s correlation coefficients between read counts per 10kb 
region for technical replicate and non-replicate pairs. 
The median and the range of Spearman’s rho for replicate pairs and non-
replicate samples using raw and dereplicated data for the problematic and 
non-problematic regions is presented. 
Raw data, Spearman’s correlation coefficient median (range) 
Non-problematic Problematic 
Replicates Non-replicates Replicates Non-replicates 
0.89 (0.80-0.92) 0.42 (-0.14-0.92) 0.93 (0.88-0.96) 0.64 (0.21-0.96) 
 
Dereplicated data, Spearman’s correlation coefficient median (range) 
Non-problematic Problematic 
Replicates Non-replicates Replicates Non-replicates 
0.89 (0.80-0.94) 0.44 (-0.15-0.94) 0.93 (0.88-0.97) 0.65 (0.24-0.97) 
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Technical replicates were sequenced to assess the reproducibility of NGS 
technology using FFPE-derived DNA. Here, different technical replicates were 
assessed: a) the same libraries derived from 4 patient samples; b) 5 libraries which 
were generated using different DNA input from 2 patients (3 libraries using 250ng, 
100ng and 25ng DNA from patient 1; 2 libraries using 100ng and 25ng DNA from 
patient 2); and c) 10 libraries derived from 5 patients of which 1 library was 
prepared using 15 PCR cycles and 1 using 18 cycles. The correlation coefficients 
between read counts in 10kb regions for each group of replicates were higher 
compared to non-replicate pairs and no difference was observed when different 
DNA input or different PCR cycles were used (Table 4-6). An example of 
chromosome 7 read counts is presented when the starting material was 250ng, 
100ng and 25ng from the same patient (Figure 4-9). 
 
Table 4-6: Spearman’s correlation coefficients for the read counts per 10kb 
region of the 3 different groups of technical replicates. 
Data free from problematic regions were used. 
 
Raw data 
Spearman’s correlation 
coefficient, median (range) 
Dereplicated data 
Spearman’s correlation 
coefficient, median (range) 
Same libraries 0.84 (0.80-0.94)  0.83 (0.81-0.91) 
Libraries using 15 vs 18 
PCR cycles 
0.88 (0.81-0.92) 0.88 (0.81-0.92) 
Libraries using different 
DNA input 
0.90 (0.90-0.90) 0.90 (0.89-0.90) 
Non-replicates 0.42 (-0.14-0.92) 0.44 (-0.15-0.94) 
 
  
Figure 4-9: Examples of copy number analysis in chromosome 7 using different amounts of DNA from the same sample. 
NGS data were generated using 250ng, 100ng and 25ng from the same sample. The log base 2 median normalised read counts for 
chromosome 7 are presented. Each dot represents a 10kb region. Similar patterns of copy number alterations are observed. Similar results 
were obtained for the other chromosomes (not shown). 
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4.4.9 GC correction 
The data free from PCR replicates and problematic regions were used to identify if 
GC content affects the data. The explained variance by GC content identified using 
ANOVA, as described in section 2.10, varied across samples. A comparison 
between GC content and median-normalised read counts (GC bias) is illustrated in 
Figure 4-10 where three examples are shown. Both positive and negative linear 
associations but also non-linear associations between GC content and read counts 
were observed. Gusnanto et al have reported the use of a Loess model to correct 
for GC bias which does not allow for additional covariates to be incorporated into 
the model (Gusnanto et al., 2012). Although some of our data showed a non-linear 
GC bias, a linear model was used to correct for the observed GC bias, which also 
included chromosome as a covariate. Three examples of chromosome 7 read 
counts before and after GC correction are shown in Figure 4-11.  
All the different associations observed in my data have been previously reported 
(Dohm et al., 2008, Chen et al., 2013) and therefore a correction was considered 
essential to remove the effect of GC content before downstream analysis. 
 
  
Figure 4-10: Comparison between GC content and median-normalised read counts.  
Smoothed scatterplots between GC content and median-normalised read count per window, where red represents the highest density of 
windows (Eilers and Goeman, 2004). a) A positive linear association between GC content and read counts; b) a positive non-linear 
association between GC content and read counts; c) a negative linear association between GC content and read counts. All of these 
associations have been previously reported and a correction model should be applied to remove the effect of GC content before downstream 
analysis. A linear model was used to correct for the GC-bias which also included chromosome as a covariate.  
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Figure 4-11: Chromosome 7 read counts before and after GC correction.  
The data are shown for samples with: a) positive linear GC bias; b) positive non-linear GC bias; and c) negative linear GC bias. It can be 
seen that some variation is smoothed after correction for GC content. For the first sample (a) some variation in read counts is preserved 
which might be interpreted as that this is real variation, and for the other samples (b and c) a lot of variation is removed. 
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4.4.10 Genome wide analysis for associations between copy 
number and patients characteristics 
The optimal approach to whole-genome NGS data analysis is still an active 
research area. Most methods utilise matched normal reference samples (which we 
did not have) and they have not been tried for FFPE material. We wanted to stay as 
close to the raw data as possible: that is that we did not want to adopt approaches 
to analysis which might be reported in the literature but flawed. In the absence of a 
standard metric for quality we tried to correct for the biases we observed but also 
exclude low quality data from subsequent analysis. 
For the development of this protocol, where there were replicates data from a single 
replicate were used. To look for associations between copy number and patients’ 
characteristics median and GC-corrected data free from both PCR replicates and 
problematic regions, from 61 unique samples were used (descriptive statistics 
shown in Table 4-7). 
Breslow thickness, mitotic rate, ulceration, AJCC stage, melanoma-specific survival 
(MSS), age of the patient, sex, tumour site and primary type were tested for 
association with the read counts from each 10kb window. 
Table 4-8 shows the number of windows that had an FDR<0.1. Fifty-one windows 
were significantly associated with age of the patient, 1,736 windows were 
significantly associated with Breslow thickness, 21,424 windows with mitotic rate, 
5,909 with BRAF mutated tumours compared to non-BRAF mutated ones but only 1 
window was associated with AJCC stage. The histograms of the p values for the 
associations between each 10kb window and mitotic rate, MSS and ulceration are 
shown in Figure 4-12. A flat histogram of p values is expected, as most windows 
will show no significant association with the tested variable, with a high peak at low 
p values for the significant associations. After regression analysis for MSS, an 
increased frequency of low p values was observed for some windows but these 
failed to reach statistical significance after multiple testing correction (Figure 4-12). 
On the contrary, after regression analysis for ulceration, no increased frequency of 
low p values was observed (Figure 4-12).  
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Table 4-7: Descriptive statistics of the sample set (n=61). 
Variable Sample set 
Age at diagnosis (years), median (range) 59.67 (25.09-76.34) 
Sex, n (%) 61 
          Male 25 (40.98) 
          Female 36 (59.02) 
Breslow thickness, mm, median (range) 2.3 (1.15-12) 
Mitotic rate, per mm2, n (%) 54 (88.52) 
Mitotic rate, per mm2, median (range) 3 (0-70) 
AJCC stage, n (%) 61 
          I 21 (36.84) 
          II 33 (54.10) 
          III 7 (11.48) 
Ulcerated tumours 22 (36.06) 
Primary type, n (%) 61 
          SSM/LMM 33 (54.10) 
          NM 24 (39.34) 
          ALM/Unclassified 4 (6.56) 
Tumour site  61 
          Head/Neck/Trunk 21 (34.43) 
          Limbs/Acral 40 (65.57) 
Deaths, n (%) 23 (37.70%) 
Deaths from melanoma, n (%) 20 (32.79%) 
Follow-up period, years, median (range) 8.03 (0.89-11.76) 
Mutation status, n (%) 60 
          BRAF 23 (38.33) 
          NRAS 21 (35.00) 
          None 16 (26.67) 
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Table 4-8: Associations between read counts in each window and tumour 
characteristics (genome-wide analysis). 
It can be seen that the number of associated windows was very variable 
between clinical features being tested. 
Variable 
Statistical model and number 
of windows with FDR <0.1 
Age (years) Linear regression, 51 
Gender (Male/Female) Logistic regression, 0 
Breslow thickness, mm Linear regression, 1736 
Mitotic rate, per mm2 Linear regression, 21424 
AJCC stage (I/II/III) Linear regression, 1 
Ulceration (yes, no) Logistic regression, 0 
Primary type (SSM/LMM, NMM) Logistic regression, 0 
Tumour site (Head/Neck/Trunk, Limbs) Logistic regression, 0 
Melanoma-specific survival Cox regression, 0 
Mutation status (BRAF/NRAS)  
          BRAF vs non-BRAF Logistic regression, 5909 
          NRAS vs non-NRAS Logistic regression, 0 
          BRAF vs no mutation in both Logistic regression, 0 
          NRAS vs no mutation in both  Logistic regression, 0 
          BRAF vs NRAS Logistic regression, 0 
 
 
  
Figure 4-12: Histograms of the frequency of p values for the associations between each 10kb window and mitotic rate, melanoma-
specific survival (MSS) and ulceration. 
A flat histogram of p values is expected, as most windows will show no significant association with the tested variable, with a high peak at 
low p values for the significant associations as is seen above for associations with mitotic rate. After regression analysis for MSS, an 
increased frequency of low p values was observed for some windows but these failed to reach statistical significance after multiple testing 
correction. On the contrary, after regression analysis for ulceration, no increased frequency of low p values was observed. The histogram of 
p values for mitotic rate is used for comparison and shows the high number of windows that reached statistical significance. 
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The FDR values for each window’s association with Breslow thickness, mitotic rate 
and BRAF mutated tumours are shown in Figure 4-13, Figure 4-14 and Figure 4-15 
respectively. These graphs show that only individual windows showed a statistically 
significant association with Breslow thickness while windows adjacent to each other 
showed a statistically significant association with mitotic rate and BRAF mutation 
status. For example, read counts from the start of the chromosome 5p arm, 
chromosome 7q and 8q arms were significantly associated with mitotic rate (Figure 
4-14). It was also observed that read counts from chromosome 10q arm were 
significantly associated with BRAF mutated tumours (Figure 4-15). As the loss of 
chromosome arm 10q has been previously associated with positive BRAF mutation 
status (Jonsson et al., 2007, Gast et al., 2010), I investigated whether I could 
identify if this observation represented a copy number loss or a gain by plotting the 
read counts from chromosome 10q arm in BRAF mutated tumours and non-BRAF 
mutated tumours (Figure 4-16). On the log scale read counts below zero represent 
copy number loss while read counts greater than zero represent copy number gain. 
Read counts below zero were seen in BRAF mutated tumours whereas read counts 
close to zero were observed for non-BRAF samples, showing that 10q arm loss 
was associated with BRAF mutated melanomas (Figure 4-16) as expected from the 
literature. 
 
 
 
 
  
Figure 4-13: The statistical significance values (-log10 FDR) across the 22 chromosomes of each 10kb window's association with 
Breslow thickness. 
The red line represents the FDR threshold. Mainly, individual windows and small regions such as in chromosome 1p were significantly 
associated with Breslow thickness. It is noted that very small regions in chromosome 2 are significantly associated with Breslow thickness. 
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Figure 4-14: The statistical significance values (-log10 FDR) across the 22 chromosomes of each window's association with mitotic rate. 
The red line represents the FDR threshold (0.1). Mitotic rate showed the most significant associations with copy number. A strong signal was 
observed in relatively small regions such as in chromosome arm 1p, 5p, and 11p but also in whole chromosome arms (7q, 8q, 20p).  
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Figure 4-15: The statistical significant values (-log10 FDR) across the 22 chromosomes of each 10kb window's association with BRAF 
mutated samples.  
The red line represents the FDR threshold of 0.1. It can be seen that a strong signal is from chromosome arm 10q where the tumour 
suppressor PTEN is coded, a gene which is known to be deleted in BRAF mutated melanomas. 
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Figure 4-16: Chromosome 10q read counts in samples with BRAF mutation 
versus samples with no BRAF mutation. 
On the log scale read counts <0 represent copy number loss while read 
counts >0 represent copy number gain. It is shown BRAF mutation was 
associated with loss of chromosome arm 10q, as has previously been 
reported. 
 
To reduce noise, the coefficients from the regression models were smoothed using 
a bandwidth of 501 windows. The advantage of smoothing the coefficients instead 
of p-values was that the direction of the association could be identified. For 
example, for mitotic rate a positive coefficient for a specific region can be 
interpreted as higher copy number associated with higher mitotic rate or lower copy 
number is associated with lower mitotic rate for that region (Figure 4-17). Positive 
associations between copy number status of whole chromosome arms such as 7q, 
8q and mitotic rate were identified. Negative associations between copy number 
status of whole chromosome arms such as 17p and 20p and mitotic rate were also 
found. 
 
  
Figure 4-17: The smoothed coefficients (based on a 501 windows running median) from the regression model for mitotic rate.  
The green lines represent the FDR threshold of 0.1. Positive associations between copy number status of whole chromosome arms such as 
7q, 8q and mitotic rate were identified. Negative associations between copy number status of whole chromosome arms such as 17p and 20p 
and mitotic rate were also found. The effect of small regions is possibly masked due to smoothing of the coefficients using a bandwidth of 
501 windows. 
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To identify if these chromosome arms 7q and 8q were gained or lost in association 
with mitotic rate the read counts of these chromosome arms for patients grouped 
based on mitotic rate tertiles (0-1, 1-5, >5) were plotted (Figure 4-18). Higher copy 
number in 8q was observed in patients with higher mitotic rate. This was not the 
case for 7q where similar read counts were observed in all patients except for a 
single sample which had the highest mitotic rate (70mm2) and showed the highest 
copy number. Linear regression models rely on the assumption that the residuals 
are normally distributed. The sample with very high mitotic rate and increased copy 
number probably affected the results where 7q appeared to be significantly 
associated with mitotic rate (as shown in Figure 4-14 and Figure 4-17). This 
suggests that a more robust regression model which will not assume normally 
distributed data should be performed in the future to identify clear associations. 
 
  
Figure 4-18: Chromosome 8q and 7q read counts in patients with different mitotic rate. 
Patients were grouped in tertiles (with mitotic rate 0-1.5, 1,5-5, 5-70). A) Higher copy number in chromosome 8q was seen in patients with 
higher mitotic rate. B) Similar copy number in chromosome 7q was seen in all patients except for a single patient which has a mitotic rate of 
70mm2. Linear regression models rely on the assumption that the residuals are normally distributed. This observation suggests that a robust 
regression model should be used in the future to identify clear associations. 
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4.4.11 Copy number and gene expression data integration 
for the chromosomal regions found to be associated with 
mitotic rate 
I report here a study of whether CNAs in regions shown to be associated with 
mitotic rate mirrored variation in expression levels of genes within those regions. 
Whole-genome DASL data were available from 47 out of 61 samples with copy 
number data. The windows significantly associated with mitotic rate based on the 
smoothed coefficients (see Figure 4-17) were merged with the DASL data based on 
the DASL probe coordinates as described in section 4.3.8. 1894 DASL probe/NGS 
window pairs were identified and Spearman’s correlation coefficients between the 
signal of each DASL probe and the read count of the corresponding NGS 10kb 
window were calculated. Thirty-three significant positive and 3 negative correlations 
were identified. Twenty-two DASL probes whose expression was significantly 
correlated with copy number were located on chromosome 7, 12 on chromosome 8 
and 1 on chromosome 16. The top 10 most significant correlations are listed in 
Table 4-9. 
To reduce noise, the NGS 10kb window read counts were smoothed using a 
bandwidth of a 501 windows running median. Then, Spearman’s correlation 
coefficients between the smoothed NGS read count and the matched DASL probe 
signal were calculated. This analysis revealed 159 significant positive and 5 
negative correlations (FDR<0.1). Two probes whose signal was significantly 
correlated with copy number were located on chromosome 1, 4 on chromosome 5, 
82 on chromosome 7, 39 on chromosome 8, 17 on chromosome 11, 1 on 
chromosome 15, 4 on chromosome 16, 6 on chromosome 17 and 9 on 
chromosome 20. The top 10 most significant correlations are listed in Table 4-10. 
The 159 DASL probes (representing 131 genes) significantly correlated with the 
smoothed NGS read counts were analysed using MetaCore™ pathways analysis 
software in an attempt to identify enriched pathways. The top 3 significantly 
enriched pathways (IL-2 signalling, cell cycle and DNA damage pathways) are 
listed in Table 4-11. 
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Table 4-9: Top 10 significant correlations between the signal of a DASL probe 
and the read count of the corresponding NGS 10kb region. 
 For this analysis the NGS 10kb windows significantly associated with mitotic 
rate based on the smoothed coefficients were identified and matched to DASL 
probes (1894 DASL probe/NGS window pairs). The gene name that the DASL 
probe targets is presented. The smoothed coefficient from the regression 
model with mitotic rate is also presented to show the direction of the 
association with mitotic rate. The last column indicates whether the reported 
gene is located in the corresponding NGS 10kb region in the hg19. 
Chr Start End Gene 
Spearman's 
rho 
FDR 
Smoothed 
coefficient 
hg19 
7 129560001 129570001 KLHDC10 0.56 0.07 18.10  
16 74900001 74910001 WDR59 0.55 0.07 -12.71  
8 144970001 144980001 PUF60 0.53 0.09 17.98  
7 130030001 130040001 TSGA14 0.53 0.09 18.10  
7 149800001 149810001 GIMAP8 -0.52 0.09 17.69  
7 123320001 123330001 WASL 0.51 0.09 17.24  
8 94810001 94820001 RBM12B 0.50 0.09 18.54  
7 94020001 94030001 CASD1 0.49 0.09 19.85  
7 100870001 100880001 CLDN15 0.49 0.09 17.61  
8 145060001 145070001 GRINA 0.49 0.09 18.04  
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Table 4-10: Top 10 significant correlations between the signal of a DASL 
probe and the smoothed read count of the corresponding NGS 10kb 
region. 
For this analysis the significant NGS 10kb windows associated with mitotic 
rate based on the smoothed coefficients were identified and matched to DASL 
probes. The read count of each NGS 10kb window was smoothed using a 
bandwidth of 501 windows running median (which results in 5Mb sliding 
windows). The gene name that the DASL probe targets is presented. The 
smoothed coefficient from the regression model with mitotic rate is also 
presented to show the direction of the association with mitotic rate. The last 
column indicates whether the reported gene is located in the corresponding 
NGS 5Mb region in the hg19. 
Chr Start End Gene 
Spearman's 
rho 
FDR 
Smoothed 
coefficient 
hg19 
8 144470001 145480001 PUF60 0.67 0.001 17.99  
7 129530001 130540001 TSGA14 0.60 0.006 18.10  
11 77420001 78430001 GAB2 060 0.006 16.79  
7 111900001 112910001 TMEM168 0.61 0.006 17.72  
11 77090001 78100001 INTS4 0.60 0.006 16.59  
8 144560001 145570001 GRINA 0.58 0.006 18.04  
8 145010001 146020001 DGAT1 0.59 0.006 19.20  
7 86360001 87370001 CROT 0.58 0.007 18.50  
20 800001 1810001 FKBP1A 0.56 0.013 -19.85  
8 95820001 96830001 C8orf37 0.55 0.014 17.61  
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Table 4-11: The top 3 overrepresented pathways identified using MetaCore™. 
For this analysis the 159 DASL probes significantly associated with the 
smoothed read count of their corresponding NGS 10kb regions were used for 
pathway analysis. 
Pathway FDR Genes (Chr arm) 
Immune response_IL-2 activation and signalling 
pathway 
0.069 
GAB2 (11q), CHUK (10q), 
SHPS-1 (20q) 
Cell cycle_Role of 14-3-3 proteins in cell cycle 
regulation 
0.096 Tp53 (17p), CDC25B (20p) 
DNA damage_ATM/ATR regulation of G2 / M 
checkpoint 
0.096 Tp53 (17p), CDC25B (20p) 
 
4.4.12 Copy number and gene expression data for the 
chromosomal regions coding for genes known to be 
involved in melanoma biology: a candidate gene analysis 
Here, I report the correlations between copy number and gene expression data of 
genes of interest. Fifteen genes which have previously been associated with 
melanoma in terms of gene expression (RAD51, RAD52, RAD54B, SPP1, TOP2A), 
mutation (BRAF, MC1R, NRAS, KIT, TERT) and copy number alteration (CDKN2A, 
EGFR, MITF, MYC, PTEN) were chosen. The correlations between the signal of 
DASL probes targeting each interesting gene and the NGS read counts of the 
region where each DASL probe is located were calculated (Table 4-12). 
Interestingly, there was a statistically significant correlation between copy number 
and gene expression measure for CDKN2A, PTEN, MYC, RAD52 and TOP2A. The 
median and the range of read counts for CDKN2A and PTEN indicate that this 
region was commonly lost. It was noted that SPP1 expression was significantly 
negatively correlated with copy number status. 
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Table 4-12: Spearman correlation coefficients between DASL and NGS data 
for the candidate genes. 
The Spearman’s correlation coefficient between each DASL probe coding for 
a candidate gene and NGS read counts of the corresponding 10kb region 
where each probe is located was calculated. The gene name that the DASL 
probe targets is presented. The log base 2 GC corrected read count for each 
region and the range are also reported in an attempt to identify if the region is 
gained or lost. Counts >0 show that the region is gained. The significant 
associations (p<0.05) are highlighted in black. The rows highlighted in red 
represent regions where the reported gene is not in the corresponding region 
in the hg19. 
Chr Start End Gene 
Spearman's 
rho 
P value 
Median read count 
(range) 
3 69780001 69790001 MITF -0.15 0.31 -0.29 (-1.45-1.42) 
3 69810001 69820001 MITF 0.04 0.79 -0.01 (1.52-1.31) 
3 70010001 70020001 MITF -0.26 0.08 -0.11 (1.91-0.50) 
4 88900001 88910001 SPP1 -0.35 0.02 -0.08 (-0.79-0.37) 
4 88900001 88910001 SPP1 -0.29 0.05 -0.08 (-0.79-0.37) 
7 55180001 55190001 EGFR -0.17 0.26 0.12 (-0.52-0.74) 
7 55190001 55200001 EGFR -0.09 0.54 0.15 (-0.70-0.65) 
7 55200001 55210001 EGFR 0.05 0.72 0.07 (-0.69-0.86) 
7 55230001 55240001 EGFR -0.19 0.20 0.32 (-0.71-1.13) 
8 95460001 95470001 RAD54B -0.08 0.58 0.11 (-0.57-1.11) 
8 95480001 95490001 RAD54B 0.04 0.79 0.21 (-0.57-0.99) 
8 128820001 128830001 MYC 0.28 0.06 0.11 (-0.42-1.04) 
8 128820001 128830001 MYC 0.33 0.02 0.11 (-0.42-1.04) 
9 21960001 21970001 CDKN2A 0.44 0.002 -0.39 (-2.95-0.25) 
9 21970001 21980001 CDKN2A 0.30 0.04 -0.54 (-4.37-0.21) 
9 21990001 22000001 CDKN2A 0.02 0.91 -0.74 (-4.82-0.28) 
10 89690001 89700001 PTEN 0.35 0.02 -0.34 (-3.10-0.38) 
12 1020001 1030001 RAD52 0.35 0.01 0.02 (-0.48-0.87) 
17 38540001 38550001 TOP2A 0.36 0.01 0.16 (-0.93-0.92) 
1 115050001 115060001 NRAS -0.10 0.51 -0.13 (-1.01-0.74) 
4 55300001 55310001 KIT 0.26 0.08 0.02 (-0.59-0.46) 
4 55300001 55310001 KIT 0.04 0.77 0.02 (-0.59-0.46) 
5 1300001 1310001 TERT 0.12 0.40 0.08 (-0.59-2.44) 
5 1300001 1310001 TERT -0.13 0.37 0.08 (-0.59-2.44) 
5 1300001 1310001 TERT 0.12 0.40 0.08 (-0.59-2.44) 
7 140080001 140090001 BRAF 0.21 0.16 0.15 (-0.91-1.21) 
15 38790001 38800001 RAD51 -0.01 0.93 -0.02 (-1.23-0.33) 
15 38810001 38820001 RAD51 0.05 0.74 -0.05 (-0.92-0.78) 
15 38810001 38820001 RAD51 -0.11 0.46 -0.05 (-0.92-0.78) 
16 88510001 88520001 MC1R 0.49 0.001 -0.21 (-1.12-0.60) 
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4.5 Discussion 
In recent years, high-throughput technologies have provided researchers with 
useful tools to address diverse biological problems.  
Next generation sequencing technology is driving advances in cancer research in 
that genomic, transcriptomic and epigenomic data can be generated to offer a more 
complete view of the cancer cell (Hawkins et al., 2010). In melanoma, whole-
genome and whole-exome sequencing data have provided new insights in the 
pathogenesis of the disease (reviewed by (Hill et al., 2013)). For example in 2012, 
Hordis et al generated whole-exome data from 121 melanoma tumours and 
reported that the high prevalence of C>T transitions attributed to UVB exposure 
was linked to an increased rate of driver mutations (e.g. RAC1), providing evidence 
that UVB mutagenesis has a direct effect in the pathogenesis of melanoma (Hodis 
et al., 2012).  
In a different study using already available whole-exome data, the authors identified 
a recurrently amplified region affecting PHGDH (phosphoglycerate degydrogenase 
- involved in cell metabolism) in melanoma samples showing further evidence that 
NGS data can provide new evidence to explore the importance of other than the 
currently known pathways related to melanoma development (Locasale et al., 
2011).  
Most NGS studies have used DNA extracted from cell lines or frozen tumours. 
Melanoma primaries are so small that cryopreservation of tissue is rarely possible: 
staging of the disease is primarily dependent upon histopathological features, so 
that freezing of even a small part of the primary is not possible lest that staging 
process be compromised. In order to use NGS to study sufficient numbers of 
tumours to give statistical power to address important clinical questions, then it is 
necessary to develop a protocol for use of formalin-fixed tumour. It is also clearly 
necessary to establish that data generated are of sufficient quality to give 
reproducible valid data. 
Recent developments in protocols have made it possible to use low amounts of 
DNA to generate libraries for NGS. Studies have reported the use of NGS of 
material from FFPE tumours (Wood et al., 2010, Conway et al., 2012, Adams et al., 
2012). In Chapter 3 I reported the successful library preparation using DNA from 
FFPE primary melanoma tumours, which enabled us to select patients from the 
Leeds Melanoma Cohort study to identify somatic CNAs in melanoma tumours 
moving towards the aim to study CNAs as potential prognostic biomarkers. This is 
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an on-going project of which the first results were presented here. These results are 
discussed as approaches to determining the validity of use of this technique for 
formalin fixed tumours. 
4.5.1 DNA samples 
The samples were selected for this study in a case control design where cases 
were patients who have died and controls were sex and Breslow thickness matched 
participants who have not died. Here, sequencing data from the first 75 samples 
are presented to test the feasibility of NGS technology using FFPE-derived DNA. 
Seventy-five samples is the largest number of FFPE primary melanoma tumours 
subjected to whole-genome NGS in the world. It is as yet a small proportion of the 
final number of samples which will be sequenced for this study and therefore the 
data reported here are as yet underpowered.  
The Leeds Melanoma Cohort is a population ascertained cohort but the samples 
analysed here and in the study overall are inevitably selected as sufficient DNA to 
generate libraries is dependent upon the thickness of the primary tumour. Thus, my 
study is biased towards thicker poorer prognosis melanomas. If a potential 
biomarker is identified however I would plan to test such a biomarker in the smaller 
tumours if a specific test can be devised to test that biomarker. 
A limitation of this work is the sampling of tumours using Tissue MicroArray (TMA) 
cores. As discussed in Chapter 2, using TMA cores does not allow confirmation of 
the tumour content throughout the core. There is potentially greater contamination 
with normal cells that in microdissected tumours. However, by using this method a 
greater range of tumours will be examined than in previous research based upon 
frozen tumours. Both DNA and RNA is extracted using a TMA core which preserves 
architecture of the block for clinical use which is considered crucial. The use of 
microdissection could possibly address some of these issues but it would be 
difficult to extract sufficient yields of DNA for whole-genome NGS studies and 
would be more time consuming for large-scale studies. My work is however 
designed to identify biomarkers for use in clinical practice and it is conceivable that 
sampling tumours using a TMA needle would be a more valid option than 
microdissection. This approach therefore seems reasonable as a standard 
approach to sampling was adopted. 
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4.5.2 Libraries 
Libraries from 269 samples have been prepared to date (September 2013) and 
92% of them were successful and produced enough yield to be sequenced. 
Although melanin score was inversely associated with DNA concentration, melanin 
score was not a predictor of successful library preparation. This result supports the 
view that BSA addition in the enzymatic reactions of library preparation can reduce 
the inhibitory effect of melanin. This is in accordance with the literature where 
addition of BSA or other proteins in PCR reactions is able to reverse the inhibitory 
effect of melanin and let DNA polymerase amplify the sequences (Eckhart et al., 
2000, Mani et al., 2001). The only predictor of successful library preparation was 
DNA input. We managed to prepare libraries from DNA samples where the amount 
used was as low as 10.5ng but also from samples where DNA concentration was 
detected as 0ng/µl using the broad range picogreen assay (range of detection 2-
1000 ng/µl). Age of the block and day of the week that the block was processed 
were not statistically significant predictors of successful library preparation. The 
median age of blocks of which successful libraries were produced was lower (10.13 
years) than the median age of blocks of which the libraries failed to be generated 
(11.19). However, there was a single case where the age of the block was 
approximately 20 years and a successful library was produced. The above 
observations, unsurprisingly, suggest that DNA yield is a successful predictor of 
library success, however a cut-off value of DNA yield under of which we were not 
able to generate a library could not yet be established. A recent study has shown 
that a library could not be produced from a single 40ng FFPE-derived DNA sample 
that appeared to have organic contamination (high 260/230 ratio) (Simbolo et al., 
2013) but this approach was not tested in this study. My work has also shown that 
PCR replication was greater in libraries produced from lower quantities of DNA, 
(see below) and as this work proceeds, an approach to defining the lower limits of 
DNA concentration which will generate reliable data must be explored.  
During my PhD, a new library preparation protocol became available which 
replaced the manual protocol as discussed in Chapter 3. To explore the possibility 
that the different protocols might affect analysis of sequencing data, 16 samples 
with DNA samples available from two cores (biological replicates) were chosen and 
one library was prepared using the manual protocol and one library using the NEB 
protocol. Similar DNA input was used for both protocols to allow direct comparison 
of the sequencing data when these become available. It was shown that library 
yields were better when the NEB protocol was used which supported our decision 
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to replace the old protocol as it is much quicker and uses less PCR cycles than the 
manual protocol. As the NEB protocol uses fewer PCR cycles it is likely that fewer 
PCR replicates will be sequenced. This will be tested by direct comparison of the 
sequencing data generated from the 16 libraries prepared using the manual and 
their matched libraries using the NEB protocol. 
4.5.3 Quality control of sequencing data 
Library quality control was not the only aspect tested to assess the feasibility of 
using NGS technology with FFPE samples. A number of quality control steps were 
performed to exclude low quality data from subsequent analysis. Up to the 
submission of this thesis, 100bp paired-end sequencing data were available from 
75 libraries (61 unique samples and 14 replicates) generated using the manual 
protocol. This protocol uses adapters with a 5bp unique barcode and a T always 
present at the 6th position to allow multiplexing. Every base is assigned a quality 
score, which reflects the probability of an incorrect call at that base for that specific 
read. The maximum quality score a base can be assigned is 40, which reflects the 
probability of 0.0001 that this base has been wrongly called. Typically, a quality 
score of greater than 28 is taken to indicate high quality data (Babraham 
Bioinformatics, 2010). The quality score assigned to the 6th base was dramatically 
low while quality scores were low for the subsequent 4 bases. The low quality score 
at the 6th position is expected, as there is no complexity across the whole sample at 
the position. However, the low quality scores observed in the subsequent few 
cycles is not easily explained (the issue was discussed with Illumina technical 
support). The signal intensity files from the sequencer revealed a drop in intensities 
of the other 3 bases for both reads at that position. It is unknown why a low quality 
score was assigned for the second pair only. The NEB protocol utilises a different 
barcoding system (indexing) where a 6bp index is present in the middle of the 
primer sequence. This 6bp index barcode is sequenced using a separate 
sequencing primer (as a completely different third sequencing run) and therefore, 
the issue described above will be not an issue in the data generated from the NEB 
libraries. For this analysis, we decided to remove the initial 4 bases (after the six of 
the barcode) from all sequences to remove these low quality calls in these data 
generated using the manual library method. 
Lower quality scores were also assigned at the 3’ end of the reads. The source of 
the lower quality scores at the 3’ end is known as a phasing artefact (Kircher et al., 
2011). Phasing occurs due to imperfections in the sequencing chemistry 
(incomplete incorporation of a nucleotide, or errors in bridge PCR yielding multiple 
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DNA species in a single spot) leading to the individual DNA molecules in the cluster 
getting “out of step” with each other during sequencing. Due to lower quality scores, 
the last 10 bases were removed from subsequent analysis. 
Finally, we searched for and removed Illumina adapter sequences at the 3’end of 
the sequenced reads. Adapter sequences will interfere with mapping efficiency of 
the DNA sequences (Minoche et al., 2011). 
In summary, based on the above observations it was considered essential to trim 
the first 10 and the last 10 bases as well as bases at the 3’ end of the sequences 
which matched part of the Illumina adapters to improve accuracy of the sequencing 
data. The trimming procedure is essential to remove low quality data and improves 
mapping efficiency (Minoche et al., 2011). The data were then aligned to the human 
reference genome and data were checked to identify other possible biases. 
4.5.4 PCR amplification 
PCR amplification is essential before NGS analysis to enrich for the fragments to 
be sequenced. After fragmentation and adapter ligation, 18 PCR cycles were used 
to amplify the ligated fragments using the manual protocol. The high number of 
PCR cycles used to generate libraries was essential due to the low DNA input 
used. We did observe a high number of PCR replicates associated with lower DNA 
input (predominantly where DNA input was less than 200ng) and increased age of 
the block. There were samples though that showed low level of sequenced PCR 
replicates even when DNA input was as low as 22.9ng or even for the DNA sample 
which could not be measured using the broad range picogreen assay as discussed 
above (0ng/µl). Two samples which were relatively recent (under 8 years) had high 
levels of replicated sequences. As above then DNA low yields are viewed as 
potentially problematic. It would be cost-effective to sequence these low DNA yield 
samples at lower depth to avoid sequencing of PCR replicates, which are likely to 
be uninformative. My intention is to revisit this when analysing the data generated 
using the NEB library protocol. 
Comparison between raw and dereplicated data (after removal of PCR replicates) 
showed an even pattern of reads removed per chromosome (Figure 4-5), except for 
chromosome 16 due to “problematic” regions in that chromosome, which suggests 
that removing PCR replicates might not adversely affect subsequent analysis of the 
data, but this has not been addressed. PCR replicates are defined based on an 
identical mapping position. A single nucleotide variation seen inside the defined 
PCR replicate read would suggest that these might not be real PCR replicates and 
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could be further explored. In the context of this work, PCR replicates were removed 
as is widely performed in NGS studies (Ding et al., 2010). To reduce the frequency 
of PCR replicates, we tried to use more than 200ng DNA whenever possible for 
subsequent library preparations. It is possible that more samples should be 
multiplexed and sequenced in a single lane when lower DNA input is used to 
address the high level of PCR replicates observed. When more data are analysed 
we might be able to distinguish samples which will perform well from samples which 
will not to allow efficient sampling selection for future studies. 
4.5.5 Problematic regions 
During the exploration to identify biases that might affect the signal of interest in our 
data, a published study reporting problematic regions in the reference genome 
sequence came to our attention (Pickrell et al., 2011). These problematic regions 
were identified to produce false-positive copy number peaks in the ENCODE ChIP-
sequencing data. Our data were in agreement with their study where increased 
coverage was seen in regions where there are multiple copies in reality but only 
one is reported in the reference sequence. Therefore, these regions were excluded 
from statistical analysis. 
4.5.6 GC bias 
Due to the massively parallel sequencing process, PCR amplification, cluster 
amplification and sequencing reactions (in which biases such as uneven coverage 
of GC-rich or AT-rich regions (Aird et al., 2011) can be easily introduced) should be 
standardised as much as possible. In the context of our work different relationships 
between GC content in 10kb regions and coverage were observed (Figure 4-10). 
This shows that the effect of GC content on coverage is not simple. These effects 
have also been reported by other studies and a correction is considered essential 
as these effects can dominate the signal of interest (Dohm et al., 2008, Benjamini 
and Speed, 2012). We decided to adopt a linear correction strategy where the 
chromosome was included as a covariate while other proposed models do not allow 
for additional covariates (Gusnanto et al., 2012). 
4.5.7 Coverage and reproducibility 
The median sequencing coverage was 1.14x (range, 0.37x-1.64x). The previous 
study by Wood et al and the most recent from the same group by Belvedere et al 
using tissue from oral or lung squamous cancers have reported CNAs in FFPE-
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derived tumours using NGS data with much lower coverage (range 0.004x-0.06x) 
(Wood et al., 2010, Belvedere et al., 2012). These studies were multiplexing more 
samples per lane and therefore less sequencing per sample was performed. We 
expect that the relatively high coverage NGS data generated here will enable us to 
detect smaller CNAs. However, this has not yet been addressed.  
Not surprisingly, the only predictor of coverage was DNA input. Neither age of the 
block or melanin content was associated with coverage. The correlation coefficients 
between non-replicate pairs was much lower for non-problematic regions than for 
the problematic regions which provides further evidence that the previously 
identified problematic regions by Pickrell et al are indeed unreliable. For non-
problematic regions the median correlation coefficient between replicate pairs was 
0.89 compared to 0.49 for non-replicate pairs, which suggests that the assay is 
suitable for FFPE samples. There was no difference between raw and dereplicated 
data, which further supports our view that PCR replicate removal might not 
adversely affect subsequent analysis. The correlation coefficients between replicate 
pairs of the same libraries, replicate pairs of libraries generated with different DNA 
input, and replicate pairs of libraries generated using different PCR cycles was high 
(Spearman’s rho range 0.81-0.94) and no difference could be observed between 
the different groups. The equivalent good correlation between replicate libraries 
generated with different DNA input (25ng versus 250ng or 25ng versus 100ng) 
shows that comparable data can be generated when even very low DNA input is 
used which is important as only small amounts of DNA are available from some 
FFPE samples. However, this is a case where an FFPE tumour produced sufficient 
DNA to run 3 independent libraries. This might not be a representative example of 
primary melanomas overall which commonly will only produce very small amounts 
of DNA sufficient for one library. As already discussed, further work will be needed 
when more sequencing data will be available to try and predict which samples need 
to be sequenced and at what depth. 
4.5.8 Copy number alterations 
Biases previously reported to affect NGS data analysis (GC bias, PCR duplication, 
problematic regions in the reference) were explored and correction was performed 
as already discussed. As more and more NGS data become available it is possible 
that these biases will be better understood or more appropriate tools and methods 
will arise to correct for them. Also there are other as-yet unknown errors that we 
might find. 
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Following the correction of biases observed and assessment of the reproducibility 
of NGS using FFPE samples, data were analysed to identify CNAs in tumours of 
patients with well-documented characteristics, such as Breslow thickness and 
mitotic rate. This analysis aimed to explore the feasibility of NGS technology to 
produce high quality data from FFPE samples. Univariable analysis was performed 
to identify CNAs associated with MSS and other tumour characteristics known to be 
predictors of survival. As matched normal reference samples were not available, it 
is not possible to accurately detect the number of alleles that had been gained or 
lost. Median normalised data on the log 2 scale though can be interpreted as read 
counts >0 depict copy number gain and <0 depict copy number loss. Regression 
analysis between each 10kb region and mitotic rate showed the most significant 
associations. CNAs of whole chromosome arms such as 7q and 8q were 
significantly associated with mitotic rate as observed in Figure 4-14 and Figure 
4-17. Frequent copy number gains of 7q and 8q have been previously identified in 
melanoma (Bastian et al., 2003, Jonsson et al., 2007, Rakosy et al., 2013). We 
confirmed that chromosome 8q gain was associated with mitotic rate but this was 
not the case for 7q where similar copy number was seen in all patients by looking at 
read counts. The linear regression model relies on the assumption that the 
residuals are normally distributed and as mitotic rate values were not normally 
distributed some of the significant associations resulted from the regression 
analysis could be erroneous. A robust regression model, which will not assume that 
the data are normally distributed should be applied in the future, and I will explore 
that after submission of this thesis. To reduce noise the coefficients were smoothed 
using a bandwidth 501 windows running median. The limitation of this approach is 
that associations between the phenotype and small regions (<<5Mb) will not be 
picked up. 
The strongest associations between CNAs and a clinico-pathological factor were 
seen for mitotic rate although regression analysis between each 10kb region and 
Breslow thickness showed individual windows and relatively small chromosomal 
regions to be associated with Breslow thickness. Regression analysis between 
each 10kb region and MSS, ulceration, AJCC stage, tumour site and clinico-
pathological subtypes of melanoma showed no significant associations. The above 
observations are hypothesised to be explained at least in part as these features are 
more complex than tumour mitotic rate. Mitotic rate is representative of how 
proliferative a tumour is while, for example, Breslow thickness depends on the 
stage of diagnosis (how readily a patient seeks advice and how effectively he is 
managed by medical services). Mitotic rate is postulated to be a much simpler 
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measure reflecting tumour biology rather than a composite of biology and health 
care. It is possible that when we increase the sample size more associations 
between copy number and tumour characteristics will be identified. 
Regression analysis was also performed between each 10kb region and 
BRAF/NRAS mutation status. The most significant association was observed 
between BRAF mutated tumours and loss of chromosome arm 10q, where the 
tumour suppressor PTEN is located. This finding has been previously identified in 
melanoma cell lines and frozen tumours (Jonsson et al., 2007, Gast et al., 2010) 
which is pleasing, suggesting validity of the data generated from small primary 
FFPE samples. 
In summary, here an agnostic simple approach was taken to explore whether copy 
number alterations were associated with tumour characteristics. This approach was 
able to validate previous findings in melanoma, such as 8q gain and 10q loss in a 
subset of tumours. While more associations where found such as between 
chromosome 1p, 6p, 17p and 20p and mitotic rate I haven’t explored if these 
regions were gained or lost. More robust methods will be explored using this small 
data set and applied to the larger dataset when available to increase power. 
4.5.9 Gene expression and copy number data integration 
It has become apparent that melanoma inter-tumour heterogeneity may be due to 
both genomic and transcriptional differences (Jonsson et al., 2007, Bastian et al., 
2003, Jonsson et al., 2010, Rakosy et al., 2007, Jewell et al., 2010). Therefore, 
integration of genomic and transcriptomic data from the same tumour sample might 
allow us to identify pathways and genetic alterations that influence the biology of 
melanoma and facilitate molecular classification of tumours. Copy number changes 
would only be expected to be strongly associated with gene expression changes in 
a proportion of genes as gene expression might also be influenced by epigenetic 
mechanisms. Recently, a study reported integration of copy number, gene 
expression and methylation data generated from 36 primary melanoma tumours 
(Rakosy et al., 2013). This study identified gene expression signatures associated 
with copy number changes in ulcerated tumours but also established inverse 
correlations between gene expression and methylation patterns for a proportion of 
genes, suggesting that transcriptional silencing of these genes is mediated through 
epigenetics (Rakosy et al., 2013).  
In the context of this work, whole-genome DASL gene expression and NGS copy 
number data were available from 47 tumours. Chromosomal locations significantly 
175 
associated with mitotic rate were identified and Spearman correlation coefficients 
were calculated between DASL probe signals and NGS read counts of regions 
where the DASL probe(s) were located (10kb or smoothed regions). Correlations 
between gene expression measures and copy number were poorer when read 
counts of individual 10kb windows were used but stronger when the smoothed 
windows of 5Mb size were used. This might reflect the reduction of noise when 
smoothed windows were used to calculate correlations. Another important source 
of this observation might be the fact that the annotation file for DASL probes 
provided by the company was erroneous. Two weeks before the submission of this 
thesis I identified that some probe coordinates were based on the human reference 
genome version hg18 while some others on the hg19. The results presented here 
therefore should be treated with caution. However, the correlations between gene 
expression measures and smoothed windows might not reflect erroneous results if 
we think that the position of most of the genes on one genome assembly (hg18) will 
possibly be with 5Mb of the corresponding position on a more recent genome 
assembly (hg19). This integrated analysis revealed 159 DASL probes whose signal 
was significantly associated with copy number and therefore were used for pathway 
analysis using MetaCore™ tool. The top three significantly overrepresented 
pathways were IL-2 signalling, cell cycle and DNA damage response pathways. 
TP53 (17p) and GAB2 (11q) were among the genes identified in these pathways. 
GAB2 amplification has been previously identified in melanomas and associated 
with metastatic potential (Horst et al., 2009) while TP53 is a known tumour 
suppressor gene known to be silenced in melanoma (Meyle and Guldberg, 2009). 
However, I have not managed to look for the direction of the association between 
the expression of these genes and mitotic rate in my data yet. More importantly, the 
data need to be re-analysed using correct probe annotations in the hg19 and after 
identification of significantly altered regions using more robust models as described 
above to draw sound conclusions. 
As an additional quality control measure, genes previously related with 
melanoma/melanoma progression were selected and correlations between gene 
expression measures and copy number were calculated. This analysis revealed 
that gene expression measures of genes previously identified to be deleted in 
melanoma (CDKN2A and PTEN) and a gene previously reported to be gained in 
melanoma (MYC) were significantly correlated with copy number. Interestingly, 
significant correlations were established for two DNA repair genes known to be 
associated with melanoma progression: RAD52 and TOP2A. RAD52 is located in 
12p region which has not been reported to be frequently altered in melanoma while 
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TOP2A is located in 17q, a region previously identified to be altered in melanoma 
(Bastian et al., 2003, Jonsson et al., 2007). Other genes failed to establish a 
significant correlation except for SPP1 whose expression was significantly inversely 
correlated with copy number. The latter observations might depict the fact that other 
mechanisms alter the expression of these genes or that the copy number data for 
10kb windows were quite noisy. Overall however the reported associations 
provided further support for the validity of the NGS data produced. 
4.5.10 Conclusion and future work 
Further work will help clarify which sample characteristics will predict performance 
with NGS assays and enable more extensive studies to assess CNAs in primary 
melanomas at the right depth. I have shown that low DNA concentrations are, not 
surprisingly, associated with lower probability of adequate library preparation and 
more PCR replicates sequenced and therefore potential data bias, but that there 
was no clear cut-off identifiable to date. I think it is likely that there is an optimal 
lower concentration which will vary according to method of library preparation (and 
therefore number of PCR cycles), and number of samples run per lane. I will 
address this in the months to come. 
I have reported evidence that the CNAs detected were in regions previously 
described in melanoma and which are biologically credible (such as chromosome 
10/ PTEN in BRAF mutated tumours) and this is evidence that my approach to 
analyzing the data is reasonable. The data reported here are addressed to 
methodology. In the future I hope to explore this further and by using more robust 
models and a larger sample set I will identify if CNAs might improve 
prognostication. Computational NGS data analysis is an active research area and 
therefore the combination of different analysis methods might be the best solution 
to accurately identify CNAs. A recent study in melanoma using aCGH reported that 
patients with bad prognosis showed more frequent small CNAs compared to 
patients with good prognosis (Hirsch et al., 2013). This suggests that a pattern of 
CNAs might prove of prognostic significance rather than a single CNA. 
NGS has successfully been used in the clinic where pilot studies have assessed 
the practical challenges of this technology to identify useful information in a 
clinically relevant time frame (Rizzo and Buck, 2012). For example, a study has 
reported the use of both whole-genome and targeted exome NGS which allowed 
the identification of mutational landscapes in tumours from patients with colorectal 
cancer and melanoma. The identification of these mutations within 24 hours of 
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biopsy enabled patients enrolment in biomarker-driven clinical trials (Roychowdhury 
et al., 2011).  
Using FFPE tissue for NGS is challenging, however these efforts enable analysis of 
large numbers of samples with mature survival data and well-annotated tumour and 
patient characteristics. Studies of this kind will undoubtedly improve our 
understanding of the biological processes associated with melanoma progression 
and allow identification of prognostic biomarkers. 
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Chapter 5  
The effect of 1α,25(OH)2D3 on the growth and gene 
expression of cultured melanoma cells 
 
5.1 Aims 
The aims of this chapter are: 
• To assess the reported anti-proliferative effect of 1α,25(OH)2D3 on 
cultured melanoma cells; 
• To assess the vitamin D receptor (VDR) status of the melanoma cell lines 
using immunocytochemistry; 
• To identify differentially expressed genes and altered pathways in 
response to 1α,25(OH)2D3 using microarray technology in cells showing 
evidence of an anti-proliferative effect when cultured with 1α,25(OH)2D3; 
• To identify if VDR target genes are overrepresented in the significantly 
expressed genes in response to vitamin D3 using an in silico approach. 
 
5.2 Background 
Vitamin D, as discussed in Chapter 1, is a fat-soluble hormone, which is very 
important to human health and has been implicated in reducing the risk of cancer 
initiation and progression (Holick, 2004). There is no doubt that vitamin D 
deficiency causes bone disease, but there are numerous reports showing that 
deficiency and insufficiency increase the risk of a multitude of health problems, 
many of which associations remain controversial. An independent association in 
the Leeds Melanoma Cohort has been reported between lower serum vitamin D 
levels at diagnosis and thicker primary melanomas and worse prognosis even 
when the data are adjusted for Breslow thickness (Newton-Bishop et al., 2009). 
Vitamin D levels at diagnosis would therefore seem to be a prognostic 
biomarker. 
The identification of an association between vitamin D levels and outcome from 
melanoma does not however establish a causal relationship between levels and 
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survival, and the group has been attempting to devise approaches to understand 
the significance of these associations. We hypothesised that if vitamin D was 
playing an active role on progression of melanoma, then we might be able to 
detect an association between gene expression in melanoma primaries stored 
from patients participating in the Leeds Melanoma Cohort and vitamin D levels in 
the patient at the time of diagnosis. A study was therefore designed to identify 
transcriptional patterns (using Illumina DASL arrays) in primary melanomas 
associated with the patients’ vitamin D levels at diagnosis, comparing tumours 
from patients with high serum vitamin D levels and tumours with low vitamin D 
levels. This project has completed data accrual but results are not as yet 
available. When these data are available, the intent is to determine if the gene 
expression patterns mirror biological pathways reported to be related to 
signalling through the vitamin D receptor (Ramagopalan et al., 2010, Heikkinen 
et al., 2011). 
Reported associations do not however prove causality and there are especial 
concerns with respect to vitamin D as levels are higher in fitter, healthier people, 
and some argue that reported associations between higher vitamin D levels and 
better outcomes might mean that the levels are merely acting as a marker of 
better lifestyles. Therefore, the aim of the work described in this chapter was to 
investigate the transcriptional changes of added 1α,25(OH)2D3 (henceforth 
referred to as vitamin D3) to a range of cultured melanoma cells. In turn, these 
observations will be compared and contrasted with the forthcoming primary 
tumour expression data when it becomes available. The cell culture work 
described here was performed in collaboration with Professor Jorg Reichrath at 
Saarland University, in Homburg, Germany. 
An anti-proliferative effect of vitamin D3 in vitro has been reported in many 
studies of different cancers reviewed by Deeb et al (Deeb et al., 2007) and in 
studies using melanoma cells reviewed in (Table 1-4). The concentrations of 
vitamin D3 used in the studies reported here (10
-10-10-7M) have previously been 
used to show a dose-dependent anti-proliferative effect and furthermore 
distinguish between vitamin D sensitive and resistant cultured melanoma cells 
(Seifert et al., 2004). These data were used to inform the experimental design of 
the work described here. 
A number of studies have previously used microarray platforms to identify gene 
expression patterns associated with the addition of vitamin D to culture media in 
different cancers but not in melanoma. A non-genomic (rapid) response through 
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Ca2+ influx and G-protein coupled receptors but also a genomic response 
through the classical VDR pathways have been reported upon vitamin D3 
stimulation in vitro and in vivo (Deeb et al., 2007). As a result, in the microarray 
experiment described in this chapter, melanoma cells were treated with vitamin 
D3 for 6, 24 and 48 hours as a means to identify both early and late 
transcriptional changes. Differentially expressed genes were identified by 
comparing the expression profiles of vitamin D3 treated, and untreated samples. 
Here, I have explored the use of bioinformatics databases to try to better 
understand the significance of these differentially expressed genes in response 
to vitamin D3. 
Gene Ontology (GO), is one such database that assigns genes to functional 
categories, and this has been reported to be useful in understanding the biology 
behind extensive lists of differentially expressed genes (Ashburner et al., 2000, 
Werner, 2008). Genes can be assigned into a category based on their location in 
the cell within ‘cellular component’ terms, based on their activity under ‘molecular 
function’ terms and based on events using one or more ‘molecular function’ 
terms from within ‘biological processes’ terms (Ashburner et al., 2000). Recent 
studies have used GO terms to understand biological functions of differentially 
expressed genes generated after statistical analysis. For example, it has been 
reported that genes involved in vitamin D metabolism, cell cycle, apoptosis, cell 
adhesion and immune response are differentially expressed in response to 
vitamin D3 (Deeb et al., 2007, Fleet et al., 2012).  
Pathway analysis has also been used to identify chains of biological events when 
microarray analysis is conducted (Werner, 2008). A number of databases, such 
as KEGG (Kyoto Encyclopaedia of Genes and Genomes) (Kanehisa et al., 
2012), have constructed pathways based on literature research and differentially 
expressed genes derived from microarray data can be mapped onto these 
databases to unravel particularly over-represented pathways (Werner, 2008). A 
recent study in breast cancer cells has shown that vitamin D3 treatment 
deregulates genes involved in the TGF-beta pathway (Milani et al., 2013). 
Another study in cultured podocytes (highly differentiated kidney cells) has 
shown that the NF-κB pathway is targeted in response to vitamin D3 treatment 
(Cheng et al., 2013).  
It is important to rank the associations found with GO terms and pathways using 
microarray data (Werner, 2008), and therefore web-based tools have been 
designed, such as MetaCore™, which uses hypergeometric distribution tests, 
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representing the probability that the reported association is due to chance (Ekins 
et al., 2007).  
Here, I report the first study designed to identify genes and pathways altered in 
response to 10-7M vitamin D3 treatment of melanoma cells using a microarray 
approach. The Affymetrix U133 plus 2 microarray platform was used as 
described in section 2.8. Generation of large-scale gene expression data was 
then processed using the MetaCore™ web-based tool to identify over-
represented biologically relevant annotations related to vitamin D3 treatment.  
 
5.3 Methodology 
The anti-proliferative and microarray work were described in detail in sections 
2.5.6 and 2.8 respectively. In summary, two different primary melanoma cell 
lines, SkMel28, MeWo and a cell line reputed to be MelJuso (which was later 
established not to be MelJuso and which is here referred to as ‘MelJuso’) were 
treated with 10-10M, 10-8 and 10-7M vitamin D3 or ethanol controls. The SkMel5 
cell line was also used but data are not presented as these cells were 
established to be SkMel28. The failure to establish the authenticity of the 
‘MelJuso’ cells was described in section 2.5.2. In an attempt to identify if this cell 
line is of melanocytic origin immunocytochemistry (ICC) was performed using 
antibodies against melanocyte markers (HMB45, Melan-A, S100, Pan Melanoma 
Cocktail). Cell proliferation was measured using the crystal violet assay after 24, 
48, 72 and 144 hours in order to confirm sensitivity to vitamin D3. I attempted to 
do this experiment initially in Leeds, but had difficulties managing delivery of the 
fat-soluble vitamin D3 in ethanol to the cells and therefore established a 
collaboration with Professor Jorg Reichrath of Saarland University, Homburg, 
Germany. Two months were spent performing the cell culture experiments within 
the laboratory in Saarland University. To identify the VDR status of the three cell 
lines reported here, VDR protein expression was measured using ICC as 
described in section 2.5.8.  
To identify differential gene expression an independent experiment was 
performed and melanoma cells were treated with the concentrations of vitamin 
D3 mentioned above or ethanol controls, and RNA was extracted after 6, 24 and 
48 hours. The RNA extracted from the cell lines whose proliferation was reduced 
in vitamin D treated cells, SkMel28 and MeWo melanoma cell lines after 
treatment with 10-7M vitamin D3 and the ethanol controls was sent for microarray 
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analysis. Microarray data generation and data pre-processing are described in 
detail in sections 2.7 and 2.7.1. 
5.3.1 Statistical analysis 
5.3.1.1 Proliferation assay 
The proliferation was measured using crystal violet staining as described in 
section 2.5.6. Each cell line was assayed 3 times, with 4 biological replicates at 
each time point. Three measurements of crystal violet cellular uptake were taken 
for each of the biological replicates. The mean of these 3 measurements for 
each biological replicate was used for statistical analysis. One way analysis of 
variance (ANOVA) test was performed using log to the base 2 transformed 
values to assess statistical significance in proliferation between treated cells with 
different concentrations of vitamin D3 compared to controls at all time points. 
Then, stratified analysis was performed using ANOVA at each time point 
independently. Finally, pairwise comparisons between treated cells and controls 
using the Mann-Whitney test were done to reassure the first analysis. A 
statistically significant difference was considered established when the 
Bonferroni-adjusted p value was <0.017 (multiple testing correction for the 3 cell 
lines analysed). Statistical analysis was done in STATA v.11 (StataCorp., 2007). 
5.3.1.2 Gene expression assay 
The analysis was performed by bioinformatician Dr Alastair Droop, using the 
LIMMA package (Smyth, 2004) available in Bioconductor (Gentleman et al., 
2004), in R (R Development Core Team, 2012). RMA-transformed probe set 
intensity values were used to identify differentially expression signatures 
between vitamin D3 treated samples at 6, 24 and 48 hours and corresponding 
controls. Briefly, LIMMA fits linear models and borrows information about the 
within group variance, calculates t and F-statistics for each probe set and 
assigns p values to identify if a probe set is statistically significantly expressed 
(Smyth, 2004). It has been shown that LIMMA outperforms other variance 
modelling strategies in the analysis of gene expression microarray data in terms 
of false-positive rate, execution time and its ability to perform well even in small 
sample sizes (Jeanmougin et al., 2010). The log fold changes (relative 
expression values) for each probe set (targeting a specific gene), reported by 
LIMMA, are the differences between the log expression value in the treated 
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sample and the control sample. Multiple testing correction was performed by 
applying false discovery rate (FDR) to the p values (Benjamini and Hochberg, 
1995). Significant difference was considered when FDR<0.1. 
For simplicity, henceforth a probe set will be referred to as a probe. As described 
in section 2.7 multiple probes target a specific gene and because the statistical 
analysis was performed at the probe level the terms ‘differentially detected 
probes’ and ‘differentially expressed genes’ are used interchangeably.  
For each cell line, LIMMA produced a list of probes whose signal was statistically 
significantly differentially detected when vitamin D3 treated cells were compared 
to controls at each time point independently. LIMMA also produced a list of 
probes whose signal was statistically significantly differentially detected between 
vitamin D3 treated cells and controls overall at all time points for each cell line 
and this list is referred to below as the “complete list”. Then, a number of 
different approaches were used using the above lists of probes to identify 
biologically interesting genes altered in response to vitamin D3. The steps are 
shown schematically in Figure 5-1. 
Firstly, unsupervised hierarchical clustering for each cell line irrespective of time 
was performed using the top 400 significant probes from the complete lists and 
heatmaps were plotted. Then, a number of analyses using various bioinformatic 
approaches were carried out as described in the following section. 
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Figure 5-1: Schematic of proliferation and gene expression experiments 
using cultured melanoma cells. 
Three melanoma cell lines were tested to identify the effect of added 
vitamin D3 on proliferation. From the 3 lines tested, 2 lines showed 
evidence of inhibition of proliferation after treatment for 144 hours and 
these lines are referred to as “vitamin D sensitive” lines. The vitamin D 
sensitive cell lines were selected for gene expression studies. RNA 
extracted from vitamin D3 treated and control cells was analysed using the 
Affymetrix U133 plus 2 whole genome array and statistical analysis was 
performed using LIMMA (Smyth, 2004) to identify differentially expressed 
genes.   
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5.3.1.3 Bioinformatics 
5.3.1.3.1 Prediction of VDR target genes 
Computational analysis was performed to predict which of the genes that were 
differentially expressed in response to vitamin D3 are direct VDR targets. VDR 
targets were defined as all genes with a VDR binding sequence known as a 
vitamin D response element (VDRE) in their promoters. The “complete lists” were 
used and the promoters of the genes were defined as 5kb upstream or 
downstream from the transcription start site. The matrix for the RXRA-VDR 
binding sequence from JASPAR database (ID:MA0074.1) was used to predict 
VDREs in the promoters of genes (Bryne et al., 2008) (Figure 5-2). The 10 
known binding sequences were used to create a position weight matrix (PWM) 
for the RXRA-VDR binding site. The defined promoters were matched against 
this PWM with a minimum score of 75% (Wasserman and Sandelin, 2004). This 
procedure was also performed for all genes (all annotated genes in the human 
reference genome version hg19) in the human genome and a one way Fisher’s 
exact test was performed to identify if VDRE enrichment was seen in the list of 
significant genes after vitamin D3 treatment. Dr Alastair Droop performed the 
bioinformatics analysis using R (R Development Core Team, 2012) and 
Bioconductor (Gentleman et al., 2004) and I performed the statistical analysis 
using Stata (StataCorp., 2011). 
 
 
Figure 5-2: RXRA-VDR heterodimer binding site from the JASPAR CORE 
database 
Visual representation of the position weight matrix (PWM). 
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5.3.1.3.2 Enrichment analysis using MetaCore™ 
MetaCore™, a commercially available web-based tool (Ekins et al., 2007), was 
used to identify biological processes and pathways that were enriched in 
response to vitamin D3. Genes that were attributed a significant FDR<0.1 by 
LIMMA at each time point for each cell line individually were considered for this 
analysis. Overrepresented GO processes and pathways were identified based 
on p values and FDRs. An FDR<0.1 was used to determine statistical 
significance. 
 
5.4 Results 
5.4.1 Proliferation assay 
The effects of vitamin D3 on the proliferation of MeWo and SkMel28 cells were in 
accordance with previously published data (Seifert et al., 2004). No difference in 
proliferation was observed when all cell lines were at low cell density (at 24, 48 
and 72 hours). MeWo and SkMel28 but not ‘MelJuso’ melanoma cells showed a 
statistically significant decrease in proliferation after 144h hours when treated 
with 10-8M and 10-7M vitamin D3 (ANOVA stratified analysis at 144 hours, 
Bonferroni-adjusted p<0.001). Figure 5-3 shows the absorbance of the crystal 
violet dye at 550nm which is relative to the number of cells per treatment group 
at each time point for all three cell lines. Henceforth, MeWo and SkMel28 cells 
will be referred to as vitamin D sensitive and ‘MelJuso’ cells as vitamin D 
resistant. Figure 5-4 shows images of vitamin D sensitive SkMel28 and vitamin D 
resistant ‘MelJuso’ cells after vitamin D3 treatment or vehicle treatment after 144 
hours. 
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Figure 5-3: Crystal violet dye uptake by vitamin D3 treated and vehicle-
treated cells after 24, 48, 72 and 144 hours for a) MeWo, b) SkMel28 
and c) "MelJuso" cell lines.  
(Figure description on the next page) 
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(Figure 5-3 description): Each column represents the mean ± standard 
deviation of 12 biological replicates from 3 independent experiments. 
Statistical significance was established when the Bonferroni-adjusted p 
value was <0.017 (multiple testing correction for the 3 cell lines analysed). 
The p values reported in the figures represent the Bonferroni-adjusted p 
values. The highlighted p values on the left corner were reported from the 
ANOVA analysis and represent the overall effect of vitamin D3 treated cells 
compared to controls irrespective of time. The stratified ANOVA analysis 
performed at each time point showed a statistically significant difference at 
144 h for MeWo and SkMel28 cells (p<0.001) but not for ‘MelJuso’ 
(p=0.02). The asterisk refers to the statistically significant difference 
between treated and control values when pairwise comparisons were 
performed using the Mann-Whitney test to re-assure the first analysis. 
 
 
  
Figure 5-4: SkMel28 and 'MelJuso' cells after 144 hours of vitamin D3 and vehicle-control treatment. 
Inhibition of cell proliferation observed at the end of the proliferation experiment for SkMel28 cells treated with 10-10M, 10-8M and 10-7M 
vitamin D3 compared to controls. On the contrary, no inhibition of cell proliferation was observed for ‘MelJuso’ cells treated with vitamin D3 
compared to controls (10x magnification). 
1
8
9
 
190 
5.4.2 Immunocytochemistry using melanocyte markers 
As described in section 2.5.2, ‘MelJuso’ cells could not be authenticated. Protein 
expression was demonstrated by ICC using antibodies raised against well-
described melanocyte markers: HMB45, Melan-A and S100. Also a Pan Melanoma 
Cocktail was used consisting of antibodies against HMB45, Melan-A and 
Tyrosinase. Non-specific binding was observed in negative controls but only in 
those cells that were rounded up or demonstrating reduced cell adherence. The 
“MelJuso” cells did show expression of the melanocyte markers tested compared to 
negative controls suggesting that these cells are of melanocytic origin (see Figure 
5-5). 
 
 
  
Figure 5-5: Melanocyte markers immunocytochemistry in ‘MelJuso’ cells. 
 The ‘MelJuso’ cells showed expression of the melanocyte markers tested compared to negative controls suggesting that these cells are of 
melanocytic origin (40x magnification). The numbers in brackets represent the staining intensity where 0 represents no staining and 3 strong 
staining. 
1
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5.4.3 VDR immunocytochemistry 
Protein expression was demonstrated by ICC using an antibody raised against 
VDR which has been used previously in the immunohistochemistry of melanoma 
tumours (Brozyna et al., 2011). A titration experiment was initially performed to 
identify the optimal dilution of the primary antibody. Figure 5-6 shows the VDR 
staining of SkMel28 cells using 3 dilutions of the primary antibody (1:2000, 1:1000, 
1:500) and the negative control. The 1:500 dilution was selected as the most 
appropriate and it was used to stain all 3 melanoma cell lines used in the 
proliferation assay. Non-specific staining was observed in all three cell lines in 
negative controls but only in those cells that were rounded up or demonstrating 
reduced cell adherence. VDR was shown to be expressed in all three cell lines 
irrespective of their sensitivity to vitamin D3 (Figure 5-7) although the MeWo cells 
appeared to show less VDR expression than SkMel28 and ‘MelJuso’ cells. 
 
  
Figure 5-6: Titration of anti VDR antibody in SkMel28 cells.  
Representative images of antibody dilutions of 1:2000, 1:1000 and 1:500 compared to negative control (40x magnification). The 1:500 
dilution was selected as the optimal concentration to stain all 3 cell lines. The numbers in brackets represent the staining intensity where 0 
represents no staining and 3 strong staining. 
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Figure 5-7: VDR immunocytochemistry using 1:500 dilution of anti-VDR antibody for MeWo, SkMel28 and “MelJuso” cells. 
All cell lines showed VDR expression compared with their controls irrespective of their sensitivity to vitamin D3 (40x magnification).  The 
numbers in brackets represent the staining intensity where 0 represents no staining and 3 strong staining. 
1
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5.4.4 Identification of differentially expressed genes in 
response to vitamin D3 
SkMel28 and MeWo cell lines were treated with vitamin D3 (10
-7M) or vehicle and 
harvested at 6, 24 and 48 hours. RNA was extracted and assayed to identify 
genes differentially expressed. One sample (a 6-hour vehicle-treated MeWo 
replicate) was degraded (RIN<7) and was not run on the array. Quality control 
measures during data pre-processing as described in section 2.7.1 showed that 
the assay was successful. Only one sample failed to pass the quality control 
analysis and was therefore excluded. Three lists of significantly detected probes 
were obtained: one for each time point, and a complete list irrespective of time 
as described in 5.3.1.2 (the full lists are shown in Appendix A.4.1). Unsupervised 
clustering was performed using the top 400 significantly detected probes from 
the complete lists for each cell line individually and heatmaps were plotted 
(Figure 5-8). 
The heatmaps show that replicates at each time point clustered together 
highlighting the reproducibility of the data. In addition, the control and treated 
samples cluster independently of one another demonstrating quite different 
profiles. The marked exception is the treated samples harvested at 6 hours 
which demonstrate gene expression profiles that are more closely related to the 
control groups.  
 
 
  
Figure 5-8: Heatmaps of the top 400 significant probes from the complete lists for SkMel28 and MeWo cell lines. 
(Figure description on the following page) 
1
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(Figure 5-8 description): The signal for each probe is represented by 
coloured panels with lighter (yellow) colours representing very low signal 
and darker (red) colours representing high signal. The heatmaps were 
plotted after unsupervised hierarchical clustering was performed 
irrespective of time for each cell line independently. In each cell line two 
large clusters were evident representing the vitamin D3 treated and the 
control group. In contrast, in both cell lines the 6-hours treated samples 
cluster with the control group. All replicates at each time point cluster 
together, highlighting the reproducibility of the data. 
 
 
At 6 hours, 129 probes were significantly differentially detected in SkMel28 cells 
and only 19 probes in Mewo cells (Figure 5-9). Analysis of the probes revealed 
that the gene CYP24A1 encoding for the vitamin D3 degradation enzyme was the 
top overexpressed gene in both cell lines at 6 hours and remained 
overexpressed at later time points too. The number of probes that were 
differentially detected at more than 1 time point in SkMel28 and MeWo cells 
independently are shown in Figure 5-9. Eight common probes were significantly 
detected in both cell lines after 6 hours, 298 at 24 hours and 544 at 48 hours 
(Figure 5-10). 
The top 10 probes differentially detected at each time point were identified and 
the genes that these probes target, the fold changes and the ranking at all time 
points are listed in Table 5-1 and Table 5-2 for SkMel28 and MeWo cells 
respectively. All probes in these tables relate to genes that demonstrated 
upregulation rather than downregulation after vitamin D3 treatment. CYP24A1, 
PRSS3, CLMN and PTGES are common genes upregulated in both cell lines at 
least at 1 time point. 
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Figure 5-9: Probes differentially detected after vitamin D3 treatment 
between time points for each cell line. 
 
 
Figure 5-10: Overlapping probes differentially detected after vitamin D3 
treatment between MeWo and SkMel28 cells.   
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Table 5-1: The top 10 significant probes at each time point (targeting 17 
genes) in SkMel28 treated cells compared to controls and their fold 
changes (FC) at all time points.  
The number in superscript indicates the ranking at each time point. When a 
predicted VDRE is located in the gene promoter it is indicated in the 
corresponding column. 
SkMel28 
Gene FC at 6h FC at 24h FC at 48h VDRE 
CYP24A1 55.4 
1
 34.6 
2
  80.4 
1
 ✓ 
LOC100127888 4.4 
2
 4.3 
12
 2.5 
127
 ✓ 
KIAA0226L 4.0 
3
 3.1 
85
 3.6 
71
 ✓ 
PRSS33 16.3 
4
 59.9 
6
 51.0 
10
 ✓ 
TRPM1 4.0 
5
 4.53 
35
 3.1 
141
 ✓ 
PI15 2.7 
6
 2.9 
33
 2.4 
116
 ✓ 
SLCO4A1 3.8 
7
 3.3 
73
 - ✓ 
CLMN 2.4 
8
 3.0 
20
 2.6 
59
 ✓ 
HEXIM1 2.7 
9
 1.8 
348
 - ✓ 
TPST1 2.9 
10
 2.6 
112
 2.8 
104
 ✓ 
ATP6V0D2 - 6.1 
1
 6.8 
2
 ✓ 
PTGES 3.8 
11
 15.9 
3
 11.0 
7
 ✓ 
SULT1C2 4.5 
13
 22.7 
4
 43.3 
3
 ✓ 
ATP6V0D2 - 6.9 
5
 6.4 
8
 ✓ 
ADORA3 4.4 
16
 13.7 
7
 18.9 
6
 ✓ 
MB - 18.8 
8
 16.9 
11
 ✓ 
C9orf135 - 7.9 
9
 6.3 
20
 ✓ 
SULT1C2 - 29.6 
10
 57.4 
5
 ✓ 
MFSD6 - 4.1 
11
 6.4 
4
 ✓ 
PRSS33 - 50.5 
14
 82.0 
9
 ✓ 
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Table 5-2: The top 10 significant probes at 6, 24 and 48 hours (targeting 16 
genes) in MeWo treated cells compared to controls and their fold 
changes (FC) at all time points. 
The number in superscript indicates the ranking at each time point. When a 
predicted VDRE is located in the gene promoter it is indicated in the 
corresponding column. 
MeWo 
Gene FC at 6 h FC at 24h FC at 48h VDRE 
CYP24A1 16.7 
1
 34.6 
6
 25.0 
19
 ✓ 
EFTUD1 1.8 
2
 2.7 
10
 2.6 
15
  
DUSP10 1.7 
3
 1.4 
338
 1.4 
478
 ✓ 
DUSP10 1.8 
4
 - 1.3 
1316
 ✓ 
HEXIM1 2.3 
5
 2.1 
140
 1.5 
1252
 ✓ 
MITF 1.8 
6
 1.5 
411
 1.4 
1225
 ✓ 
HEXIM1 1.8 
7
 1.8 
130
 1.8 
202
 ✓ 
NT5DC3 1.6 
8
 2.7 
12
 2.8 
8
 ✓ 
CLMN 2.1 
9
 4.6 
9
 4.4 
14
 ✓ 
MITF 1.8 
10
 - 1.4 
1142
 ✓ 
STARD5 1.7 
14
 4.5 
1
 4.0 
6
  
PRSS33 - 10.9 
2
 43.0 
2
 ✓ 
PRSS33 - 7.6 
3
 30.8 
1
 ✓ 
CLMN - 3.9 
4
 3.2 
17
 ✓ 
PTGES - 7.6 
5
 22.4 
3
 ✓ 
MICAL3 - 3.5 
7
 3.4 
9
 ✓ 
KLK6 - 2.9 
8
 2.4 
28
 ✓ 
ST6GALNAC1 - 4.8 
17
 8.1 
4
 ✓ 
SLC5A4 - 6.0 
21
 12.8 
5
 ✓ 
SPP1 - 2.0 
203
 5.6 
7
 ✓ 
TMEM164 - 2.4 
20
 3.0 
10
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5.4.5 Prediction of VDR target genes 
Computational analysis revealed that of the genes differentially expressed in 
SkMel28 cells as a response to vitamin D3 treatment, 83.3% related to genes 
predicted to be direct VDR targets (930/1116 genes).  Similarly, 83.5% of genes 
differentially expressed in MeWo cells were associated with VDR target genes 
(860/1030 genes). These data can be compared with an incidence of 77.5% of 
all annotated genes in the hg19 which were predicted to be direct VDR targets. 
This represents a statistically significant enrichment of VDR target genes in our 
data (Fisher’s exact p<0.001 for both lines). All regions with predicted VDREs 
are listed in Appendix A.4.2. 
5.4.6 Enrichment analysis using Metacore™ 
Enrichment analysis was performed using the list of significantly expressed 
genes at each time point to identify overrepresented GO processes and 
pathways. The top 5 overrepresented GO processes in response to vitamin D3 
for SkMel28 and MeWo cells are listed in Table 5-3 and Table 5-4 respectively. 
For SkMel28 cells, overrepresented biological processes such as cell adhesion 
and differentiation were among the top 5 at earlier time points, while processes 
involved in immune response such as IFN-γ, IL-4 and IL-10 regulation were 
among the top 5 at 48 hours. For MeWo cells, overrepresented biological 
processes such as cell proliferation, migration and regulation of transcription 
were among the top 5 at all time points. No distinguishable difference was 
observed in overrepresented GO processes between the 3 time points for MeWo 
cells. GO processes related to immune response were enriched in SkMel28 but 
not in MeWo cells when the top 5 overrepresented processes were compared. 
However, GO processes related to immune response such as IL-2, IL-3 
regulation were also enriched in MeWo cells but were less significant (data not 
shown). 
 
 
 Table 5-3: The top 5 overrepresented GO processes in SkMel28 cells after 6, 24 and 48 hours of treatment with vitamin D3 identified 
using MetaCore™. 
 SkMel28-6 hours FDR Number of genes 
1 Muscle cell fate determination 3.07x10-5 3/3 
2 Positive regulation of mucus secretion 5.32x10-4 3/7 
3 Negative regulation of ossification 8.11x10-4 4/49 
4 Regulation of norepinephrine secretion 8.11x10-4 3/30 
5 Histamine secretion by mast cell 8.11x10-4 3/11 
 SkMel28-24 hours FDR Number of genes 
1 Cell adhesion 2.30x10-11 77/981 
2 Homophilic cell adhesion 4.79x10-08 29/174 
3 Osteoblast differentiation 6.80x10-05 16/110 
4 Neutrophil homeostasis 6.80x10-05 6/11 
5 Negative regulation of fibroblast growth factor receptor signalling pathway 1.80x10-04 7/15 
 SkMel28-48 hours FDR Number of genes 
1 Antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 3.84x10-12 17/137 
2 Interferon-gamma-mediated signalling pathway 2.49x10-08 25/94 
3 Regulation of interleukin-4 production 6.10x10-08 8/42 
4 Regulation of interleukin-10 secretion 6.10x10-08 8/14 
5 Nervous system development 1.48x10-07 71/2500 
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 Table 5-4: The top 5 overrepresented GO processes in MeWo cells after 6, 24 and 48 hours of treatment with vitamin D3 identified using 
MetaCore™. 
 MeWo-6 hours FDR Number of genes 
1 Regulation of interleukin-6 biosynthetic process 1.91x10
-4 
2/19 
2 Mammary gland epithelial cell differentiation 0.002 2/22 
3 Mammary gland epithelial cell proliferation 0.002 2/28 
4 Embryonic placenta development 0.005 2/126 
5 Response to endoplasmic reticulum stress 0.005 2/152 
 MeWo-24 hours FDR Number of genes 
1 Negative regulation of transcription from RNA polymerase II promoter 1.95x10
-09
 53/762 
2 Positive regulation of transcription, DNA-dependent 3.49x10
-08
 50/1381 
3 Positive regulation of cell migration 1.97x10
-07
 23/362 
4 Negative regulation of ossification 7.09x10
-07
 10/49 
5 Intracellular protein kinase cascade 7.09x10
-07
 18/521 
 MeWo-48 hours FDR Number of genes 
1 Outflow tract morphogenesis 7.24x10
-11
 25/70 
2 Regulation of cell proliferation 2.98x10
-09
 46/1731 
3 Negative regulation of cell proliferation 3.49x10
-09
 84/792 
4 Nervous system development 3.90x10
-09
 87/2500 
5 Positive regulation of transcription, DNA-dependent 3.90x10
-09
 102/1381 
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The top 10 pathways that were overrepresented in response to vitamin D3 for 
SkMel28 and MeWo cells are listed in Table 5-5 and Table 5-6 respectively. No 
pathways were overrepresented for the 6-hour time point for MeWo and SkMel28 
cells using a threshold of FDR<0.1. Wnt and TGF-beta signalling pathways were 
enriched when both melanoma cell lines were treated with vitamin D3. Interestingly, 
a VDR-related pathway was overrepresented at both time points in MeWo cells 
only. No overrepresentation of VDR signalling was observed in SkMel28 cells when 
the list of all enriched pathways was checked. The PGE2 signalling pathway was 
among the top 10 overrepresented at both time points in SkMel28. In MeWo cells it 
was overrepresented but less significantly (ranked 24th at 24 hours and 35th at 48 
hours, data not shown). The NOTCH signalling pathway was overrepresented at 
both time points in MeWo cells but not overrepresented in SkMel28 cells at all. 
 
 
 Table 5-5: The top 10 overrepresented pathways in SkMel28 cells after 24 and 48 hours of treatment with vitamin D3 identified using 
MetaCore™. 
 SkMel28-24 hours FDR Number of genes 
1 Development_WNT signalling pathway. Part 2 8.97x10
-4
 10/53 
2 Cell adhesion_Ephrin signalling 0.008 8/45 
3 Cell adhesion_Chemokines and adhesion 0.018 11/100 
4 Signal transduction_Calcium signalling 0.030 7/45 
5 G-protein signalling_Regulation of RAC1 activity 0.047 6/36 
6 Cell adhesion_ECM remodelling 0.050 7/52 
7 G-protein signalling_Regulation of p38 and JNK signalling mediated by G-proteins 0.050 6/39 
8 PGE2 pathways in cancer 0.050 7/55 
9 G-protein signalling_RhoB regulation pathway 0.050 4/16 
10 Cytoskeleton remodelling_TGF, WNT and cytoskeletal remodelling 0.057 10/111 
 SkMel28-48 hours FDR Number of genes 
1 Cell adhesion_ECM remodelling 7.21x10
-4 
11/52 
2 Development_TGF-beta-dependent induction of EMT via SMADs 7.21x10
-4
 9/35 
3 Cardiac Hypertrophy_NF-AT signalling in Cardiac Hypertrophy 7.21x10
-4
 12/65 
4 Cell adhesion_Chemokines and adhesion 7.21x10
-4
 15/100 
5 PGE2 pathways in cancer 7.21x10
-4
 11/55 
6 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 0.002 11/64 
7 Development_WNT signaling pathway. Part 2 0.002 10/53 
8 DNA damage_ATM / ATR regulation of G2 / M checkpoint 0.003 7/26 
9 Cell adhesion_Ephrin signalling 0.003 9/45 
10 Immune response_Antigen presentation by MHC class II 0.003 5/12 
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 Table 5-6: The top 10 overrepresented pathways in MeWo cells after 24 and 48 hours of treatment with vitamin D3 identified using 
MetaCore™. 
 MeWo-24 hours FDR Number of genes 
1 Development_TGF-beta-dependent induction of EMT via SMADs 0.001 7/35 
2 Development_Notch Signalling Pathway 0.003 7/43 
3 Transcription_CREB pathway 0.003 7/47 
4 Development_PIP3 signalling in cardiac myocytes 0.003 7/47 
5 Development_TGF-beta receptor signalling 0.003 7/50 
6 Cytoskeleton remodelling_TGF, WNT and cytoskeletal remodelling 0.003 10/111 
7 Transcription_Role of VDR in regulation of genes involved in osteoporosis 0.009 7/61 
8 Development_Thromboxane A2 pathway signalling 0.016 6/49 
9 Cytoskeleton remodelling_Cytoskeleton remodelling 0.030 8/102 
10 Regulation of lipid metabolism_Regulation of lipid metabolism via LXR, NF-Y and SREBP 0.030 5/38 
 MeWo-48 hours FDR Number of genes 
1 Signal transduction_PKA signalling 3.59x10
-5 
14/51 
2 Development_WNT signalling pathway. Part 2 3.59x10
-5
 14/53 
3 Development_PIP3 signalling in cardiac myocytes 3.59x10
-5
 13/47 
4 Development_Regulation of epithelial-to-mesenchymal transition (EMT) 3.59x10
-5
 15/64 
5 Development_TGF-beta-dependent induction of EMT via SMADs 4.96x10
-5 
11/35 
6 Development_TGF-beta-dependent induction of EMT via MAPK 0.001 11/47 
7 Regulation of CFTR activity (norm and CF) 0.001 12/58 
8 Transcription_Role of VDR in regulation of genes involved in osteoporosis 0.002 12/61 
9 Development_Notch Signalling Pathway 0.002 10/43 
10 Development_Hedgehog and PTH signalling pathways in bone and cartilage development 0.002 9/36 
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5.5 Discussion 
Despite many clinical trials that have been conducted to test the effect of various 
adjuvant treatments for melanoma the only FDA-approved adjuvant regimen for 
patients with melanoma is interferon alpha IFN-α (Davar et al., 2012). This is 
used in the US and in Europe but not in the UK as the toxicity is thought to 
outweigh the small survival difference reported in meta-analyses (Mocellin et al., 
2010). More recently the reports of survival benefit from targeted therapies in 
stage IV patients (anti-CTLA-4 and BRAFi) give hope that these regimens might 
also be useful in the adjuvant setting (Davar et al., 2012, Eggermont and Robert, 
2011). As discussed in section 1.12.2, vitamin D has been studied as an anti-
cancer agent both in vitro and in vivo, showing inhibition of proliferation and 
apoptosis in various cancer models (Deeb et al., 2007). In patients with 
melanoma, there are ongoing clinical trials which aim to study the effect of 
vitamin D as an adjuvant treatment alone or in combination with other regimens 
(U.S. National Institutes of Health, 2013). Promising results have been reported 
in phase II and a single phase III clinical trial that vitamin D might be useful as 
anti-cancer treatment for patients with prostate cancer (Deeb et al., 2007). It is 
therefore noteworthy that the Leeds group has reported an observational study in 
the Leeds Melanoma Cohort in which higher serum vitamin D levels at diagnosis 
were associated with lower Breslow thickness and better prognosis even when 
adjusted for thickness (Newton-Bishop et al., 2009). Observational studies are 
useful, but must be viewed with caution: associations do not necessarily prove 
causality. This is especially a concern for measurements of serum vitamin D, as 
levels are known to be higher in leaner, fitter people. The observations of 
Newton-Bishop et al might simply reflect vitamin D levels acting as a marker of 
healthier lifestyles. Furthermore, the optimal serum levels of vitamin D for cancer 
patients are unknown; the Leeds group has continued to explore the relationship 
between vitamin D levels in the blood and melanoma. Despite a wealth of data 
referring to the potential of vitamin D as an anti-cancer agent very few studies 
have explored the transcriptional changes in melanoma in response to vitamin D3 
(as reviewed in section 1.12.3) with a view to understanding the underlying 
biology. 
A two-fold study was therefore designed: firstly to identify transcriptional patterns 
associated with a cellular response to vitamin D3 in melanoma cell lines in vitro; 
and then secondly investigating to what extent such transcriptional profiles were 
reflected in primary melanomas from patients presenting with high serum vitamin 
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D levels and those patients who presented with low vitamin D serum levels. At 
this point the in vivo primary tumour results are not yet available but our intent 
ultimately is to determine if the gene expression patterns mirror those noted in 
the in vitro cell line model and to what degree these represent biological 
pathways reported to be related to signalling through the vitamin D receptor 
(Ramagopalan et al., 2010, Heikkinen et al., 2011). Here I discuss the data 
derived from the in vitro models.  
5.5.1 Anti-proliferative effect of vitamin D3 
The anti-proliferative effect of vitamin D3 has been well studied using various in 
vitro and in vivo cancer models (Deeb et al., 2007) including (as described in 
section 1.12.3) melanoma cell lines. Two previously identified vitamin D sensitive 
(MeWo, SkMel28) and two vitamin D resistant (MelJuso, SkMel5) melanoma cell 
lines were originally selected and tested to confirm their sensitivity to vitamin D 
using a proliferation assay. These initial experiments in the Leeds laboratory 
were unsuccessful: in particular, no effect was observed after addition of vitamin 
D3 to the cells in the previously reported vitamin D sensitive cells using WST-1 or 
3H-thymidine proliferation assays (data not shown). I postulated that the addition 
of a fat soluble hormone (vitamin D) in ethanol (which was unstable) required 
optimisation. As a result, a collaboration with Professor Reichrath of Saarland 
University, in Homburg was established as he has worked extensively with in 
vitro melanoma models in response to added vitamin D3 (Seifert et al., 2004, 
Reichrath et al., 2007). Consequently, I spent two months under his supervision 
in Homburg successfully performing the cell culture experiments. A significant 
divergence from my previous protocol was the stipulation that 1% BSA was 
added to the vitamin D3 treated cell culture: this appears to reduce vitamin D3 
adherence to the plastic wells but also aids the cellular uptake of vitamin D3. 
The proliferation assays were purely performed to confirm the sensitivity of the 
melanoma cells to vitamin D3 prior to the gene expression experiments. 
Therefore, these experiments were designed and executed based on the 
standard proliferation assay utilised by the Reichrath laboratory without further 
optimisation. These assays are designed to incorporate at least 7 days of growth 
and so require initial seeding densities that are very low. As a result, growth 
curves showed that the cells were still within a lag phase during the first days of 
the experiments. After 144 hours (7 days) the cells were sufficiently confluent to 
undergo exponential growth at which point a difference in proliferation could be 
readily observed both statistically and visually when vitamin D3 treated MeWo 
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and SkMel28 cells were compared to controls confirming previously published 
data (Seifert et al., 2004). Significantly, no reduction was observed in the growth 
rate of vitamin D3 treated ‘MelJuso’ cells when compared to controls with a slight 
stimulatory effect apparent, although this failed to prove statistically significant 
(see Figure 5-3 and Figure 5-4). The data on the SkMel5 cell line are not 
presented as they were reported to be SkMel28 after cell line authentication and 
it is this issue I discuss next. 
5.5.2 Cell line authentication 
Much emphasis has been placed upon the importance of cell line authentication 
to be implemented as a routine practise in experimental work in recent years, 
especially in the case of cell lines derived from other than the original source 
(American Type Culture Collection Standards Development Organization 
Workgroup, 2010). Therefore, DNA was extracted from the four original 
melanoma cell lines assayed in Homburg and once back in Leeds cell line 
authentication was performed. The MeWo and SkMel28 cell lines were correctly 
authenticated. Alarmingly, one cell line assayed in Homburg and referred to as 
the vitamin D3 resistant cell line SkMel5 (as reported by Seifert et al., 2004), was 
actually shown to be the sensitive SkMel28 after cell line authentication, thereby 
explaining the growth retardation effect observed after treatment (data not 
shown). Even more worrying was the discovery that the cell line reputed to be 
MelJuso could not be authenticated, as the DNA profile did not match any known 
cell lines and therefore they had to be considered of unknown origin. On request, 
immunocytochemistry was performed in Homburg to demonstrate the expression 
of melanocytic markers in the ‘MelJuso’ cells as a further means of 
demonstrating their authenticity. The melanocytic markers tested are routinely 
used in the clinic to identify the presence of metastasised melanoma cells in the 
excised lymph nodes (Marsden et al., 2010); being robust and highly specific 
they do not therefore require negative controls. The ‘MelJuso’ cells expressed all 
the melanocytic markers tested and therefore were considered of melanocytic 
origin. 
5.5.3 VDR expression using ICC 
The classical pathway via which vitamin D3 is reported to act is through binding 
to the VDR-RXR complex and regulation of transcription though binding to target 
genes which contain VDREs in their promoters (Deeb et al., 2007). This is in 
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contrast to the non-canonical pathway via which vitamin D3 is speculated to act 
through a membrane VDR or cytosolic VDR which promotes Ca2+ influx and 
further activation of the protein kinase C (PKC) pathway. In addition, vitamin D3 
is also speculated to act through binding to G-protein coupled receptors (Deeb et 
al., 2007) which in turn activate phospholipase C gamma (PLCγ), Ras, PI3K and 
protein kinase A (PKA) pathways to induce MAPK signalling which itself might 
introduce cross-talk with the classical VDR pathway to promote transcriptional 
changes (Deeb et al., 2007).  
In melanoma, it has been reported that VDR expression is lost in advanced 
stage tumours (Brozyna et al., 2011). However, it is unknown whether lower 
VDR expression in advanced stage tumours is due to low serum vitamin D levels 
or a defective VDR. Furthermore it has been reported though, that the anti-
proliferative effect of vitamin D is still active even when VDR is knocked out in 
vitamin D sensitive breast cancer cells (Costa et al., 2009), which suggests that 
vitamin D3 might be able to act differently in tumours with low or no VDR 
expression via a non-canonical pathway. Both MeWo and SkMel28 cells clearly 
expressed VDR, but intriguingly, so too did ‘MelJuso’. This suggests a further 
level of complexity in which, despite the presence of VDR within a melanoma 
cell, vitamin D3 fails to induce a growth inhibitory effect. This is not surprising as 
tumour cells may well have molecular changes downstream of the VDR. A high 
percentage of SkMel28 and ‘MelJuso’ cells grown on the slides for ICC were 
rounded up or demonstrated reduced cell adherence and therefore I believe that 
this experiment should be repeated to draw firm conclusions. 
5.5.4 Gene expression work 
Previous studies have explored the transcriptional changes in melanoma cells in 
response to vitamin D3 using either a candidate gene approach or studying a 
specific mechanism elicited by vitamin D3 and these were reviewed in section 
1.12.3.  
Whole-genome microarray studies of various cancer cells have been conducted 
and genes involved in cell proliferation, apoptosis, angiogenesis and immune 
response were reported to be differentially expressed in vitamin D3 treated cells 
compared to controls (Deeb et al., 2007, Fleet et al., 2012). 
Here, I report for the first time a microarray approach to identify transcriptional 
changes specifically in vitamin D sensitive melanoma cells (SkMel28, MeWo) 
treated with vitamin D3. Three different time points (6, 24 and 48 hours) were 
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selected to identify both early and late changes in response to the hormone. The 
data reported here demonstrate clear transcriptional changes between treated 
and control cells (Figure 5-8). A progressive response to vitamin D3 was noted 
with an increase in transcriptional changes observed through time in both cell 
lines. Predictably, some genes underwent transcriptional upregulation in both cell 
lines, but significant differences were also observed, potentially reflecting varying 
tumour biology (as might be expected in tumour cell lines). CYP24A1 
(Cytochrome P450, member 24A1) encoding for the vitamin D3 degradation 
protein was the top upregulated gene at 6 hours in both cell lines and an 
increase of its expression was observed after 24 hours in treated MeWo cells 
and after 48 hours in treated SkMel28 cells. It was observed that VDR was 
overexpressed at later time points (at 48 hours in SkMel28 and both at 24 and 48 
hours in MeWo treated cells). I would suggest that the upregulation of these 
genes provides evidence to support the view that the vitamin D3 treatment 
experiment had induced specific transcriptional changes in the tumour cells. 
Particularly, CYP24A1 has been reported to be the most significantly 
upregulated gene in response to vitamin D3 treatment in most microarray studies 
using various cancer cell lines as reviewed by Kriebitzsch et al (Kriebitzsch et al., 
2009). 
Examination of the top most differentially expressed genes (presented in Table 
5-1 and Table 5-2) revealed four genes (in addition to CYP24A1) that were 
commonly upregulated in both cell lines at least at one time point. These were 
PRSS3 (Protease serine 3), CLMN (Calmin), HEXIM1 (Hexamethylene bis-
acetamide inducible 1) and PTGES (Prostaglandin E synthase). PRSS3 is a 
serine protease currently with no published direct link to vitamin D3. However, 
vitamin D3 treatment revealed a large induction of this gene at all time points 
(FC>40 at 48hours in both lines) and its function is therefore discussed. The 
induction of several proteases has been linked to tumour progression and 
metastasis until recently, where studies revealed that proteases also have 
tumour suppressive effects (Lopez-Otin and Matrisian, 2007). For example, a 
protease known as seprase was found to suppress melanoma tumourigenicity 
through regulation of cell proliferation and survival (Ramirez-Montagut et al., 
2004). PRSS3 has been reported to be silenced in oesophageal and gastric 
cancer (Lopez-Otin and Matrisian, 2007), which suggests a putative tumour 
suppressive role of PRSS3 induced by vitamin D3.  
CLMN, a retinoic acid-regulated gene, has been previously identified as 
upregulated in response to added vitamin D3 in breast cancer cultures (Milani et 
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al., 2013). It was recently reported that CLMN ectopic overexpression in murine 
neuroblastoma cells plays a role in G1/S cell cycle exit which supports its 
involvement in the anti-proliferative effect of vitamin D3 (Marzinke and Clagett-
Dame, 2012).  
HEXIM1, is mostly known for its role in inhibition of RNA polymerase II through 
the positive transcription elongation factor b (p-TEFb) but it has also been 
implicated to play a role in inhibition of metastasis though effects on cell invasion 
and angiogenesis (Ketchart et al., 2013) and promotion of apoptosis through 
positive regulation of p53 (Lew et al., 2012). As a result HEMIX1 might be 
involved in the pro-apoptotic and anti-angiogenic effects of vitamin D3. 
Finally, PTGES is involved in the synthesis of prostaglandin E2. It has been 
reported that vitamin D3 inhibits the prostaglandin signalling pathway through 
downregulation of prostaglandin E2 which is in accordance with the anti-cancer 
effects of vitamin D3 as prostaglandin signalling stimulates cancer cell growth and 
progression (Fleet et al., 2012). In our data, PTGES was overexpressed in 
response to vitamin D3, which might be explained by the reported involvement of 
PTGES in the promotion of apoptosis after induction of its expression by p53 
(Faour et al., 2006). 
Within the top ten differentially expressed genes in SkMel28, TRPM1 (Transient 
receptor potential cation channel subfamily member 1) and ADORA3 (Adenosine 
A3 receptor) were observed at all 3 time points. Both genes were also 
upregulated in MeWo cells after 24 and 48 hours of treatment but they were not 
ranked within the top 10. TRPM1, otherwise called Melastatin is reported to be 
associated with numerous cellular and homeostatic functions but it has also been 
reported as a marker in melanoma (Guo et al., 2012) in which its expression 
correlates well with melanocytic terminal differentiation. Significantly, loss of 
TRMP1 expression is a poor prognostic marker and is associated with metastatic 
potential. TRPM1 generates two transcripts: exonic TRPM1 codes for the protein 
whilst intron 6 codes for mir-211 which has been linked to tumour suppression 
(Guo et al., 2012). It is intriguing to speculate that the observed correlation 
between increased tumour thickness and low serum vitamin D3 at presentation 
(Newton-Bishop et al., 2009), may reflect a direct tumour response in which 
vitamin D3 inducible genes such as TRPM1 are responsible for increased 
proliferation. ADORA3 is a G-coupled transmembrane protein and when 
activated induces intracellular signalling. It has been reported that its stimulation 
through agonists in cancer cells suppresses cell proliferation (Stagg and Smyth, 
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2010). In melanoma, it has been reported that treatment of the melanoma cell 
line B16-F10 with an ADORA3 agonist resulted in b-catenin ubiquitination 
causing downregulation of c-Myc and cyclin D1 transcription and thereby 
suppressing tumour growth (Fishman et al., 2002).  
MITF (micropthalmia transcription factor), the master regulator of the melanocytic 
lineage, was upregulated after exposure to vitamin D3, although only in MeWo 
cells. MITF has various roles including cell cycle regulation, differentiation and 
apoptosis (Levy et al., 2006). It has been reported that MITF overexpression in 
melanoma promotes its anti-proliferative effects and that its expression is 
suppressed by BRAF mutation to overcome its growth-inhibitory effects 
(Wellbrock and Marais, 2005). It is noteworthy that MeWo cells are BRAF wild 
type and SkMel28 are BRAF mutant. It seems feasible that MITF is not 
overexpressed in the BRAF mutant SkMel28 cells because its expression is 
controlled through oncogenic MAPK signalling. 
5.5.4.1 Prediction of VDR target genes using an in silico approach 
A computational approach was followed to identify how many genes significantly 
expressed in response to vitamin D3 were direct VDR targets. A statistically 
significant enrichment of VDR target genes was observed in our data compared 
to the predicted VDR targets in all genes annotated in human reference genome 
version hg19. This approach was limited to predict genes the promoters of which 
contained the classical DR3-type VDREs using the JASPAR consensus 
sequences of the VDR-RXR complex as described in section 5.3.1.3.1. Recent 
ChIP-sequencing data in human monocytes have identified a clear shift of VDR 
binding from non-DR3-type sites to DR3 type sites when the cells are stimulated 
with vitamin D3 (Heikkinen et al., 2011). However, 10% of the genes identified to 
contain a VDRE after stimulation with vitamin D3 did not contain a DR3-type site 
(Heikkinen et al., 2011). EFTUD1 (elongation factor Tu GTP binding domain 
containing 1), which was among the top 10 upregulated genes in MeWo cells 
was predicted not to contain a VDRE by our approach. However, this gene was 
reported to possess a non-DR3 type VDRE by Heikkinen et al (Heikkinen et al., 
2011), which suggests that it is indeed a VDR target gene. This suggests that in 
the future, the identification of putative VDREs can be performed more 
accurately using the ENCODE database which includes data from ChIP-
sequencing experiments (Consortium et al., 2012). The two recent ChIP-
sequencing studies by Ramagopalan et al and Heikkinen et al reported only 
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18.2% common VDREs in vitamin D3 stimulated cells (Ramagopalan et al., 2010, 
Heikkinen et al., 2011). This might reflect the different cut-off values used to 
determine significant VDREs and the different duration of vitamin D3 treatment 
but it might also suggest that VDR utilises different binding sites in different cells 
(Heikkinen et al., 2011). As a result, further investigation of the vitamin D3 
transcriptional response is required within the context of ChIP-sequencing data 
to identify VDR target genes in melanoma cells. 
5.5.5 Pathway analysis 
Pathway analysis has helped to categorise the biological functions of genes 
significantly differentially expressed in response to vitamin D3. Pathway analysis 
performed using MetaCore™ highlighted the overrepresentation of GO 
processes, such as cell proliferation, migration and adhesion and differentiation 
in cells in response to vitamin D3. Overrepresented pathways included Wnt and 
TGF-beta signalling in both cell lines. Vitamin D3 has previously been reported to 
alter both pathways (Deeb et al., 2007, Fleet et al., 2012). In particular, it has 
been reported that Wnt signalling is inhibited through induction of CDH1 (E-
cadherin) which promotes translocation of b-catenin from the nucleus to the 
plasma membrane, inhibiting b-catenin-TCF4 signalling pathway which induces 
cell proliferation (Deeb et al., 2007). It was noted that NOTCH signalling was 
overrepresented in vitamin D3 treated MeWo cells only which suggests that 
vitamin D3 acts in different ways in different tumours. This pathway has been 
reported to play a role in the vitamin D3-mediated anti-tumour effects in a 
prostate cancer cell line model (Kovalenko et al., 2010). 
 
In summary, identification of the genes most significantly overexpressed in 
response to vitamin D3, their epigenetic control elements and the pathways 
associated with these genes offers credible support for the view that vitamin D3 
has anti-tumour effects. Future work should include validation of these results 
and in particular detailed examination of the pending patient tumour data set. It is 
vital to explore whether transcriptional changes identified in vitro are mirrored in 
vivo, and to what extent these effects are moderated by complex tumour biology. 
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Chapter 6  
Osteopontin plasma concentrations in cutaneous 
melanoma 
 
6.1 Aims 
This chapter describes work carried out to assess plasma osteopontin levels as 
a potential prognostic biomarker in melanoma. 
The aims are: 
• To evaluate the suitability of stored EDTA plasma samples from the 
Leeds Melanoma Cohort to measure osteopontin concentrations using a 
commercial immunoassay (R&D systems);  
• To evaluate the performance of the osteopontin assay using stored EDTA 
plasma samples; 
• To assess the difference in osteopontin plasma concentrations between 
patients with melanoma and healthy controls; 
• To correlate osteopontin plasma concentrations with tumour 
characteristics; 
• To identify the prognostic value of osteopontin plasma concentrations. 
 
6.2 Background 
AJCC staging is the gold standard to assess prognosis in melanoma 
incorporating tumour characteristics such as Breslow thickness and ulceration, 
lymphatic metastasis, distant metastasis and lactic dehydrogenase (LDH) serum 
level (Balch et al., 2009). Features, such as age, sex and tumour site reviewed 
by (Homsi et al., 2005) have also shown prognostic significance but are not 
included in the AJCC staging system. Although the predictive value of the AJCC 
staging system is improving, there is still variance in outcome that cannot be 
explained with the current prognostic factors (Ross, 2006). There is a need 
therefore to improve available prognostic biomarkers. 
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Circulating markers tested so far for their prognostic significance or use in 
disease monitoring have proven of little clinical utility in early stage patients 
(Hofmann et al., 2009, Paschen et al., 2009). Potential serologic markers that 
have been investigated so far in melanoma were discussed in the introduction 
(section 1.10). In this chapter, I report an assessment of the prognostic and 
disease monitoring utility of plasma osteopontin levels in patients with 
melanoma. Increased osteopontin gene expression levels in primary melanomas 
were reported by the Leeds group to be of independent prognostic significance 
(Conway et al., 2009) using an agnostic approach: the DASL platform. We 
further wanted to investigate if plasma circulating osteopontin levels were of 
similar prognostic value and/or might detect asymptomatic disease recurrence.  
Osteopontin, coded by the secreted phosphoprotein 1 (SPP1) gene, was first 
described as a secreted glycoprotein overexpressed after malignant cell 
transformation (Senger et al., 1983, Senger et al., 1989) and characterised as a 
bone matrix protein (Franzen and Heinegard, 1985). Osteopontin belongs to the 
small integrin-binding ligand N-linked glycoproteins (SIBLINGs) family (Fisher et 
al., 2001). SIBLINGs, which are secreted proteins, promote cell adhesion, 
motility and survival through binding to integrins, CD44 and metalloproteinases 
(Figure 6-1) (Bellahcene et al., 2008). 
As a result of its involvement in these pathways, osteopontin has been 
extensively studied in cancer biology as a potential biomarker or a therapeutic 
target. It is expressed in different cell lineages and has been described as 
important in tumour progression and metastasis in many cancers (El-Tanani et 
al., 2006) including melanoma. In 2005, SPP1 gene expression was reported to 
be greater in vertical growth phase primary and metastatic melanomas than in 
naevi and melanomas in situ (Smith et al., 2005) which suggested that the 
glycoprotein might be associated with disease progression. This association was 
also suggested by three immunohistochemical studies (Rangel et al., 2008, Zhou 
et al., 2005, Maier et al., 2011). Our group confirmed increased expression of 
SPP1 in primary tumours to be of independent prognostic value for melanoma 
(Conway et al., 2009) indeed the gene whose expression was most strongly 
associated with outcome. Other groups reported supportive evidence using 
different gene expression assays (Jaeger et al., 2007, Soikkeli et al., 2010) or 
immunohistochemistry (Rangel et al., 2008, Kashani-Sabet et al., 2009, Alonso 
et al., 2007). 
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Figure 6-1: The role of osteopontin and other SIBLING proteins in cell 
adhesion and metastasis. 
A, B) At the primary site, SIBLING proteins are secreted by cancer cells 
which promote their proliferation and survival, C) Cancer cells can detach 
from the primary site and invade the stroma. Osteopontin enhances cell 
motility and invasion into the surrounding tissue. The insert shows SIBLING 
proteins bound to their receptors (osteopontin binds to αvβ3 integrins 
and/or CD44). Local proteolysis is mediated through binding to specific 
metalloproteinases (MMPs). D) SIBLINGs promote the migration and 
adhesion of activated endothelial cells, E) The expression of SIBLINGs on 
the surface of cancer cells protects themselves from complement-mediated 
lysis. F) At distant sites, SIBLINGs proteins are secreted by cancer cells 
and promote their proliferation and survival as at the primary site. Reprinted 
by permission from Macmillan Publishers Ltd: [Nature Reviews Cancer] 
(Bellahcene et al., 2008), copyright (2008). 
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Increased blood levels of osteopontin have been reported as associated with 
progression in many cancers (Rittling and Chambers, 2004), including breast 
cancer (Rodrigues et al., 2007), head and neck cancer (Li et al., 2011, 
Snitcovsky et al., 2009), pancreatic ductal adenocarcinoma (PDA) (Sullivan et 
al., 2009), hepatocellular cancer (Sun et al., 2010) and endometrial cancer (Cho 
et al., 2009). An increased osteopontin level was reported as a predictor of 
outcome in non-small cell lung cancer (NSCLC) (Mack et al., 2008, Isa et al., 
2009) and to be reduced after tumour resection of NSCLC (Blasberg et al., 
2010). No association was found between osteopontin levels and disease course 
in mesothelioma (Wheatley-Price et al., 2010). A small number of studies have 
reported increased osteopontin plasma levels in uveal melanoma (Reiniger et al., 
2007, Haritoglou et al., 2009) which were highly correlated with the presence of 
liver metastasis (Kadkol et al., 2006).  
Elevated osteopontin plasma concentrations have recently been reported in two 
studies in metastatic melanoma (Kluger et al., 2011, Maier et al., 2011). In both, 
comparison was made between samples from patients with and without 
concurrent metastatic disease.  
Here, I report a pilot study of 185 patients with melanoma recruited to the Leeds 
Melanoma Cohort in which the prognostic value of osteopontin was tested. This 
is the first study looking at osteopontin plasma level as a prognostic marker in 
early stage disease patients (AJCC I to III) taking into account factors already 
known to be of prognostic value. The work was done collaboratively with 
Professor Rosamonde Banks at the University of Leeds. The Human 
Osteopontin Immunoassay kit (R&D systems), described in detail in section 2.11, 
was used to detect osteopontin levels in stored plasma samples from the Leeds 
Melanoma Cohort. Prior to use, the assay was evaluated based on guidelines of 
immunoassay development (DeSilva et al., 2003) and stored plasma samples 
were assessed for their suitability to measure osteopontin concentrations 
accurately using the immunoassay. 
 
6.3 Detailed methodology 
The Leeds Melanoma Cohort is a large population based cohort of melanoma 
patients recruited since 2000. Samples have been collected from participants but 
a proportion have been mailed to the laboratory. In order to limit variation 
between samples, all samples were therefore processed in the laboratory after a 
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delay of 24 to 72 hours: that is samples obtained in Leeds which were not mailed 
were left on the bench before processing resulting in variation in the time from 
venepuncture to processing with a median of 1 day (range, 0-4 days). There are 
no published data for the stability of osteopontin plasma levels in stored 
samples. Therefore, to investigate the potential impact of delays in processing 
we first investigated the stability of osteopontin levels over time. In order to do 
this, additional blood samples were obtained as described in section 2.2.3. In 
these samples osteopontin was measured to determine if there was change due 
to delays in processing. EDTA plasma samples were used in the assay as 
proteolytic cleavage of osteopontin by thrombin during the clotting process 
occurs in serum samples (Ayache et al., 2006). To confirm this, osteopontin 
concentration was measured in matched plasma and serum samples from 
patients with renal cell carcinoma. 
A total of 185 patients were identified from participants bled at recruitment to the 
Leeds Melanoma Cohort for whom stored plasma samples were available 
(Newton-Bishop et al., 2009). Participants were recruited to the study within 3-6 
months after diagnosis, when possible (Newton-Bishop et al., 2009). Samples 
were selected as follows: a) 76 samples from participants who were believed to 
be disease-free at venepuncture (53 treated stage I/II, 23 treated stage III), and 
who have not relapsed in the subsequent period of a median of 7.5 years (range, 
1.1-11.2); b) 82 from participants who were believed to be disease-free at 
sampling but subsequently relapsed (57 treated stage I/II, 25 treated stage III); 
and c) 27 who had metastatic disease at sampling (17 untreated stage III, 10 
untreated stage IV). A patient was defined as disease-free if they had had their 
primary excised or their lymph nodes removed and there was no known clinical 
evidence of further disease. A minimum period of 6 weeks between surgery and 
venepuncture was used based on a study in NSCLC patients which showed that 
osteopontin plasma levels were elevated in the period 6 weeks after surgery, 
possibly due to the involvement of osteopontin in wound healing (Blasberg et al., 
2010). Thirty healthy controls were also included in the study to compare 
osteopontin levels with those in the normal population. No difference in age and 
gender was observed between controls and cases. 
6.3.1 Enzyme-linked immunosorbent assay (ELISA) validation 
A commercial ELISA assay kit (Quantikine; R&D Systems) was used to measure 
osteopontin levels as described in section 2.11. This kit was selected in 
conjunction with Professor Rosamonde Banks based on a study that showed it 
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has the highest sensitivity and specificity between other commercially available 
kits (Plumer et al., 2008). Prior to use, the assay was validated examining intra- 
and inter-assay precision, parallelism and recovery using recombinant 
osteopontin protein purchased from Abcam, and interference as previously 
described (Wind et al., 2011, Sim et al., 2012). Intra-assay precision was 
assessed by running three quality control samples five times in one plate while 
inter-assay precision was assessed when two quality control samples were run 
in duplicate across nine different plates. The parallelism test (or otherwise 
demonstration of dilutional linearity) is critical to identify if any components of the 
sample interfere in the ability of the assay to detect the analyte (interfering matrix 
effects). Here, for the parallelism test, serial dilutions of 3 samples were run in 
duplicate. The recovery test also determines if anything in the matrix interferes 
with the analyte determination. Here, for the recovery test, a low, high and a 
blank spike were introduced into plasma samples and were run in duplicate, 
except for the blank spike into the plasma samples which was run thrice in 
duplicate across the plate to give a more accurate ‘true value’ of how much 
protein was spiked into the samples. Interference is the effect of a substance 
present in the sample that might affect the accurate determination of the analyte. 
No interference was found from the following substances tested: bilirubin, 
haemolysis, triglycerides or rheumatoid factor (data not shown) (Sim et al., 
2012).  
Samples passed the intra- and inter- assay precision test, and parallelism test 
when coefficient of variation (CV)<15% (Food and Drug Administration, 2001). 
The recovery of the recombinant protein should be within 80-120% (Food and 
Drug Administration, 2001). 
6.3.2 Statistical analyses 
All samples were assayed in duplicate and the osteopontin concentrations 
(ng/ml) presented here are the mean of the two replicates. The differences in 
osteopontin levels between matched EDTA plasma and serum from four patients 
with renal cell carcinoma (RCC) were tested using the Wilcoxon matched-pairs 
signed-ranks test. Also, the potential effects of differences in sample processing 
time on osteopontin plasma concentrations were assessed using the results from 
the matched samples processed at different time points (same day versus four 
days after venepuncture) and analysed using the Wilcoxon matched-pairs 
signed-ranks test. 
221 
Following the successful validation assay, 215 plasma samples were screened. 
First, osteopontin differences between healthy controls and cases grouped 
according to AJCC stage at venepuncture were compared using the Kruskal-
Wallis test and multiple linear regression. Second, we looked at osteopontin as a 
prognostic indicator for patients with no evident disease so that patients with 
metastatic disease at sampling were excluded from subsequent analysis to test 
for the prognostic significance/disease monitoring of osteopontin in apparently 
disease-free early stage patients. 
Factors previously shown to be associated with survival in the Leeds Melanoma 
Cohort were assessed for association with osteopontin levels: Breslow thickness; 
body mass index (BMI); AJCC stage; tumour site and mitotic rate; age at 
diagnosis; sex; tumour ulceration (ulcerated, not ulcerated); sentinel node biopsy 
(SNB) status; and vitamin D serum levels (nmol/l, adjusted for season) (Newton-
Bishop et al., 2009), using Mann-Whitney U tests, Spearman Correlations and 
Kruskal-Wallis tests where appropriate. Multiple Linear regression was used to 
identify possible independent predictors of osteopontin level.  
Odds ratios (OR) and 95% Confidence Intervals (CI) were estimated from logistic 
regression models for the effect of osteopontin levels on risk of death from 
melanoma and death from any causes. Due to the skewed frequency distribution 
of osteopontin levels, log-transformed osteopontin level (to the base 2) was 
entered into the models so that the estimated OR would be interpreted as the 
OR associated with a doubling of osteopontin level at recruitment. Osteopontin 
level was also considered as a categorical variable by grouping into approximate 
tertiles (≤49.35, >49.35-≤64.34, >64.34). Both unadjusted and adjusted ORs 
were calculated for osteopontin; the adjustment variables were: age; sex; BMI; 
site of the primary; season-adjusted vitamin D level; and stage at sampling. 
Here, the vitamin D variable was grouped into six categories, to show the effect 
based on 20nmol/l increments (≤20, >20-≤40, >40-≤60, >60-≤80, >80-≤100, 
>100). Secondary analyses incorporated time-to-event data and Kaplan-Meier 
curves were plotted. Hazard ratios (HR) and 95% CI were estimated from Cox 
proportional hazards models for the effect of osteopontin level on melanoma 
specific survival (MSS) and overall survival (OS). OS was defined as the period 
between recruitment to the Leeds Melanoma Cohort and death, and MSS as the 
period between recruitment and death from melanoma. The median follow-up 
time was 4.3 years (range 0.6-10.7 years). An arbitrary significance level of 
p<0.05 was used. STATA version 10 (StataCorp., 2007) was used for statistical 
analyses.  
222 
6.4 Results 
6.4.1 Validation assays 
6.4.1.1 A comparison of levels in EDTA plasma versus serum 
Stored matched EDTA plasma and serum samples from five patients with renal 
cell carcinoma were used to assess the difference in osteopontin levels between 
the two sample types. A significant difference in osteopontin concentrations 
between plasma and serum samples was observed (CV>20%) with serum 
samples having lower concentrations as expected (Table 6-1). Wilcoxon 
matched-pairs signed ranks test showed no statistical significance (p=0.12), but 
this could be explained due to small sample size. It was noted that osteopontin 
levels in serum were in the region of 50% lower than those measured in plasma, 
but only plasma samples were used to further validate the assay.  
 
Table 6-1: Osteopontin concentrations in matched plasma and serum. 
 Patient 1 Patient 2 Patient 3 Patient 4 
Plasma Concentration (ng/mL) 45.11 71.79 36.73 286.65 
Serum Concentration (ng/mL) 21.45 31.30 18.75 137.03 
% CV 52.5 56.4 48.9 52.2 
 
6.4.1.2 Sample processing time 
Plasma samples processed immediately and samples processed four days after 
venepuncture from 4 healthy controls and 5 patients with melanoma were used 
to test for an effect due to delays in processing (Table 6-2). No significant 
difference in levels was observed between them (CV<20% and p=0.18, based on 
Wilcoxon matched-pairs signed ranks test). The samples stored from the Leeds 
Melanoma Cohort were therefore judged suitable for use in this evaluation of 
osteopontin as a disease marker for melanoma. 
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Table 6-2: Osteopontin plasma concentrations in day 0 versus day 4 
processed samples. 
 
Normal 
1 
Normal 
2 
Normal 
3 
Normal 
4 
Patient 
1 
Patient 
2 
Patient 
3 
Patient 
4 
Patient 
5 
Day 0: 
Osteopontin 
level (ng/ml) 
51.10 64.55 69.58 45.11 37.95 30.93 233.65 109.96 68.35 
Day 4: 
Osteopontin 
level (ng/ml) 
50.48 63.49 65.11 42.38 37.06 30.45 236.08 96.76 68.54 
%CV  1.2 1.6 6.4 6.1 2.3 1.5 1.0 12.0 0.3 
 
6.4.1.3 Parallelism test 
The parallelism test was determined in three patients’ samples processed after 4 
days (Table 6-3). Serial dilutions of each sample were used to check for 
interfering matrix effects. All samples passed the test with CV<15%. However, 
the 1:12.5 dilution of sample 3 was above the upper limits of the assay range 
and therefore the concentration could not be calculated. 
 
Table 6-3: Parallelism test for the serial dilutions of three samples 
Sample 
Back calculated OPN concentration from each 
dilution (ng/ml) 
%CV 
 1:12.5 1:25 1:50 1:100  
Sample 1 34.5 35.9 41.1 45.6 12.9 
Sample 2 28.1 29.6 33.3 34.9 10 
Sample 3 - 230.3 248.4 272.5 8.4 
 
6.4.1.4 Recovery test 
In the recovery test, low and high spikes were introduced into sample diluent and 
three sets of duplicates were run. The mean of the low spike in buffer was 
8.7ng/ml, and the high spike in buffer was 15.6ng/ml. The recovery test was run 
twice using a recombinant protein purchased from R&D but it failed (data not 
shown). There was a concern that this was due to the form of protein used for 
recovery studies, which was tagged. As a result, a repeat of this assay was 
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performed using a different source of recombinant protein spike purchased from 
Abcam. The results of the final recovery test are shown in Table 6-4. Although 
one sample failed, this was due to a replicate. If the second replicate is removed, 
the recovery is 111%. All other samples passed the test. 
 
Table 6-4: Recovery test 
Sample Sample1  Sample 2 Sample 3 
Low spike concentration (ng/ml)  9.96 14.02 11.73 
Low spike Recovery (%) 102.3 124.8 104.9 
Pass / Fail Pass Fail Pass 
High spike concentration (ng/ml)  15.56 18.11 19.68 
High spike Recovery (%) 93.1 96.0 109.6 
Pass / Fail Pass Pass Pass 
 
6.4.1.5 Intra and inter-assay precision 
The results of intra-assay precision are shown in Table 6-5 where the %CV 
between the 5 replicates of each QC sample was always <15%. The results of 
inter-assay precision is shown in Table 6-6 where the CV for each QC sample 
run across 8 or 9 different assays was always <15%. 
 
Table 6-5: Intra-assay precision measured using 3 QC samples run 5 times 
on a single assay. 
Assay Low QC sample Mid QC sample High QC sample 
1 1.88 4.78 9.61 
1 1.76 5.00 10.00 
1 1.91 5.02 9.46 
1 1.82 5.07 9.49 
1 1.82 4.79 9.29 
Mean 1.84 4.93 9.57 
SD 0.06 0.14 0.27 
Intra Precision (%CV) 3.1 2.8 2.8 
  
225 
Table 6-6: Inter-assay precision measured using 1 QC sample measured 
across 8 assays and 1 QC sample across 9 assays. 
Assay Low QC sample High QC sample 
1 2.19 - 
2 1.84 9.57 
3 1.91 9.25 
4 1.92 9.75 
5 1.9 9.86 
6 1.97 10.69 
7 1.78 9.05 
8 1.78 9.61 
9 1.76 9.75 
Mean 1.89 9.69 
SD 0.13 0.49 
Inter Precision (%CV) 7.1 5.0 
 
6.4.2 Cross-sectional analysis of plasma osteopontin in all 
cases and healthy controls 
The normal range of osteopontin level, as it was measured in 30 healthy 
controls, was 28.6-118.8ng/ml with a median level of 59.2ng/ml. Of the 185 
melanoma patients 158 had treated stage I-III, 17 had untreated stage III and 10 
untreated stage IV disease (median osteopontin levels 54.7ng/ml, 54.6ng/ml, 
and 74.0ng/ml respectively) (Figure 6-2). A statistically significant difference in 
osteopontin levels was observed between the 4 groups (Kruskal-Wallis test 
x2=8.69, p=0.03; Figure 6-2). To explore this further, we performed multiple linear 
regression which showed that untreated stage IV patients had significantly higher 
osteopontin levels than the controls and the treated stage I-III patients in age-
adjusted models (p=0.004 for untreated stage IV versus controls, p<0.001 for 
untreated stage IV versus treated stage I-III patients; Table 6-7). No significant 
differences were seen between controls and the treated stage I-III or the 
untreated stage III patient groups (p=0.59 and 9=0.92 respectively; Table 6-7). 
In healthy controls 95% of samples had osteopontin levels <103.14ng/ml. This 
cut off was therefore taken as the upper end of normal.  We found 2.5% of 
patients with treated stage I-III (4/158), 17.6% of patients with untreated stage III 
(3/17) and 30% of patients with untreated stage IV disease (3/10) had levels 
higher than this cut off (Fisher’s exact=0.001). The cut off that had been 
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previously reported is 76 ng/ml (95th centile) (Sennels et al., 2007), which is the 
80th centile in our control group. 
 
 
Figure 6-2: Box plots of osteopontin plasma levels in healthy controls and 
cases (grouped according to AJCC stage). 
The edges of the box represent the 25th and 75th centiles and the whiskers 
represent the 5th and 95th centiles. Adapted from (Filia et al., 2013). 
 
Table 6-7: Age-adjusted linear regression coefficients for the relationship 
between AJCC stage and log transformed osteopontin levels when 
either controls or treated I-III groups were used as the baseline group. 
Observations 
Controls 
(baseline group) 
Treated I-III 
(baseline group) 
  Coeff (95% CI) P value Coeff (95% CI) P value 
Controls 30 5.50 (5.10-5.91)  -  
Treated I-III 158 -0.06 (-0.27-0.15) 0.59 5.44 (5.10-5.79)  
Untreated III 17 0.02 (-0.30-0.34) 0.92 0.07 (-0.20-0.33) 0.63 
Untreated IV 10 0.57 (0.19-0.96) 0.004 0.62 (0.28-0.97) <0.001 
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6.4.3 Osteopontin in patients free of disease at sampling 
Age was positively correlated with osteopontin level in the disease-free patient 
group (Spearman’s rho=0.2, p=0.02, Table 6-8; and overall Spearman’s 
rho=0.21, p=0.004, data not shown). AJCC stage at sampling was borderline 
associated with osteopontin levels (p=0.06; Table 6-8) with higher median level 
seen in patients with treated stage III melanomas compared to those with treated 
stage I-II disease (64.3ng/ml and 54.1ng/ml respectively). Neither age nor stage 
at sampling were independent predictors of osteopontin level in a multiple linear 
regression model. There was no difference in osteopontin levels between SNB 
positive (n=38) and SNB negative (n=41) participants (Table 6-8). 
Logistic regression showed a trend for increased risk of death from any cause 
with increasing osteopontin level but this was not statistically significant: adjusted 
OR was 1.24 (95%CI 0.52-2.96) for the middle versus lowest tertile, and 1.39 
(95%CI 0.56-3.42) for the highest versus lowest tertile, adjusted for age, sex, 
BMI, site of primary, season-adjusted vitamin D level, and stage at sampling 
(Table 6-9). Time-to-event analyses showed support for that trend (Figure 6-3 
and Figure 6-4 for MSS and OS respectively). When the 95th centile cut off was 
used 4/158 of the treated stage I-III patients had higher levels.  Three out of four 
relapsed early (<1.6 years) and the remaining patient after 6 years. In total 
154/158 of the treated stage I-III patients had osteopontin levels below the cutoff. 
Of these 79/154 were subsequent relapsers, 60 of which relapsed <1.6 years.  
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Table 6-8: The relationship between osteopontin levels and other 
characteristics of the participants who were disease-free at sampling 
(univariable analysis). 
Adapted from (Filia et al., 2013). 
Variable N= 
Median 
osteopontin (range) 
Test statistic and p value 
Osteopontin (ng/ml) 158 54.7 (27.9-140.0)  
Age  158  Spearman’s rho=0.2, p=0.02 
Sex 158   
      Male   85 54.6 (27.9-122.4) 
Mann-Whitney, z=-0.4, p=0.67 
      Female   73 54.8 (12.0-174.4) 
BMI 155   
      <18.5     1 49.5 
Kruskal-Wallis, χ
2
=0.9, p=0.82 
      ≥18.5 - <25    62 56.1 (28.4-174.4) 
      ≥25 - <30   57 53.3 (27.9122.4) 
      ≥30    35 54.4 (12.0-113.9) 
Breslow thickness (mm) 156   
      ≤1   11 47.7 (30.8-102.2) 
Kruskal-Wallis, χ
2
=2.5, p=0.47
 
      >1 - ≤2    49 54.6 (31.2-174.4) 
      >2 - ≤4    57 54.5 (12.0-98.4) 
      >4    39 55.2 (27.9-113.9) 
Tumour site 158
   
      Trunk   71 53.9 (29.2-122.4) 
Kruskal-Wallis, χ
2
=5.7, p=0.13
 
      Head/Neck    16 53.0 (29.3-102.0) 
      Limbs   55 55.2 (12.0-174.4) 
      Acral/Rare   16 68.0 (27.9-98.9) 
Mitotic rate (mm
-2
)
 
 128   
     <1   20 55.6 (31.2-93.0) 
Kruskal-Wallis, χ
2
=3.2, p=0.20       1-6    69 52.4 (12.0-140.0) 
      >6    39 56.6 (35.2-98.8) 
Ulcerated tumours 158
   
      Not ulcerated    98 54.6 (28.4-122.4) 
Mann Whitney, z=-1.0, p=0.32
 
      Ulcerated   60 56.6 (12.0-174.4)
 
Vitamin D (nmol/l) 150  Spearman’s rho=-0.1, p=0.30 
Stage at sampling 156   
      Treated I/II  110 54.1 (27.9-122.4) 
Mann Whitney, z=-1.9, p=0.06
 
      Resected III   48 64.3 (28.4-93.2) 
SNB status   79   
      Positive   38 55.2 (28.4-93.2) 
Mann Whitney, z=-0.1, p=0.96 
      Negative   41 57.6 (30.8-122.4) 
 Table 6-9: Association of osteopontin plasma levels with risk of death in participants who were disease-free at sampling.  
Adjusted models include age, sex, BMI, tumour site, season-adjusted vitamin D level and stage at sampling. Adapted from (Filia et al., 
2013). 
 
Alive, 
Died from melanoma 
 
Alive, 
Died from any cause 
 
  OR (95%CI) P value  OR (95%CI) P value 
Continuous osteopontin       
  Unadjusted model 83, 75 1.11
1
 (0.60-2.07) 0.74 79, 79 1.33
1
 (0.71-2.49) 0.37 
  Adjusted model 82, 65 0.85
1
 (0.42-1.70) 0.64 78, 69 1.05
1
 (0.52-2.12) 0.88 
Categorical osteopontin (tertiles)       
Unadjusted model ≤49.35 83, 75 1  79, 79 1  
 >49.35 - ≤64.34  1.41 (0.65-3.04) 0.38  1.52 (0.70-3.29) 0.29 
 >64.34  1.46 (0.68-3.15) 0.33  1.83 (0.85-3.97) 0.12 
Adjusted model ≤49.35 82, 65 1  78, 69 1  
 >49.35 - ≤64.34  1.14 (0.48-2.69) 0.77  1.24 (0.52-2.96) 0.63 
 >64.34  1.02 (0.41-2.52) 0.96  1.39 (0.56-3.42) 0.48 
1 OR is interpreted as the OR associated with doubling the original osteopontin variable. 
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Figure 6-3: Kaplan-Meier analysis survival (MSS) estimates for osteopontin 
plasma concentrations in participants who were disease-free at 
sampling. 
Adjusted HR 1.26 (95%CI 0.67-2.37), p=0.48 for middle versus low 
osteopontin tertile. Adjusted HR 1.19 (95%CI 0.62-2.28), p=0.61 for high 
versus low osteopontin tertile. Adjusted models include age, sex, BMI, 
tumour site, season-adjusted vitamin D level and stage at sampling. 
Adapted from (Filia et al., 2013). 
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Figure 6-4: Kaplan-Meier analysis survival (OS) estimates for osteopontin 
plasma concentrations in participants who were disease-free at 
sampling. 
Adjusted HR 1.34 (95%CI 0.72-2.52), p=0.36 for middle versus low 
osteopontin tertile. Adjusted HR 1.44 (95%CI 0.77-2.72), p=0.26 for high 
versus low osteopontin tertile. Adjusted models include age, sex, BMI, 
tumour site, season-adjusted vitamin D level and stage at sampling. 
Adapted from (Filia et al., 2013). 
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6.5 Discussion 
6.5.1 Osteopontin assay validation 
Differences in osteopontin concentrations between plasma and serum with 
serum having lower levels due to osteopontin cleavage during clotting had 
previously been described (Ayache et al., 2006). Here, we validated that finding, 
and therefore EDTA plasma samples were used in the osteopontin ELISA assay. 
It was noted that osteopontin levels in serum were generally about 50% lower 
than those observed in plasma samples, which might suggest that serum could 
also possibly be used to measure osteopontin as a potential biomarker, but this 
was not addressed. 
The commercial assay was validated successfully having optimal intra- and inter-
assay precision, passing parallelism and recovery tests but also having shown 
no interference from other analytes (Sim et al., 2012). The stored plasma 
samples from the Leeds Melanoma Cohort were also shown as suitable to be 
used in the assay measuring osteopontin concentration accurately without any 
difference due to the delayed processing after venepuncture which had occurred 
in that study. 
6.5.2 Osteopontin plasma levels in cutaneous melanoma 
There were previously no published data on osteopontin plasma levels and their 
prognostic significance in cutaneous stage I to III malignant melanoma. The 
Leeds group had previously reported a study which showed that higher tumour 
osteopontin gene expression levels in patients with melanoma were predictive of 
both relapse and death (Conway et al., 2009). I have therefore carried out a 
study of osteopontin levels as a prognostic biomarker measured in plasma 
samples, after assay validation, taken from melanoma patients at recruitment to 
the Leeds Melanoma Cohort.  
The strength of this study is that we looked for the first time at osteopontin levels 
in patients with melanoma soon after excision of their primary tumour and for 
whom good follow up data were available. We also investigated for the first time 
if osteopontin levels could predict outcome from melanoma. The weaknesses are 
that this study is underpowered to look at outcome, only a single test sample was 
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other blood markers known to have some prognostic significance, such as LDH 
or S100.  
Currently, Breslow thickness, tumour ulceration, mitotic rate, lymph node 
metastasis, site of distant metastasis and serum LDH levels are the prognostic 
markers which are included in the most recent version of AJCC staging system. 
Age, tumour site and sex are also powerful prognostic factors (reviewed by 
Homsi et al. (Homsi et al., 2005)). Even if all these factors are considered, the 
variance in survival within stage is still significant; thin tumours for example might 
progress to advanced disease (Slingluff et al., 1988). Therefore there is an 
urgent need for identification of new prognostic biomarkers. There is also a need 
for a blood based screening test to detect early recurrence, especially now that 
more effective drug treatments are emerging (Flaherty et al., 2010, Robert et al., 
2011). 
A clinically useful biomarker should be measured easily, reliably and at low cost, 
by a sensitive and specific assay (Kulasingam and Diamandis, 2008). The 
impact of NGS in characterisation of tumours on the conduct of clinical trials but 
also in the clinical practise is very promising as already discussed in Chapter 4. 
However, it requires the use of tumour tissue. In the context of melanoma, 
tumour tissues are small and therefore it is crucial the tissues to be used 
effectively in case more clinical tests are required in the future after diagnosis. 
There is a great interest in developing blood tests which can give information on 
tumour cells indirectly (Sawyers, 2008). Instead of studying the tumour cells, it is 
possible to study the proteins secreted by tumour cells in the serum or plasma. A 
potential prognostic blood biomarker could also easily be used to monitor 
disease progression at low cost. 
A number of serological prognostic biomarkers have been studied in melanoma 
as it was discussed in section 1.10. LDH serum level is most widely used (Balch 
et al., 2009) but is a poor marker of early recurrence and is commonly somewhat 
raised in otherwise healthy individuals. Serum levels of S100, the melanoma 
inhibitory activity protein (MIA) and amyloid A have been identified as potential 
prognostic biomarkers in advanced disease (Gogas et al., 2009). However, they 
failed to predict outcome in early-stage disease-free disease (Utikal et al., 2007) 
having a low sensitivity in a subgroup of patients (Hofmann et al., 2009). MIA 
serum level was tested for its prognostic significance in 1079 stage I/II patients 
with melanoma suggesting the usefulness of measuring MIA level in the follow-
234 
up of patients but with low sensitivity in a subgroup of patients (Hofmann et al., 
2009). 
Osteopontin plasma levels have been reported to be much increased in 
metastatic melanoma in two studies since I started my study (Kluger et al., 2011, 
Maier et al., 2011). The authors of one of these suggested that osteopontin 
levels might best be used in a panel of plasma markers that were elevated in 
untreated stage IV compared to treated stage I/II patients (Kluger et al., 2011). 
Highly elevated osteopontin plasma levels were observed in metastatic 
compared to non-metastatic patients and an increase in sensitivity for the 
detection of metastatic disease was observed when S100 plasma levels were 
combined with osteopontin (Maier et al., 2011). The extent of metastatic disease 
was not discussed in either of these studies. Our study was not designed to test 
these observations but the data provide some support, in that higher osteopontin 
levels were observed in our small number of samples from individuals known to 
have untreated stage IV disease at sampling when compared to individuals with 
treated stage I-III disease. There are good biological reasons to support that 
osteopontin is involved in tumour progression and metastasis (Rittling and 
Chambers, 2004) through binding to integrins and metalloproteinases, and 
through activation of Ras, protein kinase C or PI3K/Akt signalling pathways (Das 
et al., 2005). 
 A significant difference in osteopontin levels was observed between healthy 
controls and patients with melanoma grouped according to AJCC stage, but 
most of this difference was explained by high levels in patients with stage IV 
disease. Using the 95th centile measure in healthy controls as a cut off however 
showed evidence of a trend to increased rates of results above that level with 
disease progression.  
When only the disease-free patients were analysed in logistic regression models 
adjusted for known prognostic factors we saw a trend for increased risk of death 
with increasing osteopontin level. This provides support for the view that 
increased osteopontin levels might predict occult disease. Medical services in 
Leeds comply with the published UK melanoma guidelines, which state that 
there is no need for routine screening (imaging) in stage I to III patients. So, the 
possibility that there may have been occult disease in our disease-free patients 
should be considered. Therefore we did not look at time to relapse in this study. 
Osteopontin plasma levels did not correlate with tumour levels; however, there 
were only 34 samples with matched plasma and tumour levels from the DASL 
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microarray experiment (data not shown). The plasma and tumour levels also 
failed to show a strong correlation using qRT-PCR gene expression data from 37 
tumours (data not shown). These numbers are too small to investigate if there is 
a strong correlation. However, it is known that gene expression levels and 
protein levels do not always correlate (Vogel and Marcotte, 2012). Another 
possible explanation is that this single measurement in the blood taken at 
recruitment to the study might not reflect the tumour levels at diagnosis although 
recruitment in the study was performed within 3-6 months when possible. 
Serial measurements of osteopontin plasma levels at frequent intervals after 
diagnosis may prove to be more informative than a single measurement. A study 
in uveal melanoma (Barak et al., 2011) showed a significant increase in 
osteopontin level from 12-18 months to 6-12 months prior to clinical confirmation 
of metastasis. The trend of the increase of osteopontin level was not significantly 
different compared to the osteopontin measurements in disease-free patients but 
this could be due to the small study size. When we used a measure of 
osteopontin level higher than 95th centile, relapse occurred in significant numbers 
of melanoma patients with results within the normal range sampled within 19 
months of relapse. It seems unlikely therefore that a single measurement of 
osteopontin will have sufficient sensitivity and specificity for use in clinical 
practice. It may however be the case that biologically different tumours are 
associated with increased levels of different tumour markers and that a panel of 
markers will be necessary. Therefore the possibility of studying the longitudinal 
monitoring utility of osteopontin level in conjunction with other markers should 
also be assessed in future studies with imaging of patients with high levels to 
detect occult metastases. 
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Chapter 7  
Final discussion 
 
7.1 Melanoma genomics and prognostic biomarkers 
The genetic changes, which “drive” melanoma, were unknown until recently. 
Progress was slower than for many cancers, partly because melanoma tumours are 
small and fresh/frozen tissue hard to come by. Some of this delay occurred 
because the most common “driver” mutant BRAF was not recognised as a proto-
oncogene till systemic large-scale screening became possible. BRAF as an 
oncogene was reported in 2002 (Davies et al., 2002). Although much more is 
known now about BRAF and other drivers, the rapid emergence of resistance in 
patients treated with BRAF inhibitors, and lack of treatment for patients without 
BRAF mutations means that much more information is needed about genomics to 
inform treatment decisions. In this thesis I describe attempts to evaluate next 
generation sequencing (NGS) as a tool to further investigate melanoma genomics 
with particular reference to primary tumours. 
The American Joint Committee on Cancer (AJCC) staging scheme is the gold 
standard to assess prognosis in melanoma (Balch et al., 2009). However, there is 
still variance in outcome that cannot be explained with the current prognostic 
factors (Ross, 2006), which highlights the need to identify new prognostic 
biomarkers. Increasing efforts have been made to identify new, more accurate 
molecular prognostic markers. In this thesis I have evaluated osteopontin plasma 
levels as a potential biomarker in early stage disease (AJCC stage I-III) patients 
with melanoma. 
7.1.1 Identification of tumour prognostic biomarkers using next 
generation sequencing 
Primary melanoma tumours are small and therefore rarely cryopreserved. To 
investigate somatic alterations in primary melanoma tumours, the use of formalin-
fixed paraffin-embedded (FFPE) tissue is therefore necessary. The principal aim of 
this thesis was to assess the use of whole-genome next generation sequencing 
(NGS) technology to identify copy number alterations (CNAs) in melanoma using 
FFPE-derived DNA. NGS offers substantial benefits over array-based approaches 
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for copy number analysis: more accurate estimation of high CNAs as counting 
sequences does not suffer from signal saturation (Meyerson et al., 2010); the 
potential of higher resolution to identify small CNAs and precise estimation of the 
breakpoints of CNAs (Meyerson et al., 2010); it can be performed using low 
amounts of DNA while array-based methods usually require large amounts of 
FFPE-derived DNA (greater than 500ng).  
There are only two studies reporting CNAs using FFPE primary melanoma tissue 
on the aCGH platform and both have used greater than 500ng DNA input (Bastian 
et al., 2003, Curtin et al., 2005). Recent studies have demonstrated the successful 
performance of low-coverage NGS (range 0.004x-0.06x) for copy number analysis 
using small amounts of FFPE-derived DNA from oral tumours and lung squamous 
cell lines and tumours (Wood et al., 2010, Belvedere et al., 2012). Reproducible 
results between FFPE and matched frozen tumours on the NGS platform have 
been reported using small data sets (Wood et al., 2010, Schweiger et al., 2009). 
These results are promising but further effort is needed to assess the feasibility of 
this technology to allow effective use of melanoma tumour tissue in future large-
scale studies. In this thesis I report such a study using relatively higher coverage 
than reported by Wood et al by multiplexing fewer samples per lane. 
I have shown that low DNA concentrations are, not surprisingly, associated with 
lower probability of adequate library preparation and more PCR replicates 
sequenced but that there was no clear cut off identifiable to determine a lesion not 
worth sequencing or worth sequencing at lower depth. It is possible that a more 
accurate quantification method (use of the higher sensitivity picogreen kit) could 
serve as a better indicator of what is worth sequencing, but this was not assessed. 
Efficient and cost-effective use of FFPE samples for biomarker discovery and 
testing will require the identification of the depth of sequencing that can be 
performed based on the concentration of DNA input, which is a requisite for future 
studies. 
Previously reported biases such as sequencing of PCR replicates, GC-bias and 
errors in the human reference genome sequence (Dohm et al., 2008, Pickrell et al., 
2011) were assessed and corrected by applying statistical models or removal of 
data to minimise false positive copy number changes. Future work on the human 
reference genome assembly may resolve problems such as the errors in the 
reference and allow the identification of CNAs in these regions that we might miss 
at the moment. Improvements in sequencing technology will also reduce 
sequencing errors such as those observed at the 3’-end of the fragments (phasing 
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artefact). Currently, quality filtering is suggested at the expense of removing part of 
the data (Minoche et al., 2011). This means that we might miss some changes 
which we might identify by re-analysing the data in the future. 
The median coverage for chromosomes 1-22 was 1.01x (range, 0.33x-1.46x). With 
this coverage smaller CNAs are likely to be identified than those reported by other 
whole-genome studies (Wood et al., 2010, Belvedere et al., 2012), but the exact 
resolution has not yet been determined. Some of these samples could be re-
sequenced to increase depth, however this would only be possible when large 
amounts of DNA was used to generate the libraries (high complexity libraries) to 
avoid sequencing of PCR replicates. This suggests that the identification of 
translocations would be limited using these samples. 
I have reported evidence that the CNAs detected were in regions previously 
described to be associated with melanoma and which are biologically credible (such 
as chromosome 10/ PTEN in BRAF mutated tumours). This provides evidence to 
justify this sequencing approach. Correlations between whole-genome DASL 
expression and NGS copy number data from the same tumours further supported 
the validity of these data. There are still 265 samples which need to be analysed 
which will increase our statistical power to identify reliable CNAs associated with 
outcome or other tumour characteristics. 
The conclusion from my work is that NGS should provide sufficiently robust data for 
assessing/applying a proposed genomic biomarker, but the larger data set which is 
pending will increase the confidence with which I can assess its likely value. If a 
potential biomarker is identified, its applicability would need to be tested in a more 
representative sample set (i.e. including smaller tumours) using specially designed 
tests. 
NGS can also be used to identify transcriptional changes (known as RNA-
sequencing) (Meyerson et al., 2010). In Chapter 2, I report the evaluation of an 
Illumina protocol designed to prepare libraries using FFPE-derived RNA. The 
advantage of RNA-sequencing over traditional microarray approaches is that 
alternative splice variants and transcripts from gene fusion events can be identified 
(Meyerson et al., 2010). The sequencing data produced from these libraries have 
not been analysed yet. The intent was to assess the consistency across matched 
FFPE and frozen tissue, and with analyses conducted on microarrays. This would 
allow a design of a large-scale study as described above to assess the feasibility of 
NGS using RNA from FFPE primary melanoma tumours. 
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7.1.2 Osteopontin as a potential plasma biomarker 
Primary melanoma tumour tissues should be used efficiently in case clinical tests 
are needed in the future after diagnosis. Therefore there is a great interest in 
studying the proteins secreted by tumour cells in the serum or plasma instead of 
studying the tumour cells directly (Sawyers, 2008). A prognostic blood biomarker 
allowing detection of early relapse in the clinic is desirable especially as targeted 
therapies come on line. In Chapter 6 I present an assessment of osteopontin 
plasma levels using a commercial ELISA assay as a potential prognostic biomarker 
in early-stage melanoma patients. Following the validation of the assay, higher 
osteopontin levels were observed in our small number of samples from individuals 
known to have untreated stage IV disease when compared to individuals with 
treated stage I-III disease. A trend for increased risk of death with increasing 
osteopontin level was observed when only disease-free patients were analysed, but 
this did not reach formal significance. The greatest limitation of this work is that 
osteopontin levels were not compared with other well-studied serum markers, such 
as LDH.  
My conclusion from this work, which has been published (Filia et al., 2013), is that 
measurement of the osteopontin plasma level is not likely to be useful as a 
prognostic biomarker for early-stage disease patients. It may however be the case 
that biologically different tumours are associated with increased levels of different 
tumour markers and that a panel of markers will be necessary. A study in uveal 
melanoma has reported a significant increase in osteopontin level from 12-18 
months to 6-12 months prior to clinical confirmation of metastasis (Barak et al., 
2011). It would therefore be interesting to study the longitudinal monitoring utility of 
osteopontin level in conjunction with other markers in the future. In the future serum 
proteomic profiling studies may serve as a means to discover new prognostic 
biomarkers in melanoma which could be tested alone or in combination with other 
markers to assess their prognostic significance.  
 
7.2 Biomarkers in response to vitamin D 
Most of the adjuvant therapies trialled in melanoma patients have not proved very 
promising (Molife and Hancock, 2002, Eggermont et al., 2009) except for IFN-α and 
Ipilimumab (anti-CTLA4) (Davar et al., 2012, Eggermont and Robert, 2011). Vitamin 
D has been reported as a potential new adjuvant therapy with promising results in 
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prostate cancer (Deeb et al., 2007). In patients with melanoma, there are ongoing 
clinical trials which aim to study the effect of vitamin D as an adjuvant treatment 
alone or in combination with other regimens (U.S. National Institutes of Health, 
2013). In Chapter 5 I presented an in vitro study designed to examine the anti-
tumour effects of vitamin D in melanoma. It is intriguing that these findings could 
ultimately lead to the identification of predictive biomarkers that would show likely 
benefits to vitamin D supplementation. The up-regulation of VDR and CYP24A1 
after vitamin D treatment in both cell lines suggests that the detected changes are 
specific to vitamin D. These have been the most widely reported changes in 
response to vitamin D in various cancer models (Kriebitzsch et al., 2009, Deeb et 
al., 2007). 
The pathways significantly overrepresented in my data included Wnt, TGF-β, cell 
adhesion and proliferation pathways, which have been reported to be altered in 
other cancer models in response to vitamin D (Deeb et al., 2007, Fleet et al., 2012) 
which increased confidence that the results are vitamin D specific. Enrichment of 
different pathways such as NOTCH signalling only in MeWo cells might reflect 
tumour heterogeneity. The overrepresentation of pathways such as G-protein 
signalling at 6 hours in SkMel28 cells implies a non-genomic effect, however, this 
needs detailed examination of the genes involved in the reported pathways and 
identification of possible VDREs in their promoters. The in silico methodology used 
here predicted that most of the genes differentially expressed in response to vitamin 
D were VDR target genes but the limitation of this approach was highlighted when 
one of the genes not predicted to be a VDR target has been reported in a recent 
ChIP-sequencing experiment as a VDR target containing a-non classical VDRE 
(non-DR3 type) (Heikkinen et al., 2011). It is therefore, essential to compare the 
data with available ChIP-sequencing data (such as those held in the ENCODE 
database) to identify potential non-genomic effects. It might also be that 6 hours 
was a late time point to identify non-genomic effects as these effects have been 
reported to be rapid within 40 minutes or 2-3 hours (Deeb et al., 2007). 
The greatest limitation of this work is that gene expression data were not available 
from the vitamin D resistant cell line to compare with our results but this could be 
performed in the future. Future work should also include the identification of 
whether transcriptional changes identified in vitro are mirrored in vivo using whole-
genome DASL gene expression data from patients from the Leeds Melanoma 
Cohort, and to what extent these effects are moderated by complex tumour biology. 
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7.3 Concluding Remarks 
In the course of this period of study I have investigated a number of biomarker 
discovery pipelines. The challenging nature of primary melanoma material has 
meant that until recently the focus of biomarker discovery was by necessity focused 
on small studies utilising fresh material or alternate tissue sources such as serum 
and plasma. The work I have presented on osteopontin has demonstrated that 
identifying biomarkers in serum and/or plasma present their own challenges and will 
be difficult using existing tissue-banked material. In contrast interrogation of archival 
FFPE blocks has provided a wealth of data with respect to differential expression of 
genes and their copy numbers. These approaches seem most likely to offer novel 
biomarker findings and my own analysis of the data obtained during this research 
will be concluded in the near future. Most significantly this research has shown that 
it is now possible, using advanced genomic techniques, to mine the wealth of data 
sourced from primary melanoma without reliance on fresh tissue. 
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Chapter 8  
Appendix A 
 
A.1 Cell line authentication reports 
A.1.1 Cell lines used at Leeds University 
A) MeWo 
B) SkMel28 
C) SkMel5 
D) MelJuso 
A.1.2 Cell lines used at Saarland University, Homburg, Germany 
A) MeWo 
B) SkMel28 
C) SkMel5 
D) MelJuso 
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A.2  Quality control plots before and after microarray gene 
expression data pre-processing 
A.2.1 Density distributions of log-intensities of each sample 
before and after Affymetrix U133 plus 2 microarray gene 
expression data pre-processing (MeWo) 
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A.2.2 Density distributions of log-intensities of each sample 
before and after Affymetrix U133 plus 2 microarray gene 
expression data pre-processing (SkMel28) 
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A.2.3  Density plots of log-intensity distribution of each sample 
before and after HT WG-DASL gene expression data pre-
processing 
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A.3  Illumina adapter sequences 
The standard Illumina adapter sequences with 5 barcode bases and a T added. 
5’ adapter: 5’- ACACTCTTTCCCTACACGACGCTCTTCCGATCTCAACC*T-3’ 
3’ adapter: 5’-P-GGTTGAGATCGGAAGAGCGGTTCAGCAGGAATGCCGAG-3’  
The highlighted bases represent the barcodes. The full list of the 40 different 
barcodes is shown in the table below (5’ adapter sequence shown). 
Barcode Sequence  
1 CAACC-T 
2 AACCA-T 
3 AAGGA-T 
4 AATTA-T 
5 ACACA-T 
6 GCATG-T 
7 TCGAT-T 
8 CGATC-T 
9 AGCTA-T 
10 GGTTG-T 
11 TGCAT-T 
12 GCCGG-T 
13 GATCG-T 
14 CCTTC-T 
15 TACGT-T 
16 TCAGT-T 
17 CAGTC-T 
18 CGTAC-T 
19 TATAT-T 
20 AGTCA-T 
21 GAAGG-T 
22 GACTG-T 
23 CATGC-T 
24 TCCTT-T 
25 GCGCG-T 
26 CCGGC-T 
27 ACGTA-T 
28 TCTCT-T 
29 ACTGA-T 
30 GGAAG-T 
31 TAATT-T 
32 CACAC-T 
33 GAGAG-T 
34 CCAAC-T 
35 ACCAA-T 
36 GCTAG-T 
37 TGACT-T 
38 AGAGA-T 
39 GGCCG-T 
40 CGCGC-T 
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A.4  Gene expression results in melanoma cell lines in 
response to vitamin D 
A.4.1 Lists of differentially detected probes in response to 
vitamin D 
These lists are in a Microsoft Office Excel spreadsheet on the attached cd under 
the name “Appendix A-4-1.xlxs”. Differentially detected probes after 6 hours of 
treatment with vitamin D, after 24 hours, after 48 hours, and the complete lists for 
each cell line (MeWo and SkMel28) are presented in separate worksheets within 
the Excel file. 
A.4.2  Lists of predicted VDREs in the promoters of differentially 
expressed genes in response to vitamin D and of all 
annotated genes in the hg19 
These lists are in a Microsoft Office Excel spreadsheet on the attached cd under 
the name “Appendix A-4-2.xlxs”. Lists of predicted VDREs in the promoters of 
differentially expressed genes (complete lists used) in response to vitamin D for 
MeWo and SkMel28 cells and of all annotated genes in the hg19 are presented in 
separate worksheets within the Excel file. 
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